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ABSTRACT 
Background and Methods: Blood transfusion saves lives and improves health but the 
presence of transfusion transmissible infections can have untoward consequences. When 
undetected, these infections can cause significant morbidity and mortality to transfusion 
recipients.  On the other hand, a high prevalence of transfusion-transmitted infections (TTI) 
leading to rejection of a large proportion of donated blood can result in blood shortages 
and subsequent increase in mortality. Malaria and bacterial infections are transfusion 
transmissible but there is limited data concerning these infections in sub-Saharan Africa. 
Although the burden of transfusion-transmitted malaria in malaria endemic countries are 
unknown, it is recommended that all donated blood is screened for malaria parasites and 
presumptive treatment be given to transfusion recipients.  Bacterial contamination in sub-
Saharan Africa has been reported to occur in between 8 - 17% of stored blood but the 
effect of contamination on transfusion recipients has not been determined. Syphilis is 
currently the only bacterial infection for which routine screening is recommended but 
screening is not being performed in many blood centres including Komfo Anokye Teaching 
Hospital (KATH) in Kumasi, Ghana where this study took place.  
This study examined the effects of transfusion-transmitted malaria (TTM) and bacterial 
infections (including syphilis) on transfusion recipients in a malaria endemic area.  Four 
malaria screening tests were compared to assess their usefulness in the context of African 
blood banks.  Pregnant women, children and immune-compromised transfusion recipients 
from the Departments of Obstetrics and Gynaecology, Paediatrics, Medicine and Oncology 
in KATH were enrolled into the study. 
 Results: Anti-malarial drugs were routinely prescribed with paediatric transfusions.  Fifty 
patients were evaluated after receiving blood transfusions that were positive for P. 
falciparum by PCR and seven recipients developed PCR-detectable parasitaemia. In only 
one recipient (2%) was TTM confirmed. The prevalence of P. falciparum malaria in 
transfused blood was 4.7% (21/445) by microscopy, 13.7% (60/440) by rapid diagnostic 
test, 18% (78/436) by polymerase chain reaction and 22.2% (98/442) by enzyme 
immunoassay. 
Bacterial contamination was found in 11.5 %( 95% CI 7.0-16.0%) (23/200) of donated blood 
units but only half of the recipients were observed to developed adverse signs of 
transfusion related sepsis.  The mean duration of storage of blood was 2 days. The 
prevalence of syphilis sero-positivity in donated blood was 8.0% (95% CI 4.3-11.7%). 
Seroconversion took place in an 8 year old girl, after receiving a syphilis sero-positive unit 
of blood.  
Conclusions:   This thesis has shown that malaria parasites may be commonly detected in 
donor blood but TTM occurs infrequently in recipients living in malaria endemic areas. The 
high rate of bacterial contamination and its associated transfusion related sepsis poses a 
safety risk to transfusion recipients.  Transfusion-transmitted syphilis remains a risk for 
transfusion recipients in blood centres with a high prevalence and short duration of storage 
of donor blood. 
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CHAPTER 1 
INTRODUCTION 
1.1 Blood transfusion 
Blood transfusion is the transfer of blood or blood components from one individual 
(donor) to another (recipient) (1). This procedure is usually performed by the 
intravenous route but other uncommon routes such as the intra-osseous can be 
used for example in very shocked children where venous access is difficult (2). 
Blood transfusion is an essential part of modern health care and when 
appropriately administered, transfusions can save lives and improve health.   
 
Overview of blood transfusion history 
Blood transfusion has developed over a prolonged period. It can be traced from the 
time of Hippocrates (~430 BC), when venesection was widely practised, until about 
100 years ago when it became part of routine clinical practice (3). The complete 
description of systemic blood circulation and the functions of the heart and vessels 
by William Harvey in 1628 was a major breakthrough and this discovery has proved 
to be the cornerstone of the practice of transfusion (4). The first transfusion; from 
one dog to another took place in Oxford in 1666 and was performed by Richard 
Lower (3).  James Blundell, an obstetrician at Guy’s and St. Thomas’ Hospitals in 
London is credited with the first human to human transfusion in 1818 (5).  
 
Blood transfusion safety 
Blood safety encompasses actions aimed at ensuring that everyone has access to 
blood and blood products that are as safe as possible, available at reasonable cost, 
adequate to meet the needs of patients, transfused only when necessary and 
provided as part of a sustainable blood programme within the existing healthcare 
system (6).  In 1975, the 28th World Health Assembly in Geneva passed a resolution 
to address the issue of blood safety. Resolution WHA28.72 urges member states to 
promote the development of national blood services based on voluntary non-
remunerated donation of blood (7).  
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Current status of global blood safety 
The World Health Organisation Global Database on Blood Safety (GDBS) was set up 
in 1998 to collect and analyse data from all countries on blood and blood product 
safety as the basis for effective action to improve blood transfusion services 
globally (8).  The latest report in 2010 is based on data from 173 countries (9).   
There were 93 million blood donations and 50% of them were collected in 
developed countries despite being home to only 16% of the world’s population. The 
average donation rate in developed countries is 45.4 donations per 1000 
population compared with 3.6 donations in developing countries and 10.1 in 
transitional countries.  
 
Screening for transfusion-transmitted infections 
There are many countries in the developing world that are unable to screen all 
donated blood for the 4 major transfusion-transmitted infections which are the 
human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) 
and syphilis. The lack of effective screening worldwide results in up to 16 million 
new infections with hepatitis B, 5 million new infections with hepatitis C and 
160,000 cases of HIV infection each year (10).   
 
1.2 Transfusion in sub-Saharan Africa 
Blood transfusions are indispensable in sub-Saharan Africa. They play a key role in 
the correction of anaemia and the prevention of deaths in pregnant women and 
children. Severe anaemia results in one million deaths each year in children less 
than 5 yrs old (11) and 26% of maternal haemorrhage deaths were due to lack of 
blood (12). Blood shortage is therefore an important consideration when 
transfusion is discussed in sub-Saharan Africa (13). 
Blood transfusions are an effective way of transmitting infections and account for 
an estimated 5-10% of all HIV infections in sub-Saharan Africa (14).  Comparing the 
different routes of transmission for HIV, blood transfusion was more than 90% 
efficient while maternal-to-child transmission, unsterile injections and heterosexual 
transmission had efficiencies of 30-35%, 0.30% and 0.01-0.02% (15, 16).   
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History of blood transfusion in sub-Saharan Africa 
It is possible that blood transfusions may have been performed without 
documentation or publication in the medical literature.  The earliest published 
reports of transfusion in Africa were from Belgian Congo in 1923 and 1940.  Belgian 
Congo and Senegal are the only two colonies in sub-Saharan Africa with published 
accounts of what could be described as a transfusion service or programme prior to 
1950 (16). There was a sharp growth in 1950 to 12 countries and by 1955 there 
were 19 countries where transfusion was performed (Table 1.1). This sudden 
increase may have been because transfusion techniques were successfully 
developed during the World War II and European countries were eager to introduce 
it into their colonies. 
 
Table 1.1: First reports of blood transfusion in sub-Saharan Africa 
Year Location 
1924 Congo (Belgian) 
1943 Senegal 
1950 Angola, Cameroon, Dahomey, Ivory Coast, Guinea, 
Mali, Mozambique, Niger, Togo, Upper Volta 
1951 Southern Rhodesia (1926 for Europeans only) 
1952 Nigeria 
1953 Kenya 
1954 Gold Coast (Ghana) 
1955 Chad, Congo (French), Gabon 
This table has been adapted from W. H. Schneider and E. Crucker 2006 (16). 
 
Blood safety in sub-Saharan Africa 
Although all 46 member countries in the WHO African Region are signatories to the 
World Health Assembly resolution WHA28.72 of May 1975, not much progress has 
been made towards blood safety.  A combination of factors has resulted in the 
subcontinent facing major challenges in its quest for blood safety. These include a 
high prevalence of blood borne disease agents, poverty, organizational deficits and 
a lack of resources in the face of poorly developed health infrastructure (17, 18).  
On the other hand the recommended centralised blood collection from voluntary 
donors for safe blood, based on the Western model, may not be appropriate for 
Africa (19).  Alternative systems may have to be embraced and used concurrently 
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(20). Further, open mindedness about innovative ways to improve supply and 
safety of blood is needed to promote more evidence based approaches in low 
income countries (21). 
 
Current blood safety indicators in sub-Saharan Africa 
Data from the GDBS (22) show that a hundred percent testing for TTI is currently 
being performed for HIV, HBV and HCV by 95%, 83% and 59% of the reporting 
member states respectively.  Prevalence rates of TTI are difficult to report because 
of different testing algorithms and different denominators. The rates of blood units 
being discarded for testing positive to TTI were exceptionally high and ranged 
between 21.0% and 26.6% for countries such as Sao Tome, Mali and Mauritania.  
 Limitations of GDBS: The data published by the GDBS is based on responses to a 
questionnaire sent to national health authorities. This information is provided from 
the national transfusion services that are often based in urban centres and have 
good documentation processes. Because family replacement donations usually 
come from hospital facilities where there are no adequate central collating systems, 
input from such facilities is not reflected in these reports, and this leads to biased 
data (19,21).  The GDBS data has to be interpreted with caution, especially the data 
from Africa.  
 
1.3 Transfusion-transmitted infections (TTI) in Ghana and West Africa 
The focus in Ghana as in many other places has been on the 4 major TTI namely 
HIV, Hepatitis B and C and syphilis.  A hundred percent of blood banks in the 
country screen for HIV, HBV and HCV but only 20% screen for syphilis. The average 
national prevalence rates in donors for HIV, HBV, HCV and syphilis were 1.27%, 
10.14%, 0.99% and 1.48% respectively. The national prevalence of all the screened 
TTI is higher in replacement donors than in voluntary donors (23). In contrast, 
recent evidence from Kumasi (24), Cameroon (25) and Guinea (26) has shown no 
difference in prevalence between first time volunteer donors and replacement 
donors.  
5 
 
In Kumasi, where the current study took place, despite screening for the major 
viruses, it has been demonstrated that the residual risk is high. The estimated 
residual risk of HIV is 1 in 2578 and for HCV is 1 in 1450 (27).  
The amount of blood discarded varies from region to region across Ghana. Those 
regions performing pre-donation screening of TTI discard less than those doing post 
donation screening. The Upper East region discarded 1.42% of blood units collected 
while Eastern region discarded 15% of the blood collected.   
As well as the major TTI some other viruses have been investigated as TTI in 
Ghanaian donors. These include human erythrovirus B 19, West Nile virus and GB 
virus C (28-31).  
There are a few publications from West Africa that describe the prevalence of the 
major viruses in their hospitals or in the centre. A mathematical model based on 
such data has estimated the incidence of TTI in some African countries including 6 
from West Africa (32). The incidence in West Africa is generally lower than in East 
or Southern Africa. Within the sub-region, the highest incidence was for TTI- HIV 
was 164 and 112 per 100,000 donations in Senegal and Ghana. Senegal had the 
highest incidence of TTI-HBV and TTI-HCV. With an incidence of 81, 431 and 96 per 
100,000 donations for HIV, HBV and HCV, Mali was the country with lowest 
incidence of all 3 viral TTI.  
 
Transfusion-transmitted malaria in Ghana and West Africa 
There has been no study to determine the prevalence of malaria in Ghanaian 
donors and neither has there been any study to determine the effects of blood 
transfusion on malaria. In the West African sub region, eleven studies have been 
conducted, one in Benin and ten in Nigeria to determine the prevalence of malaria 
in blood donors. The prevalence of malaria in blood donors, determined by 
microscopic examination of peripheral blood ranged from 4% to 55% (33, 34). 
These studies were conducted at different malaria endemic areas and transmission 
seasons. 
Determining the prevalence of malaria parasitaemia in blood donors, however, 
does not provide the actual risk of transfusion-transmitted malaria especially in a 
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malaria endemic area where majority of recipients may have some immunity that 
protects them from clinical disease.  
 
Bacterial contamination of donated blood in Ghana and West Africa 
Bacterial contamination is not routinely tested for in donated blood. Platelet 
concentrates are however routinely screened in some developed countries because 
of the high risk of bacterial contamination (35).  In Ghana, two studies (36, 37) have 
recently been published, one from the northern sector (Tamale) and another from 
the southern sector (Accra) of Ghana. The studies determined the rates of bacterial 
contamination of donor blood to be 17.5% in Tamale and 9% in Accra. Neither of 
these studies looked at the clinical effects on the recipients of the blood.  No other 
studies have been identified across West Africa. 
 
Transfusion-transmitted syphilis in Ghana and West Africa 
Transfusion-transmitted syphilis has not been documented to have occurred in 
Ghana or in the West African sub region. Studies tend to identify sero-positivity 
among donors but not in recipients. There are 2 published studies on blood donors 
in Ghana (38, 39). Both studies were conducted in the capital city of Accra and the 
sero-reactivity was 13.5% and 7.5% respectively. The rates from these published 
studies are higher than that reported by the blood banks in the annual report. It is 
uncertain why these discrepancies exists but it may be due to the fact that 
published studies used particle agglutination assays, which are more sensitive than 
the VDRL that is used for screening in the national programme. A very low sero-
reactivity prevalence of 0.3% among donors has been reported by the National 
Centre for Blood Transfusion in Mali (40).  Although they attribute this low 
prevalence to widespread use of antibiotics, there must be other reasons including 
the screening test used which in this case was the - Venereal Disease Research 
Laboratory (VDRL) non treponemal test which has a low sensitivity.  Olokoba et al 
also found a low sero-positivity rate of 1.3% in donors from North-eastern Nigeria 
(41). 
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Transfusion practices in Ghana and West Africa 
In Ghana, the national blood policy is silent on transfusion-transmitted malaria. It 
recommends all donor blood should be screened for HIV, HBV, HCV and syphilis but 
many blood banks, including the hospital, where this study was carried out, do not 
screen for syphilis. Regular audits are not carried out and there are insufficient 
publications to adequately describe what the current practices are within the 
country. In Nigeria for example, an audit showed inappropriate use of platelet 
transfusion in 81% of instances and a 36% unnecessary use of fresh frozen plasma 
(42). Transfusion practices, like any other branch of medicine, should be derived 
from evidence based guidelines and the documentation of these practices can help 
evaluate them against any emerging new evidence. A hospital in the Ashanti region 
of Ghana has recently shown a decrease in the rates of transfusions and of malaria 
infections following the implementation of malaria control programme in that area 
(43).  
 
1.4 Study location: Ghana 
Ghana is an English speaking West African country that lies along the Gulf of Guinea 
and shares borders with Burkina Faso, Togo and Cote D’Ivoire (Figure 1.1).  
Its population, according to provisional results from a census in 2010 is 24,223,431 
with 51.3% females (44).  The country is administratively divided into 10 regions 
(Figure 1.1).  The capital city of Ghana is Accra, which is located in the Greater Accra 
region. Vegetation varies across the country, low sandy shores and grassy plains in 
the south, tropical rain forest in the middle and low bush savannah in the north. 
The majority of people are farmers and cocoa, timber and gold are the main source 
of foreign exchange.  Some of the demographic, health and economic indicators of 
Ghana are shown in Table 1 (table derived from UNICEF) (45). 
 
The health sector in Ghana 
Ghana has 2189 health facilities, of which 952 are government owned, 181 are 
owned by religious organisations, 75 are quasi-government and 980 belong to the 
private sector. Out of the total number of health facilities, 2 are teaching hospitals, 
10 regional hospitals, 91 district hospitals, 124 other hospitals, 558 health centres, 
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1085 clinics and 320 are maternity homes. Ghana operates a National Health 
Insurance Scheme so regular contributors do not have to make direct payments to 
the health providers. The Scheme was established in 2003 and currently covers 
about 60% of the population.   
In 2009, malaria accounted for 32.9% of all admissions and was the leading cause of 
admission across the country. The top 3 causes of death in Ghana were malaria 
(13.4%), HIV related conditions (7.4%) and anaemia (7.3%). Syphilis prevalence 
varies depending on the population examined. Among prison officers in Accra sero-
prevalence was 7.9% but among prison inmates it was double the figure at 16.5% 
(46). 
 
Table 1.2: Country statistics for Ghana (table taken from UNICEF website 
http://www.unicef.org/infobycountry/ghana_statistics.html). 
Indicator  
Under-5 mortality rate (per 1000 live births), 2009 69 
Infant mortality rate (per 1000 live births), 2009 47 
Neonatal mortality rate (per 1000 live births), 2009 27 
Annual no. of births (thousands), 2009 766 
Annual no. of under-5 deaths (thousands), 2009 50 
Gross national income per capita (US$), 2009 700 
Life expectancy at birth (years), 2009 57 
Total adult literacy rate (%), 2005-2008 66 
Estimated adult HIV prevalence rate (aged 15-49), 2009 1.8 
Estimated number of people living with HIV (thousands) 2009 260 
Malaria 2006-2009, % households owning at least one ITN 33 
Malaria 2006-2009, % under-fives sleeping under ITNs 28 
Malaria 2006-2009, % under-fives with fever receiving anti-malarial 
drugs 
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Kumasi  
Kumasi is located in and is the capital city of the Ashanti region of Ghana. Ashanti is 
the region with the highest population in Ghana and has a population of 4,725,046.  
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There are 530 health facilities in the region including Komfo Anokye Teaching 
Hospital, the site for this study. 
Komfo Anokye Teaching Hospital (KATH) 
Komfo Anokye Teaching Hospital (KATH) is the 2nd largest hospital in Ghana (Figure 
1.2).  It is a 1000 bed hospital and serves as the referral centre for the upper half of 
Ghana. KATH has 10 clinical directorates that provide specialized services to the 
public.  Blood transfusion services in the hospital are provided by the Transfusion 
Medicine Unit. 
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Figure 1.1: Map of Ghana showing its boundaries, regions and proposed centres (shown 
by red arrows) for the National Transfusion Service 
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Figure 1.2: The front view of the Komfo Anokye Teaching Hospital (KATH) 
 
 
 
Blood transfusion in Ghana  
The National Blood Transfusion Service (NBTS) of Ghana has adopted a national 
blood policy since April 2006 (47). However, the legislative instrument backing the 
policy is yet to be passed through Parliament for enactment into a law. There is also 
a national guideline on the clinical use of blood and blood products. Funding has 
been secured for the NBTS to construct three centres to coordinate the supply of 
blood and blood products across the country. These will be located in the southern 
(Accra), middle (Kumasi) and northern (Tamale) parts of Ghana as shown by arrows 
in the map of Ghana (Figure 1).  The national average for the proportion of 
voluntary blood donations is 38.4%.  Blood banks in each hospital screen their own 
blood for HIV, Hepatitis B and C and syphilis depending on local preferences and 
availability of test materials.   
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Blood transfusion in KATH 
The Transfusion Medicine Unit (TMU) of the Komfo Anokye Teaching Hospital is 
responsible for obtaining the blood donations, storage and distributing of blood in 
the hospital. The TMU is organised into sections including donor organisation, 
donor care, and laboratory sections. It is currently only able to provide whole blood, 
concentrated red cells (packed cells) and fresh frozen plasma for transfusion. Each 
year about 15, 000 transfusions are carried out in KATH.  
Blood donors and donation:  KATH depends on both voluntary non-remunerated 
blood donors (VNRBD) and replacement donors (48).  Seventy percent of blood 
used in the hospital is from voluntary donations. The VNRBD are predominantly 
recruited from secondary schools but there are other sources such as walk in 
donors and donors from public drives which are held in conjunction with local FM 
radio stations. The replacement donors come to the hospital to donate and replace 
blood used for a hospitalized family member or friend. There are no recognised 
paid blood donors.  
Screening of blood:  Blood donors are screened for HIV, hepatitis B and hepatitis C 
prior to donation. This is known as pre-donation screening. When screening is 
carried out on the blood after the unit of blood has been donated it is referred to as 
post-donation screening. Donors that are initially positive for any of these viruses 
are deferred and asked to return a couple of weeks later by which time 
confirmatory tests will have been performed. Screening is initially by rapid tests and 
confirmation is by ELISA.  
The rates of the transfusion-transmitted infections screened for in KATH for 2011 
are as follows: prevalence of HIV is 0.8%, prevalence of HBV is 8.5% and prevalence 
of HCV is 0.4% (personal communication with head of KATH transfusion unit). Blood 
donors are not screened for syphilis or malaria and there are no blood cultures 
done for bacterial contamination. 
 
1.5 Justification for the study 
In September 2008, a workshop was held in Mombasa, Kenya for key stakeholders 
in blood transfusion services in sub-Saharan Africa. The purpose was to develop and 
prioritize a research agenda and to fill gaps in the evidence needed to improve the 
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supply and safety of blood for transfusion (49).   Key among the priority area’s 
identified was transfusion-transmitted infections and transfusion reactions.  
Transfusion researchers, transfusion service directors, representatives of 
transfusion users including senior obstetricians, anaesthetists and paediatricians 
and funders, confirmed that there is limited knowledge about the morbidity and 
mortality due to transfusion-transmitted malaria and the benefits and feasibility of 
screening for malaria are unknown. There is almost no information about whether 
there is clinically significant bacterial contamination of blood packs and the patterns 
and prevalence of transfusion reactions in sub-Saharan Africa. 
 
Transfusion-transmitted malaria 
It is important to determine the consequences of blood transfusion if the blood 
contains malaria parasites. Effects may vary according to age and immunity. 
Knowledge about adverse effects will give an indication of whether it is important 
to screen donated blood for malaria parasites. 
Malaria is a well known transfusion-transmissible infection but there remains great 
uncertainty with regards to its effect on those receiving blood, especially in malaria 
endemic regions.  Some national programmes and guidelines recommend routine 
use of anti malarials. There is little evidence to support or oppose current practices 
and opinion remains divided as to whether malaria screening should be carried out 
on all blood donors. The gold standard for diagnosis of malaria is microscopy but 
this method is time consuming and may miss low levels of parasitaemia. Rapid 
malaria test kits are gradually becoming available and PCR technology has high 
sensitivity. A critical evaluation of these tests is needed to determine their 
usefulness in screening donors. 
 
Bacterial contamination 
Bacterial contamination and its effects on transfusion recipients in the developing 
world is another poorly researched field of transfusion. Bacteria readily proliferate 
in blood and under poor storage conditions a tiny inoculum of bacteria can 
proliferate to reach dangerous levels which, when transfused, may cause significant 
morbidity or mortality. In sub-Saharan Africa, children are major users of blood. 
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Because paediatric packs are expensive and not readily available, adult units are 
split into smaller aliquots with the potential risk of bacterial contamination. It is 
important to identify the presence of contamination and the factors that contribute 
to it. In developing countries where quality assurance and monitoring systems are 
not followed, identifying factors that cause or enhance bacterial contamination will 
be helpful to draw up policies that enhance blood safety.  
 
Transfusion-transmitted syphilis 
Syphilis has been known as a transfusion-transmitted infection for more than 100 
years but there still remain questions about the value of screening.  Some evidence 
suggests that because the prevalence of syphilis is low and because the Treponema 
pallidum is no longer viable after a few days of refrigeration of the blood, the 
transmission of syphilis by blood is negligible.  In addition, the serological tests used 
may not necessarily detect infectious donors. There is, however, insufficient 
evidence to justify stopping screening for syphilis in blood donors and the practice 
of syphilis screening continues.   
This study seeks to provide some evidence of whether these transfusion-
transmitted infections are occurring in Ghana and to identify any effects they have 
on recipients of transfusion. 
 
1.6 Study objectives 
Aim 
The aim of this study is to determine the prevalence of malaria, bacterial 
contamination and sero-positive syphilis in donated blood and to determine any 
effects of these transfusions on recipients living in a malaria endemic area. 
Objectives 
The specific objectives of the study are: 
 To describe the impact of policies relating to malaria transmission and blood 
transfusion on clinical practice in endemic countries 
 To determine the prevalence of malaria parasitaemia, bacterial 
contamination and syphilis sero-positivity in donated blood and blood 
products for transfusion. 
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 To identify any adverse effects on recipients of donated blood/blood 
products that had malaria parasites or bacterial contamination.  
 To compare microscopic, serological and molecular methods for screening 
blood for malaria parasites 
 
1.7 Thesis outline 
Chapter two provides a review of the literature that this thesis is based upon. There 
are four main sections. A brief summary on general transfusion-transmitted 
infections is presented followed by a detailed focus on malaria, general bacteria 
and finally syphilis.  The review also examines the applicability of screening 
methods and tests in sub-Saharan Africa.  The study organisation and general 
methodology is described in chapter three.  
In chapters four, five, six and seven, different studies are presented. A study 
evaluating transfusion practices in relation to policies in transfusion-transmitted 
malaria is presented in chapter four.  Chapter five describes a study which 
determines the existence of transfusion-transmitted malaria in a malaria endemic 
country. A study on bacterial contamination and its effects is described in chapter 
six and one on transfusion-transmitted syphilis is described in chapter seven. In 
chapter eight, a general discussion of the study findings is presented and in chapter 
nine the conclusions and recommendations are made. 
 
 1.8 Summary 
In this chapter an overview of blood transfusion in Africa and the current status of 
blood transfusion safety in Ghana and West Africa have been presented. The 
justification and study aims have also been presented. In the next chapter, a review 
of the literature on transfusion-transmitted infections is presented.  
 
16 
 
CHAPTER 2  
LITERATURE REVIEW 
2.1 TRANSFUSION-TRANSMITTED INFECTIONS  
Introduction    
Different types of organism including viruses, bacteria and parasites can be 
transmitted by transfusion of blood or blood products although this is not their 
primary route of transmission. The risk of transmitting a particular infection is 
related to the prevalence of the infection in the region, but also depends on other 
factors such as the virulence of the organism and ability to survive storage 
conditions. Some organisms, such as HIV, are ubiquitous whereas others, such as 
Plasmodium, are endemic in specific regions.  With the current globalisation and 
the ease of travel around the world, transfusion recipients in non endemic 
countries can still be infected by a non endemic infection like malaria.   
 
Emerging infections 
The American Association of Blood Banks has recently identified 68 infectious 
agents that can be transmitted by transfusion and there may be more yet to be 
identified (50). Besides the major transfusion-transmitted infections such as HIV, 
hepatitis B and hepatitis C,  novel agents such as prion proteins, responsible for 
prion diseases or spongiform encephalopathy, have recently been recognised  
(51,52).   
The risk to recipients of the major transfusion-transmitted infections is declining, 
both in developed and developing countries. This is due largely to a continuing 
focus on improvements in donor selection and advances in testing for infectious 
agents (53).  
 
Screening of donated blood 
Laboratory testing only forms part of donor screening. There are general guidelines 
available which guide transfusion practices but each country must adapt them to 
suit their needs. The WHO recommends that at a minimum, blood should be 
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screened for HIV, hepatitis B (HBV), hepatitis C (HCV) and syphilis; furthermore, and 
where appropriate, malaria and Chagas disease should be screened for in donated 
blood (54).  One of the ways to prevent transfusion-transmitted infections (TTI) is to 
ensure that all donated blood is screened for the major transfusion infections. Not 
all countries are able to screen donated blood units.  Out of 162 countries providing 
worldwide data for the Global Database for Blood Safety, 39 countries are not 
routinely testing blood donations for one or more of the 4 major TTI (8).  The WHO 
estimates that lack of effective screening results in up to 16 million new infections 
with HBV, 5 million new infections with HCV and 160,000 cases of HIV infection 
every year (10).  
Because of constantly emerging threats, transfusion-transmitted infections will 
continue be a challenge in blood safety. Preventive approaches such as 
comprehensive donor questioning and evaluation, and mandatory screening for 
HIV, HBV, HCV and syphilis will need to remain in place so that potentially infectious 
blood will be eliminated. Newer tests for emerging pathogens will have to be 
quickly introduced when necessary.  
 
Challenges in blood donor screening 
Serological screening tests have been developed and validated in developed 
countries.  When used in Africa, higher levels of IgG consistently increase the 
frequency of falsely reactive tests. This phenomenon has been observed for HIV, 
HCV and Human erythrovirus B 19 serological testing (55-58). 
Confirmatory testing should be performed for all initially reactive screening assays. 
In syphilis testing, the current recommendation is for initial screening tests to be 
performed with a non-treponemal assay and confirmed with a treponemal assay 
(See section2.4.6). However, many of the published studies use a single treponemal 
or non-treponemal test.  It is unclear why this is being done in Africa.  Sero-
reactivity and sero-positivity rates cannot therefore easily be compared. In the 
syphilis section of this thesis, sero-reactivity is used when only one test was 
performed and sero-positivity is used when a second test was performed to confirm 
initially reactive donor blood. 
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For malaria in endemic countries, there are no recommended confirmatory tests to 
detect parasitaemia in blood donors. WHO recommends that screening for 
parasitaemia be done with microscopy.  Alternatively a highly sensitive enzyme 
immunoassay can be used for evidence of antigenaemia (59).  Microscopy also 
remains the only US Food and Drugs Board approved endpoint for assessing 
outcomes in malaria vaccine and drug trials (60). In this thesis, reference is not 
made to a confirmatory test in the sections dealing with malaria. 
 
2.1.1 Transfusion-transmitted viral infections 
Some of the important transfusion-transmitted viruses are human 
immunodeficiency viruses types1 and 2 (HIV-1/2), hepatitis B virus (HBV), hepatitis 
C virus (HCV), and human T-cell lymphotrophic virus types I and II (HTLV-I/II). Other 
viruses, including West Nile virus (WNV), Epstein-Barr virus, human parvovirus B19, 
and GB virus C, can also be transmitted by blood products (61). Transfusion-
transmitted infections existed long before HIV emerged. The transmission of a viral 
agent through blood transfusion was first reported in 1943 but since the 
recognition of HIV and its potential to infect those who receive a transfusion from 
an infected blood donation, blood safety has been the subject of strong advocacy 
with global support from major organisations (62,63). 
The risk of transfusion-transmitted viral infections has been reduced to minimal 
levels in developed countries but in developing countries, the risk is higher. Recent 
estimates of the risk in Africa of acquiring HIV, HCV and HBV were 1, 2.5 and 4.3 per 
1000 units respectively (32).  In contrast, the estimated risk per unit in the US of 
acquiring HIV, HCV and HBV was 1: 1.9 million, 1:1.6 million and 1:180,000 
respectively (64) 
 
2.1.2 Transfusion-transmitted parasitic infections 
Malaria, Chagas disease, and babesiosis are some of the diseases that can result 
from transmission of parasites by transfusion. Chagas disease and babesiosis are 
briefly mentioned here but malaria will be discussed extensively. 
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Chagas disease 
Chagas disease, also called American trypanosomiasis is caused by Trypanosoma 
cruzi. It is widespread in South America, Central America and Mexico (65). Up until 
2007, there have been seven documented cases transfusion-transmitted Chagas 
disease (53), six of which were associated with transfusion of platelet concentrates 
(Young C 2007).  With the continuous decline of the major transfusion infections, 
more attention is being paid to others like T. cruzi (53). An enzyme immunoassay 
was introduced in 2006 for screening blood to detect antibodies to T Cruzi.  
 
Babesiosis 
Babesia microti is an intracellular parasite that has similarities with malaria. Its 
transmission from animal reservoirs to humans is by ticks (66). Transfusion-
transmitted babesiosis, has occurred across the world (67) but most cases reported 
have come from the United States of America (68). Although it is usually 
asymptomatic, it can also be fatal (65). Twelve of the over 70 cases reported 
between 1979 and 2008 led to a fatal outcome (69).  Tests available include blood 
smears to detect the parasite but this is not sensitive. Indirect immunofluorescence 
assay (IFA) is regarded as the gold standard (66). 
 
2.2 TRANSFUSION-TRANSMITTED MALARIA 
Introduction to malaria 
Malaria is the most important parasitic disease of man (70), with 3.28 billion people 
living in areas that have some risk of malaria transmission (71).  Clinical malaria may 
be caused by any of 5 Plasmodium spp. that are known to infect humans. These 
include P. falciparum, P. vivax, P. ovale, P. malariae and P. knowlesi (72).   P. 
knowlesi, a parasite of long tailed macaque monkeys, has since 2004 been 
identified as causing human disease (73) and it can be rapidly lethal especially when 
a high parasitaemia is reached (74). The most severe forms of malaria are caused by 
P. falciparum (75).  
WHO recently estimated, that there were 225 million cases of malaria worldwide 
with a majority (78%) of these cases coming from Africa.  The global number of 
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malaria deaths in 2009 was 781,000, of which 91% occurred in the Africa region 
(76).  
 
Malaria transmission 
Transmission of malaria parasites primarily occurs through the bite of the blood 
feeding female anopheles mosquito. Besides transmission by mosquitoes, direct 
inoculation is another well documented mode of acquiring malaria.  Direct 
inoculation has resulted in malaria after accidental exposure in healthcare workers, 
among injecting drug users sharing used needles and in blood transfusion (77,78).  
Malaria transmission by transfusion is the most common form of direct inoculation 
and is discussed extensively in this thesis. For transfusion-transmitted malaria, the 
exact life cycle of P. falciparum has not been described. 
A review in 2005 found 22 published cases of occupational P. falciparum malaria 
following accidental blood exposure (79). All cases were from countries non 
endemic for malaria.  Accidental exposure to infected blood may be challenging to 
diagnose in areas where infections are not endemic (80) but with increasing travel 
to malaria endemic areas and the possibility of more patients being admitted and 
treated for malaria, this route may become more important in occupational health 
(79).  
 
Susceptibility to malaria infection 
All persons living in malaria endemic areas are susceptible to infection but there are 
some people who are particularly susceptible to acquiring infection including 
children and pregnant women (81). 
Children are most susceptible to malaria but infants and neonates appear to be 
protected from malaria for the first 3-6 months (82). This may be due to maternal 
antibodies. Immunity to malaria is slowly acquired after years of repeated exposure 
to Plasmodium. This is reflected by the decrease of incidence of clinical episodes 
and a decrease in parasite densities with increasing age, in persons living in malaria 
endemic areas (83). Despite many control efforts, hospital admissions, severe 
malaria and deaths due to malaria remain concentrated in children under 5 years 
(84).    
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Pregnant women are at a greater risk of infection and of symptomatic malaria 
disease than the non pregnant adult (85). The ability of pregnant women to limit 
parasite replication is impaired in pregnancy, resulting in higher parasite densities 
than in non pregnant adults. This happens in pregnancy because, there is a 
transient depression of cell-mediated immunity that allows foetal allograft 
retention and also there is immunosuppression mediated by pregnancy associated 
hormones and proteins (86,87). Age may also be an independent risk factor as 
younger pregnant women are more susceptible to malaria in some settings (88). 
Malaria has been found to be a complicating factor of febrile neutropenia (89). 
Patients with malignancies and on chemotherapy are likely to be more susceptible 
to malaria than healthy persons. The relationship between sickle cell disease (SCD) 
and malaria can be complex. The presence of haemoglobin S is associated with 
reduced parasitic invasion of erythrocytes, impaired multiplication and accelerated 
clearance of parasites by the spleen (90). It is assumed that homozygous SCD would 
confer resistance to malaria, however co-existence of the two is associated with 
increased mortality and morbidity and malaria is the most common cause of crises 
in endemic countries (91). Malaria is a significant problem in people with sickle cell 
disease (92). 
 
Transfusion-transmitted malaria 
Transfusion-transmitted malaria (TTM) occurs when the infection in the patient is 
caused by the same parasite that was present in the donated blood. The first case 
of TTM was reported by Woolsey in 1911 (93). This was due to the blood in the 
syringe flowing back when the direct method of transfusion from artery to vein was 
used (94).   
 
2.2.1 Epidemiology of transfusion-transmitted malaria  
Transfusion-transmitted malaria in non-endemic countries 
Most of the published data on TTM are from non endemic countries for malaria. 
This may be due to the ease of diagnosis in non-endemic countries compared to 
endemic countries where it cannot be readily proven whether malaria which 
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develops post-transfusion is from the blood received or from a re-infection or 
recrudescence.  
Excluding deliberate infections for malaria therapy or for experimental purposes, 
there were about 350 cases of accidentally induced human malaria reported 
between 1911 and 1950 (94). During the period 1950-1972, 1,756 cases were 
reported to have occurred in 49 countries. The role of surveillance activities of the 
global malaria eradication programme from various countries and the reports 
forwarded to the WHO were of considerable value in providing reliable data (95). 
There is still the possibility that some cases of TTM were missed or not reported. As 
transfusion of blood and its components increased, more cases of TTM were 
expected. However, with an increased awareness of this problem, more 
interventions have been introduced to reduce its occurrence including screening 
tests and deferral of donors who have travelled to malaria endemic countries. . 
Currently, there is about one case of TTM every 3 years in France (96,97). In the UK, 
only 2 confirmed cases of TTM have been reported since 1996 (98). Three cases of 
TTM were reported in the US in 2009. Prior to 2009, the last case of TTM was 
reported in 2007 (99). In Japan, there have been 22 cases of TTM since 1945 (100). 
 
Incidence of transfusion-transmitted malaria in sub-Saharan Africa 
There are no published studies on the incidence of TTM in malaria endemic regions.  
This may be due to the use of malarial prophylaxis in recipients, making it difficult 
to follow up patients to determine incidence.  A study in Sudan found that the 
prevalence of post transfusion malaria in transfusion recipients was 3.5%, four days 
after transfusion (101).  All patients in the study (twelve) who received malaria 
positive blood became malaria positive (by microscopy). There were also two 
patients who did not receive malaria positive blood but still developed malaria 
parasitaemia 4 days after transfusion. Genotyping was not done to determine if the 
parasites in the patients were the same as the ones received from the donated 
blood. In malaria endemic countries post transfusion malaria cannot be equated to 
TTM because there are other sources of transmission.   In non endemic countries 
however, post transfusion malaria is likely to be the same as TTM because the 
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transfusion is likely to be the only source of parasitaemia in a recipient who has had 
no previous exposure to malaria.  
 
Prevalence of malaria in blood donors in sub-Saharan Africa 
The prevalence of malaria in blood donors depends on the endemicity in the 
country or region and the transmission season. For example, during a high 
transmission season in a high endemic area, the prevalence of asymptomatic 
parasitaemia is high in all age groups, reaching up to 94% (102). Similarly it is 
reasonable to expect a high prevalence of asymptomatic donors in endemic 
countries (103).  Our recent review of published prevalence studies shows a wide 
variability of malaria prevalence across sub-Saharan Africa (104). The prevalence of 
malaria varied from 0.7% in Nairobi, Kenya (low malaria endemicity) to 55% in 
Anambra, South-eastern Nigeria (high malaria endemicity). The prevalence of 
malaria varies across Africa and even within countries.  
Asymptomatic donors with parasitaemia may be a source of transmission but it is 
unknown whether presence of parasitaemia in donors translates into infection or 
disease for the recipient. The presence of parasitaemia in donated blood raises 
some important issues including 
1. How much parasitaemia in donors translates to infection or disease in 
recipients 
2. Whether blood banks can afford to discard all malaria positive blood that is 
donated and 
3. What is the best screening method to detect malaria parasitaemia?  
 
Incubation period for transfusion-transmitted malaria  
The incubation period for TTM is variable (105) but for falciparum, it ranges from 
seven to 27 days.   This variability may depend on factors such as inoculum size and 
the intrinsic factors of the recipient such as age, level of immunity, presence of 
protective red cell abnormalities such as sickle cell etc. Recent observations from 
TTM cases indicate that the incubation period may last several months (99). 
Determination of incubation periods is based on the ability of the patient to 
recollect exactly when the symptoms started and on knowing the date of the 
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implicated transfusion. This is not always known. In an observation from non-
immune subjects in Yugoslavia, 3 children who received blood from the same 
source had varying incubation periods of 7, 15 and 23 days.  Assuming that they 
each received the same dose of parasites then, it was the recipient’s immunity that 
played the major role in determining the incubation period (106). Inoculum size in a 
transfused unit of blood can be huge. When one parasite /µl is found, that 
translates to about 500,000 parasites in a unit of blood.   
 
Parasite viability 
Plasmodium parasites can survive refrigeration for up to 18-20 days (59,93) but a 
recent study shows that refrigeration is detrimental to their survival (107). There 
was a 7.1 fold reduction after 14 days but parasites remained detectable by 
microscopy for 28 days when stored in blood at 4°C. Parasites also did not show in 
vitro replication when cultured after 14 days storage. This may be an indication of 
the parasite losing viability after prolonged refrigeration. More studies are needed 
to authenticate this.  
 
Presentation of transfusion-transmitted malaria 
It is not expected that symptoms of TTM should be different from the usual 
symptoms of malaria which include fever chills, myalgia, headache, vomiting and 
diarrhoea.  In a study by Ali et al who found 14 patients with post transfusion 
malaria after receiving P. falciparum positive blood, there was no clear clinical 
presentation of TTM except for the presence of fever (101).  
 
2.2.2 Prevention strategies of TTM in sub-Saharan Africa 
Preventive strategies targeted against TTM could be  
A) Pre-transfusion interventions aimed at the donor. Included in pre-transfusion 
interventions are  
 screening the blood donor for parasitaemia,  
 donor deferral and/or pre-treatment  
 in vitro treatment of blood with anti-malarials  
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B) Post-transfusion interventions where recipients receive a full course of anti-
malarials. 
 
2.2.3 Screening tests 
Introduction 
This section of the review focuses on test methods that can be used in the diagnosis 
of malaria. The two ways whereby malaria can be detected is by direct and indirect 
detection. Methods for direct detection include light microscopy, antigen detection 
(both immunochromatography/rapid diagnostic tests and antigen enzyme linked 
immunoassay) and molecular tests. Indirect detection is by antibody serology. 
 
Light microscopy  
For light microscopy, two types of blood film preparations are used, the thick and 
thin film.  The thick film is used for detection of the parasite and the thin film for 
the identification of the species. For the examination of a thick film, 100 microscope 
fields should be looked at. In a good standard thick film, this is approximately 0.25µl 
of blood (108,109).  Microscopy has a limit of detection of 20-30 parasites/ µl of 
blood and low parasitaemia can be missed by microscopists (110,111). 
Microscopy enables parasite densities to be determined as this may be important 
for classification of severity. Accurate determination of parasite densities is done on 
a thin film by counting parasites against at least 100,000 red blood cells (112). This 
is time consuming. There are other methods but one that is commonly used is to 
count the number of parasites per white blood cell in a thick film and multiply by 
8000, which is presumed to be the average WBC count per µl (113). This method is 
used in busy clinics and for field studies but is not very accurate.  
The stains that can be used are Giemsa, Fields and Leishman; with Giemsa being the 
commonly used and the best all round stain (114). The Giemsa stain is stable over 
time and its staining quality is consistent over a wide range of temperature. Giemsa 
stains the smear well, even in the hands of inexperienced persons, and is therefore 
the stain of choice in peripheral health laboratories (114).  
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Importance of microscopy in malaria 
Microscopy remains the gold standard for malaria diagnosis (115).  Giemsa 
microscopy is regarded as a suitable diagnostic instrument for malaria control 
programmes (116). Microscopy is the only U.S. Food and Drug Administration 
(FDA)-approved end point for assessing the outcomes of drug and vaccine trials, 
and for serving as a reference standard in the evaluation of new tools for malaria 
diagnosis (60).   
 
Microscopy use in blood donor screening   
Screening is not performed routinely in blood donors in endemic countries but it is 
the method most frequently used to screen for malaria in blood donors and 
recipients in clinical studies in sub-Saharan Africa (104). Table 2.1 shows a summary 
of advantages and disadvantages of employing microscopy as a screening test for 
blood donors. Gametocytes cannot directly cause disease in humans so if they are 
found by microscopy in blood, the blood may still be given. 
 
Table 2.1: A summary of the pros and cons of using microscopy as a screening test in 
blood donors 
Pros Cons 
 Ability to determine parasite 
density. Donated blood with very 
low parasite density may be used 
in times of blood shortage 
 Allows for identification of all 
species. It is yet to be established 
if particular species are most 
relevant for TTM but if it is, the 
species identification is important. 
 Allows differentiation between 
asexual parasite stages: Donated 
blood with gametocytes may be 
acceptable since they do not 
cause disease. 
 Not very sensitive: Inherently 
unable to detect low parasitaemia 
such as below 20-50 parasites/µl 
 Turn-around time is slow (at least 
30 minutes per sample) and not 
suitable for screening large 
numbers 
 Experienced personnel required  
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Malaria rapid diagnostic tests 
Test principle: Immunochromatographic or rapid diagnostic tests (RDT) are based 
on the capture of malarial antigens.  There are several formats that are 
commercially available including dipsticks, cards and cassettes but the principle 
remains the same. Immunochromatographic procedures utilise monoclonal or 
polyclonal antibodies, conjugated to either gold particles or liposome’s containing 
selenium dye, to capture the malaria antigen of choice.  Migration of liquid across a 
nitro-cellulose membrane allows the captured malaria antigen to bind to a second 
immobilised monoclonal antibody, thus producing a visible coloured line (117). 
Antigens detected: Two malarial antigens, histidine-rich protein-2 (HRP-2) and 
parasite lactate dehydrogenase (pLDH) have been studied extensively.  Plasmodia 
aldolase is another antigen that has over the past few years been introduced (118) 
and it can be found in all species of Plasmodium (119). 
Histidine Rich Protein-2 (HRP-2):  HRP-2 is present only in P. falciparum (119). Tests 
conducted in many field studies across areas with different malaria endemicity, 
show a varied but consistently good sensitivity and specificity, ranging from 85% to 
100% (120-127). 
HRP-2 tests have performed well but because the HRP-2 antigen is present only in 
P.  falciparum, the test cannot be used for the detection of other human malaria 
parasites such as P. vivax, ovale or malariae (128). HRP-2 also persists in the 
bloodstream after malarial episodes and so the test cannot be used to monitor anti-
malarial therapy (129). 
In areas where a single species is responsible for malaria infections, an RDT for that 
specific species may be preferred especially since these have lower costs (130).  
Plasmodium Lactate Dehydrogenase (pLDH):  The metabolic Plasmodium enzyme 
pLDH is actively produced by the malaria parasite during their growth in red cells. 
All four human malarial parasites produce a unique isomer of pLDH activity (131).  
Tests for P. vivax based on specific LDH (pLDHv) has recently been developed and 
evaluated in the Republic of Korea (130) where P. vivax accounts for 99.9% of all 
malaria cases (132,133). Also, pLDH has been found to be a good marker for 
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following active malarial infections and is therefore useful in monitoring treatment 
(134). Many authors (135-137) acknowledge the monitoring potential that pLDH 
provides; since it becomes negative soon after parasite clearance. The OptiMAL® 
assay is one of the widely used commercial products that measures pLDH by a rapid 
immunochromatographic test.  
 
Performance of RDTs 
Several clinical trials using RDTs report 88-100% sensitivity and 92-95% specificity 
for the detection of P. falciparum (117,138). The sensitivity of RDTs decreases 
markedly if there are <100 parasites/µl (139). In comparative studies where 
parasite counts were less that 50 parasites/µl, RDT could not detect 50% of positive 
sample (140).  RDTs are not a replacement for microscopy but where microscopy is 
not possible, RDTs should be introduced (141). 
RDTs have been used since the early 1990s and they can perform with high 
accuracy. An issue of concern, however, is the variation in product performance in 
some published trials. There is a need for accurate, evidence based information on 
the performance for each commercially available RDT (139,142-148).  This observed 
variation may be due to poor conditions under which test materials were 
transported or kept. Quality assurance for RDTs therefore remains a key focus by 
the World Health Organisation (149). Since 2006 the WHO has embarked on an 
evaluation of commercial RDTs and so far, 118 products have been evaluated by 
2011 (150). A fourth round of evaluation has just begun (151). 
A newer generation of 3 band RDTs now use Plasmodium aldolase, a pan malarial 
antigen, in addition to HRP-2 to identify non-falciparum infections (152).  This 
combination will distinguish P. falciparum from other species but will not 
differentiate between the non-falciparum species. 
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RDT as a screening test 
RDTs can be performed faster than microscopy and generally do not require more 
than 15 minutes. They are simpler to perform and there is low subjectivity in the 
results. RDT can therefore be used to screen many donors or samples quickly. 
The main drawback for RDTs as with microscopy is the low sensitivity at lower 
parasite concentrations because healthy blood donors will likely have low 
parasitaemia. The tendency of HRP-2 tests to remain positive after treatment will 
result in false positive results and therefore more blood being rejected that 
necessary.  
RDTs have been used to screen for malaria in donors in Nigeria. An evaluation in 
donors with 2 RDTs; Optimal (based on HRP2 and Clinotech (based on msp and 
circumsporozoite protein) showed inconsistent results. Prevalence by microscopy 
was 20.2% and prevalence was 3.8% and 57.8% by Optimal and Clinotech 
respectively (103). RDTs have also been tried in countries with no or low 
transmission. In Iran (100 donors) and Turkey (2229 donors) all RDT results were 
negative compared to PCR and microscopy testing which detected 2 positive 
samples in Iran (153,154). At a regional blood centre in India, routine screening is 
done for blood donors using HRP2, pLDH and aldolase based RDTs. Of 11,736 
donated units of blood, 3 were found to be positive and they were confirmed with 
microscopy (155). 
 
Antigen detection ELISA 
Enzyme linked immunoassays have been developed that are capable of detecting 
malaria antigens (156-158). The antigen being detected is also HRP-2 as used for 
the RDTs.  In this technique, wells are coated with monoclonal antibodies against 
HRP-2 of P. falciparum. This method has been evaluated in Thailand and is 
commercially available (159). Antigen ELISA has been recommended for evaluation 
in blood banks for screening but surprisingly, there are not many published studies. 
A recent study conducted among blood donors in Venezuela found that the 
sensitivity and specificity was very high, 100% and 98% respectively (160). 
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Antigen ELISA as a screening test 
This test has similar attributes as described for RDT but an added advantage is the 
capacity to test many samples at a go because of the setup in a 96 well plate (159). 
 
Polymerase chain reaction 
The development of malaria nucleic acid amplification techniques has been based 
on the polymerase chain reaction (PCR) method. PCR is a method which is used to 
amplify nucleic acid sequences of the malaria parasite which may be present in 
blood.   Following PCR the amplification product can be detected using gel 
electrophoresis followed by ethidium bromide staining. Based on various 
modifications, different types of PCR methods exist including nested PCR, multiplex 
PCR and real time PCR. 
PCR is the most sensitive and specific method to detect malaria parasites (161). 
Sensitive PCR techniques have been developed that are capable of detecting 
parasites at a density of one per microlitre in contrast with 10-50 parasites per 
microlitre, which is the threshold of an experienced microscopist (162). There are 
PCR methods that detect less than one parasite per microlitre (0.7 parasites /µl) 
(163). Due to its superior sensitivity PCR is being proposed as the gold standard for 
the laboratory diagnosis of malaria (164,165). However, because PCR is not widely 
available, some authors’ (166,167) still maintain that microscopy is the gold 
standard.   
The PCR technique is robust (162). DNA has been extracted from samples and 
stored for duration of a few months to more than 20 years (83,168,169).  
 
Uses of PCR   
PCR now plays an important role in the molecular detection of drug resistant 
parasites.  This is performed by identifying or detecting mutations at specific points 
in the genome and which are associated with resistance. Mutations in the 
dihydrofolate reductase (dhfr), dihydropteroate synthetas (dhps) and P. falciparum 
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chloroquine resistance transporter (pfcrt) genes are some of the well defined 
molecular markers of resistance for pyrimethamine, sulfadoxine and chloroquine 
respectively (170).  
PCR is able to detect lower levels of mixed infections than was previously thought 
(171). It has also been used to differentiate between malaria re-infection and 
recrudescence. In endemic areas, where persons could be bitten by infected 
mosquitoes on a regular or daily basis, it is possible that parasites may be found in a 
patient’s blood a couple of weeks after treatment, despite the treatment being 
effective.  By using polymorphic loci studies, the presence of the same parasite 
remaining in a specimen can identified.  The most frequently used antigens for 
genotyping are merozoite specific protein 1 and 2 (MSP1 and MSP2) and glutamate-
rich protein (GLURP) (83,172-174). Methods for genotyping parasites include 
restriction fragment length polymorphism, amplified fragment length 
polymorphism, isoenzyme electrophoresis, microsatellite and single nucleotide 
polymorphism. To help standardize genotyping methods and reporting, a 
document, Recommended Genotyping Procedures to identify parasites population 
(RGP) has been produced by a collaboration of WHO and Medicines for Malaria 
Venture (172). 
 
PCR as a screening test 
PCR is currently the most sensitive method for detecting parasites and can detect 
parasites below the threshold for microscopic detection (165). Such a highly 
sensitive and specific test would be ideal especially as low parasitaemia is expected 
in donors but PCR requires an extensive capital investment. Advanced 
infrastructure is required for training personnel, quality control, maintaining 
equipment and preventing contamination (152). Such a high operational cost will 
be unaffordable for many malaria endemic countries that are also developing 
countries. It is unlikely that PCR will be suitable for routine purposes in the near 
future (165) although it may become more accessible in the longer term. 
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PCR has been compared with microscopy and HRP2 rapid detection test to screen 
blood donors in a study in Sudan (175). Using PCR as the gold standard, the 
sensitivity of microscopy and the RDT was 61.9% and 66.7% respectively and the 
specificity was 100% and 94.9% for microscopy and RDT respectively.  
 
Serology 
Serological testing is an indirect way of determining malaria infection. It involves 
the detection and measurement of Plasmodium antibodies. The indirect fluorescent 
antibody testing (IFAT) and Enzyme linked immunosorbent assay (ELISA) are the 
most commonly used methods to measure Plasmodium antibodies titres with IFAT 
being the “gold standard” (176,177). 
In malaria endemic regions, most of the adult population have had frequent 
exposure to malaria parasites and will have antibodies to Plasmodium. The 
prevalence of Plasmodium antibodies among blood donors in countries such 
Senegal and Nigeria range from 65.3% to 100% (178,179). The high detection rate 
seen in these studies would imply the exclusion of all these donors if it were used as 
a screening test. Since the presence of antibodies does not indicate a current 
infection and does not indicate infectivity, serological testing is not an appropriate 
screening test for donors in malaria endemic areas.  
 
Antibody detection as a screening test   
Screening by antibody serology has no place in malaria endemic countries. However 
in non-endemic countries there are some advantages and disadvantages. IFAT has 
been a reliable serological test for malaria for decades.  It has good sensitivity and 
specificity (180). On the other hand, the process of slides manipulation is time 
consuming (181,182) and reading the result is subjective (180).  The ELISA method 
is available in automated formats and therefore allows large volumes of samples to 
be processed quickly. There is no subjectivity with ELISA unlike in IFAT which is 
subjective especially in samples with low antibody levels (177).   
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Serological screening tests have been used in non-endemic malaria countries 
because the presence of antibodies in a donor indicates a prior exposure in the 
donor, who may then be excluded for a period depending on the guidelines in that 
country (93,183). Countries that currently screen at risk donors include the UK, 
Denmark, Finland and New Zealand (184). The enzyme immunoassays currently 
available use recombinant antigens that provide a higher sensitivity (180). 
 
2.2.4 Deferral and pre-treatment of donors 
The WHO recommends that donor selection criteria should be developed in 
endemic countries to identify and collect blood from donors at the lowest risk of 
infection, both during the malaria season and during the rest of the year (59).  It 
also recommends pre-treatment of the donors with anti-malarials if indicated (185).  
These measures are not used in most of Africa (186).  There may be several reasons 
why screening is not being done. Indeed, screening and deferral of malaria infected 
donors is believed to be impossible to implement in countries where prevalence of 
malaria is high, and where the deferral of donors will reduce by a third, the 
available amount of blood (18). 
Donor selection is difficult with healthy adults who are asymptomatic carriers as 
they will not present with fever and questioning does not identify such donors as 
carriers.   There are a few countries that defer donors in Africa. In Zimbabwe, which 
has low malaria endemicity, the approach is to question donors if they have visited 
a malaria area within the previous 21 days (187). If they have, and if they did not 
take prophylaxis, they are deferred for 6 weeks. If they have visited a malaria 
endemic area, and contracted malaria, they are deferred for 6 months after they 
have received a full course of treatment and have been clinically symptom free of 
malaria. There is no evidence of how successful this strategy has been in Africa.  In 
non-endemic countries, stringent deferral policies are in place for travellers to 
malaria endemic countries. Currently in the US, there is little risk even with the 
increased travel, and the incidence of TTM is less than 1 case per year. However the 
down side is that more than 100,000 donors are deferred, many of whom may 
never return to give blood (53). Cost effectiveness studies from Canada has shown 
34 
 
that compared to standard screening questionnaire, the addition of donor 
screening by PCR to the standard screening questionnaire is economically attractive 
(188). 
Pre-treatment as a strategy is impractical and is not commonly used.  Most donors 
in malaria endemic countries are replacement donors and they go to donate blood 
for relatives who urgently need blood. Effective treatment will require about 72 
hours and both the donor and recipient cannot realistically wait for that duration. It 
will therefore not be feasible for such donors to be treated for malaria. 
 
2.2.5 Anti-malarials in blood bag 
The in vitro processing of donor blood with anti-malarials in blood bags to kill 
parasites before the blood is transfused has been suggested as an additional 
measure to prevent TTM. Two anti-malarials, quinine and sulfadoxine-
pyrimethamine (SP) have been used experimentally and found to effective against 
parasites in blood bags (189,190).  In a study in Sudan, SP for example at a dose of 
179.65 µg/L killed 99% of all parasites within 24 hours parasites.  There are 
however concern that such an intervention can contaminate the blood bag and has 
the potential to increase the spread of resistance to the particular anti-malarial 
(191).  In vitro processing of donor blood with anti-malarials has remained an 
experimental intervention and has not been used in blood for patients. 
 
2.2.6 Presumptive medication of blood recipients 
Presumptive treatment of transfusion recipients in malaria endemic countries is 
recommended by the WHO (185) and countries such as Senegal and Kenya have 
implemented this recommendation (192). There is little data on the extent to which 
anti-malarials are currently being used as presumptive treatment.  In the past, 
administration of anti-malarials such as chloroquine to recipients of blood 
transfusions was a widespread practice. Resistance to chloroquine means that it has 
largely been replaced by the more expensive artemisinin-based therapies. This has 
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increased 5-7 fold the cost of treating all transfusion recipients with anti-malarials 
making this practice unaffordable on a wide scale (192,193). 
Opinion is divided on who should receive anti-malarial prophylaxis. While some 
follow the WHO recommendations (194-197) others in contrast recommend 
restricting malaria treatment to selected ‘at risk’ transfusion recipients such as 
neonates (34,179,198). 
Unfortunately all these suggestions are only based on expert opinion but without 
sufficient evidence. 
 
2.3 BACTERIAL CONTAMINATION AND TRANSFUSION RELATED SEPSIS 
Introduction  
Bacterial contamination of refrigerated whole blood has been a recognised 
complication of blood transfusion since the 1950’s (199). With the introduction of 
sterile, single use plastic collection sets and component therapy, the frequency of 
septic reactions decreased dramatically (64). Despite this decrease, the risk of 
bacterial contamination has remained a major cause of transfusion related 
morbidity and mortality (200-202). Among the blood components, it is recognised 
that platelet concentrates, which are stored at room temperature, provide a more 
hospitable environment for the contamination and growth of a wide range of 
organisms compared to red blood cells (RBC) which are stored at +40C (203). The 
majority of published data considers blood component transfusion with few studies 
about whole blood because the developed world now predominantly uses blood 
components and products. In sub-Saharan Africa, where whole blood continues to 
be used widely, septic transfusion reactions due to bacterial contamination have 
been described as a major but under-reported and unappreciated risk of 
transfusion (204,205). 
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Definition and classification  
The Serious Hazards of Transfusion (SHOT) scheme in the UK was one of the first 
haemovigilance systems and was launched in 1996. Transfusion-transmitted 
infection (206) were defined as a post transfusion infection in which   
 there was no evidence of infection prior to transfusion, and no evidence of 
an alternate source of infection and either  
 at least one component was donated by a donor who had evidence of the 
same transmissible infection or 
 at least one component received by the infected recipient was shown to 
contain the agent of infection 
Transfusion associated bacterial contamination is identified based on the results of 
culture of the blood of the recipient and/or the transfused unit, genotyping of the 
isolated organisms, the presence of symptoms, and the use of an antimicrobial. At 
present there is a lack of uniformity in definitions used worldwide as individual 
haemovigilance systems from different countries have different reporting systems 
and investigation requirements (207-209).  Confirmation of cases from 
haemovigilance systems are usually retrospective as the transfusion reaction which 
has occurred must be investigated before a final confirmation can be made. A 
classification by the Canadian Haemovigilance system (210) based on confirmation 
of a set of criteria is shown in table 2.2. 
Consensus definitions for all bacterial events are being developed jointly by the 
International Society of Blood Transfusion Working Parties on transfusion-
transmitted infectious diseases and haemovigilance to harmonise the current 
situation (211). 
 
 
 
 
37 
 
Table 2.2: A classification system for transfusion-transmitted bacterial contamination 
Possible  
Bacterial contamination is considered “Possible” if it meets the following criteria:  
 The recipient's blood culture is positive.  
 Contamination of the blood sample or laboratory contamination is not suspected.  
 The recipient presents signs and symptoms of sepsis (nothing else explains it).  
 A blood, blood component, or blood product (plasma derivative) cultures was not 
done.  
 No specimen was available  
 A blood culture was not ordered  
 
Probable  
 Bacterial contamination is considered “Probable” if it meets the following criteria:  
 Positive blood, blood component, or blood product (plasma derivative) culture.  
 Contamination of the blood sample or laboratory contamination is not suspected.  
 The recipient presents signs and symptoms of sepsis (nothing else explains it).  
 The recipient's blood culture was not done.  
 No specimen was available.  
 A blood culture was not ordered.  
 The recipient's blood culture is negative.  
 The recipient is already taking antibiotics.  
 
Definite  
Bacterial contamination is considered “Definite” if it meets ALL of the following criteria:  
 The same bacteria are found in the recipient and the blood, blood component, or 
blood product (plasma derivative).  
 Contamination of the blood sample or laboratory contamination is not suspected. 
 
 
2.3.1 Epidemiology of bacterial contamination 
The precise incidence of bacterial contamination of blood and blood products is 
unknown. This is because different studies use variable methods of detection and 
apply different case definitions (212). In addition, the number of confirmed and 
reported cases of bacterial sepsis can be considered the tip of the iceberg because 
there are many more cases which could not be confirmed and others that may have 
had no apparent harm and therefore not reported (211).  Despite these 
underestimations, bacterial contamination has become the most common 
infectious risk from transfusion (213), in part due to the success with reducing viral 
transmission (214).  
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In the US, bacterial contamination poses a greater infectious threat in transfusion 
medicine than combined risks of receiving a blood product or component 
contaminated with HIV-1 or 2, hepatitis C virus, hepatitis B virus, and human T-cell 
lymphotrophic virus I or II (215). Surveillance reports from the UK between October 
1996 and December 2009 also show that bacteria are the commonest cause of 
transfusion-transmitted infections. Forty out of 66 reported incidents (60%) of 
transfusion-transmitted infection within the period were due to bacteria compared 
to 17 (25%) that were due to viruses including HBV, HCV, HEV, HIV and human T-cell 
lymphotrophic virus (HTLV) (98).  Similarly, from 1997 and 2007 in Germany, 71 
cases of confirmed transfusion related bacterial infections compared to 46 
confirmed cases of transfusion associated virus infections were reported (216).  
Studies across Europe and North America show that the rate of bacterial 
contamination in platelets is about one per 1-3,000 units, while clinical sepsis or 
septic transfusion reactions is 1 per 5-20,000 transfusions (208,217-219).  Blood and 
blood component haemovigilance data from France shows that the risk of bacterial 
transfusion reaction in apheresis platelet concentrates is 69.1 per 1,000,000 units 
and for RBC’s is 10.4 per 1,000,000 units. The risk for whole blood is 12.9 per 
1,000,000 units.  The risk of a fatal outcome per 1,000,000 units is 12.0, 0.7 and 1.1 
for platelets, RBCs and whole blood respectively (220). 
Few studies have investigated bacterial contamination in blood transfusions in sub-
Saharan Africa. There are two studies from Ghana and one from Kenya. The 
frequency of bacterial contamination of paediatric whole blood in Kenya was 8.8% 
(205) and that for whole blood in Northern Ghana was 17.5% (36). Another study in 
Southern Ghana (37) found a 9% overall contamination rate in blood and blood 
components.  Contamination in whole blood alone was 13% (24/192), surprisingly 
higher than bacterial contamination of platelets which was 9% (2/22) although the 
number of platelets screened was small (37). All three studies in Africa did not 
follow up the transfusion recipients to determine the occurrence of any septic 
reactions or adverse events.  The contamination frequency reported in Kenya is 
2500 times greater than that of bacterial contamination RBCs in developed 
countries (205).   
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Organism and the sources of contamination 
Organisms 
A wide spectrum of organisms has been associated with transfusion-transmitted 
bacterial infection including skin, enteric and environmental organisms. 
Staphylococcus epidermidis, S. aureus, other coagulase-negative staphylococci and 
Bacillus spp are the common organisms which contaminate platelets.  Yersinia 
enterocolitica and Pseudomonas spp commonly contaminate RBC (221). A summary 
of the reported organisms are shown in table 2.3 with Y. enterocolitica being the 
most common. Most of the bacteria associated with transfusion reactions are 
aerobic or facultative species but a few anaerobes such as Propionebacterium acnes 
and Clostridium perfringes have been associated with septic reaction (222). 
Table 2.3: Distribution of organisms responsible for bacterial contamination of blood 
components 
RBCs Platelets 
Yersinia enterocolitica – 46% Staphylococcus spp – 42% 
Pseudomonas spp – 25% Streptococci spp – 12% 
Serratia spp – 11% Escherichia coli – 9% 
Others – 18% Bacillus spp – 9% 
 Salmonella spp – 9% 
 Serratia spp – 8% 
 Enterobacter – 7% 
 Others – 4% 
           (Adopted from Wagner SJ 2004 (223)) 
 
Sources 
Organisms that contaminate blood or blood components will generally come from four 
main areas (213). These are: 
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1. Donor bacteraemia 
2. Donor arm contamination 
3. Contaminated collection equipment 
4. Contamination during processing and storage. 
These four areas from which bacterial contamination occurs can be grouped into 
two sources; endogenous (donor bacteraemia) and exogenous (donor arm 
contamination, contaminated collection equipment and contamination during 
processing and storage) sources of infection. 
 
Endogenous sources  
Endogenous sources occur when the organisms are circulating in the donor blood 
and are then taken into the blood pack.  It is expected that donors who are unwell 
will not be allowed to donate. Donors however may feel well but have bacteraemia 
(asymptomatic) or may have undergone a minor surgical or manipulative procedure 
which will cause a transient bacteraemia. Examples of organisms which have been 
implicated with endogenous sources are Yersinia enterocolitica, Salmonella spp, 
Bacteroides spp and streptococci (224,225). Y. enterocolitica causes enterocolitis, 
characterised by diarrhoea, low grade fever and abdominal pain in the donor and 
about 75% of implicated blood donors recalled having had diarrhoea in the days 
preceding or following their blood donation (226).  
 
Exogenous sources  
Exogenous sources refer to organisms which contaminate blood from outside the 
body (i.e. from skin, collection equipment or during processing and storage (224). 
Contamination during collection is the major cause of bacterial contamination of 
platelet units and the majority of the organisms are normal skin flora (227).  In an 
interesting report, Serratia marcescens was found to have contaminated transfused 
blood. A follow up investigation identified 0.73% of 1515 blood bags were 
contaminated (228).  Bacteria implicated in transfusion-associated sepsis are 
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typically endotoxin-producing Gram negative bacilli that are found in soil, water and 
faeces, such as Y. enterocolitica, Pseudomonas spp, Escherichia coli and Salmonella 
spp (61,229) . 
 
2.3.3 Pathogenesis 
Bacteria may undergo three general phases when in contaminated blood. 
Lag phase 
Initially, low numbers of bacteria (between 10-100)  may be present in blood/blood 
components but non-specific host defence mechanisms including complement 
activation in the presence of plasma or phagocytosis  by leukocytes after 
opsonisation can eliminate or inactivate the bacteria (230). This can be described as 
the self limiting phase.  There are instances when bacteria may survive in the blood 
but will not multiply. Those that survive begin to multiply and enter the exponential 
phase (231). Different bacteria exhibit variable lag phases and this adds to the 
uncertainty of a reliable detection time (232). 
 
Exponential phase 
This phase may also be referred to as phase of continuous growth. A bacterial load 
of less than 20 in the component of blood can grow up to 108-9/ml and this accounts 
for life threatening complications of transfusion (233). The exponential phase ends 
when available nutrients are exhausted or due to accumulation of toxic products of 
metabolism. 
 
Death phase  
This phase occurs because of depletion of cellular reserves. In this phase there may 
not be bacteria alive but sufficient endotoxin may have been produced to cause 
severe morbidity and mortality (231). 
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Severe sepsis and shock are the consequences of a generalised and uncontrolled 
inflammatory response to infection, rather than the direct effect of microorganisms 
(234,235).   The severity of the clinical presentation depends on both inoculum and 
bacterial virulence (236).  Higher bacterial concentration and more virulent 
organism present with severe reactions. 
 
2.3.4 Factors promoting bacterial contamination 
Inadequate skin disinfection 
Contamination, especially from the skin is most common during blood collection 
(237). This happens because even after disinfection, some bacteria remain on the 
skin and the hypodermic needle used for phlebotomy becomes inadvertently 
contaminated. Bacteria can remain deep in the skin sweat glands and contribute to 
contamination (66).   Skin that has several folds, has been scarred or dimpled 
provides an environment where skin bacteria can grow and are protected from 
disinfectant (238). This has been observed in frequent donors who have been 
scarred from repeated needle pricks.   
 
Storage conditions of blood 
Platelets are the components of blood that have the highest frequency of bacterial 
contamination (202).  Whereas red cells and whole blood are stored refrigerated, 
platelets are stored at room temperature and thus provide a suitable environment 
for bacterial proliferation. For most bacterial species, growth in platelet units can 
occur, rapidly reaching the log phase within 24-48 hours. An exception is 
Staphylococcus epidermidis which is a slower growing organism and reaches the log 
phase in 48-72 hours.  
In blood banks of countries with unstable economies, erratic or no electricity 
supply, whole blood may not be stored under optimum refrigeration conditions 
(205) and therefore may be subjected to similar risk as platelets for bacterial 
contamination and proliferation. Certain bacteria such as Yersinia spp and 
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Pseudomonas spp can survive in temperatures of 2-8oC and may therefore cause 
bacterial contamination and sepsis even when blood is stored under refrigerated 
conditions (239). 
 
Paediatric transfusion practices 
A further risk factor for bacterial contamination is the practice where, for lack of 
pre-prepared small volumes of blood for paediatric transfusions, small volumes are 
drawn from the standard larger ones for individual patients. This results in a breach 
of the integrity of a closed system (205). 
 
2.3.5 Presentation of transfusion related sepsis 
Clinical presentation of transfusion induced sepsis may vary depending on the state 
of the patient and also on the type of organism causing the bacterial 
contamination. Potential signs and symptoms observed are listed in Table 2.4 (240).   
 
Table 2.4: Signs and symptoms of transfusion related sepsis 
 Fever (temperature 38.0⁰C or higher) or an increase in temperature 
of more than 1.0⁰C 
 Tachycardia (heart rate ≥ 120/min) or an increase in heart rate of 
more than 30/min 
 Rigors/chills 
 Hypotension (drop in systolic blood pressure of more than 30mm 
Hg) 
 Nausea, vomiting, diarrhoea, dyspnoea, bleeding, oliguria or other 
symptoms of shock 
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The onset of clinical signs is usually rapid and occurs during or shortly after 
transfusion (241).  Fever and chills will typically present first, within 2 hours of 
transfusion. Subsequently, nausea and vomiting follows and patient can rapidly 
progress into haemodynamic shock. 
Blood heavily contaminated with Gram negative bacteria introduces large amounts 
of both the microorganism and endotoxin into the circulatory system, leading to 
rapidly developing severe sepsis or shock (225). 
In recipients who are ill prior to transfusion, signs may be missed or misconstrued 
to be previously existing , leading to misdiagnosis and death (242,243). 
 
Mortality 
Reported case fatality rates in transfusion associated septic reactions range from 
17.4 to 31.3% for platelet transfusions and 24 to 60% for RBCs (207,208,218) . 
Transfusion associated sepsis is the most frequent cause of death from infectious 
agents of transfusion, representing 17-22% of all fatalities (223). In the US, 
transfusion-transmitted sepsis is the third most reported transfusion related 
fatalities reported to the Food and Drug Administration (FDA) and 68% of the 
deaths were due to Gram negative organisms, Klebsiella pneumoniae being the 
commonest isolated organism (244).  
Gram negative bacilli are associated with a particularly poor outcome. Yersinia 
enterocolitica sepsis for example has an overall fatality rate of 54.5% (225). 
Providencia rettgeri is an opportunistic pathogen usually associated with severe 
burns or long term indwelling catheters but it is a rare cause of transfusion fatality 
(245). Coagulase negative staphylococci have also been associated with death 
(246). 
 
2.3.6 Detection of transfusion associated bacterial contamination 
The introduction of better detection methods for viruses and the subsequent 
successful reduction of the risk of viral transmission via blood components, has 
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focused attention on the risk of transfusion associated bacterial sepsis (241).  
However recovery of bacteria from blood/blood products may depend on the 
number of bacteria present and the provision of appropriate conditions for growth. 
Strategies to detect the presence of bacteria in blood components include 
 Quality control testing 
 Routine surveillance screening or other pre-release testing 
 Visual inspection of components prior to issue from the blood centre, at the 
hospital transfusion laboratory, and at the bedside prior to administration 
 Careful monitoring of patients during and after transfusion  
 
Some countries now have routine pre-release surveillance screening of platelets, 
because of the high risk of contamination associated with platelets. The 
introduction of routine culture of platelets in the US and Canada has reduced the 
risk of septic transfusions by 50% (247). 
Surveillance can be active or passive. In active surveillance, units are tested prior to 
transfusion, and any units found to be contaminated are either discarded (if the 
results are available prior to transfusion) or tracked to determine any adverse 
outcomes (if results are available only after transfusion).  With passive surveillance 
clinically apparent transfusion reactions following a transfusion are examined 
retrospectively and testing of units is performed if samples are available. Passive 
surveillance greatly underestimates incidence of contamination (248).  Studies have 
shown that active surveillance detected 32-fold more bacterially contaminated 
platelet units and 10.6-fold more septic reactions than passive surveillance (236). 
 
Detection systems 
Various methods exist for bacterial detection. There are two broad categories for 
detection of contaminated platelet components; initial release tests and point of 
issue tests which are performed immediately prior to transfusion to prevent the 
transfusion of platelet components contaminated with high levels of bacteria that 
may cause severe clinical septic events. The technologies available for detection 
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include: visual inspection; measurement of glucose and pH levels; Gram stain; 
oxygen consumption; carbon dioxide production; detection of bacterial nucleic acid 
sequences; fluorescent flow cytometric detection of bacteria; endotoxin detection; 
bacteria-specific antigen detection; and automated bacterial culture (249). None of 
these tests are used routinely for whole blood. 
Bacterial culture: Bacterial culture is used as an initial release test for platelet 
components. Two culture systems in use are the automated liquid culture system 
(BacT/ALERT) and the Pall enhanced Bacterial Detection system (eBDS) (250). The 
Bactec and VersaTREK systems have also been validated and are sometimes used. 
The eBDS is used to detect contamination in platelet units using measurement of 
reduction in oxygen concentration resulting from bacterial growth. Consisting of a 
disposable sample pouch, an incubator and an oxygen analyser, the system is 
incubated for 24 hours after the sample is introduced. The oxygen levels are then 
analysed to obtain a result. In a study comparing detection of low bacteria (1-
10CFU) at 24 hours and 30 hours, eBDS had detection rates of 95% and 97% 
compared to Bactec detection rates of 89% and 94% (251).  
The BacT/Alert system is considered to be the gold standard for detection of 
bacterial contamination of platelet concentrates (252). The assay is validated to 
detect common contaminants at concentrations as low as 1 to 10 colony forming 
units (253).  Although BacT/Alert has reduced the risk of transfusion of bacterially 
contaminated platelets, the method is not ideal because of false negative results 
(254). 
 
Other detection systems 
Flow cytometry is less sensitive than culture but it is suitable for testing platelets 
prior to transfusion. It is fast and relatively simple and uses equipment and 
techniques widely available in many developed country laboratories (255). 
Molecular methods such as real-time PCR show high sensitivity and specificity, with 
results available within hours. Such methods are now being recommended as a 
suitable alternative to culture methods (256).  
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Other methods of detection which are used prior to transfusion are measurement 
of pH and glucose (223,257).  
 
Monitoring of patients 
With the exception of platelets, blood or blood components are not routinely 
screened for bacteria. Monitoring of transfusions for septic reactions is a way of 
identifying bacterial contamination. Look-back investigations reveal that recipients 
may display signs indicative of a possible acute transfusion reaction which are not 
reported or investigated (258). Early recognition and reporting of signs with 
subsequent investigations will improve diagnosis.  
 
2.3.7 Prevention of transfusion-transmitted bacterial infection  
A combination of measures is needed to prevent or reduce bacterial contamination 
of blood. This is because there are multiple ways in which contamination can occur 
and therefore all efforts must be made to address each potential source.  
General measures 
Continuous training and efficient supervision is required to ensure optimal product 
processing, handling and storage of blood.  
General infection control measures such maintaining clean fridges, blood warmers 
or water baths and containers for transporting blood.  Monitoring of fridges for a 
consistent storage temperature 40C for whole blood is important to ensure product 
integrity.  
 
Donor deferral 
It is helpful to ask donors about recent dental procedures or minor procedures 
which could lead to transient or asymptomatic bacteraemia. Other specific 
questions to identify osteomyelitis are useful (241). Donors with such risk factors 
should be deferred. Although about half of donors implicated in Yersinia 
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enterocolitis have had gastrointestinal symptoms in the 30 days before donation, 
about 13% of all donors have had gastrointestinal symptoms in the previous 30 
days (226,259,260). Gastrointestinal symptoms in the 30 days before donation are 
therefore neither sensitive nor specific for Yersinia bacteraemia. Gastrointestinal 
symptoms should not be used as a donor question because it will screen out an 
unacceptable number of healthy donors.  
 
Donor skin disinfection 
Universally applied effective donor skin cleansing is an obligatory requirement to 
minimise the incidence of post transfusion septicaemia (224). A fatal case of 
transfusion-transmitted Clostridium perfringens sepsis (261) was attributed to 
faecal contamination of the skin of the donor and this highlights the importance of 
skin cleansing. Improving donor skin disinfection is a critical target for prevention 
(243). Skin cleansing does not totally eliminate contamination but just minimises 
the risk. This is because skin disinfection only reduces the load of bacteria present 
on the skin (262,263). 
 
Diversion of donor blood 
Diversion is based on the principle that contamination from the donor’s skin will be 
present in the initial flow of blood and therefore a redirection of the initial flow of 
blood from the collection bag into a pouch reduces the contamination. Diversion of 
blood alone reduces contamination with skin bacteria in both whole blood and 
platelets by 50% (264). When diversion of blood is performed in combination with 
improved donor skin cleansing, there is a reduction of bacterial contamination by 
47-77% (265).  
 
Bacterial detection 
Culture based pre-release screening of platelet concentrate with early sampling has 
been proven to detect bacteria and to prevent transfusion of some but not all 
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contaminated units (266). In a study of one million apheresis platelet concentrates, 
the rate of septic reactions decreased from 18 to 5.4 reactions per million 
transfused units but the fatality rate did not decrease (247).  Current bacterial 
detection systems are unable to completely eliminate the risks associated with 
bacterial contamination and none of the currently available laboratory techniques 
are ideal (217) 
 
2.3.8 The challenges in transfusion-transmitted bacterial contamination 
Detecting bacterial contamination before it causes harm in a transfusion recipient 
poses particular challenges. Unlike the situation for viruses where the donor is the 
source of infection and therefore pre-donation testing can be performed, bacterial 
contamination can occur during collection or storage and therefore the ideal time is 
to screen just before the blood is used. Blood culture results are not immediately 
available, and therefore recipients will receive the blood before it is determined 
whether the blood is contaminated or not. Other quicker methods such as glucose 
or pH determination are insufficiently sensitive. 
The major challenge is to use tests that provide high sensitivity and specific results 
at or near the time of blood unit issue (222). Another dilemma is whether to accept 
all coagulase negative staphylococci as pathogens capable of producing harm in the 
recipient since they are usually skin contaminants (221) 
 
Pathogen reduction  
Pathogen reduction offers a pro-active approach to further reduce the risk of 
transfusion infections (230). Many techniques exist for pathogen reduction. 
Pathogen inactivation techniques such as methylene blue and solvent-detergent 
have been used for treatment of plasma intended for transfusion. Photochemical 
treatment with amotosalen and ultraviolet A light have also been used for fresh 
frozen plasma and platelets (169,202). Using log reduction assays, the efficacy of 
these procedures to reduce bacterial contamination has been demonstrated 
(267,268).   Pathogen inactivation techniques have been used widely and 
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successfully in Europe but not in North America (184,269). Reasons for slow 
acceptance of these methods include concerns about safety (including 
carcinogenicity), cost effectiveness and the inability to inactivate certain pathogens 
such as spore forming bacteria, (202,269,270). 
An advantage of pathogen reduction techniques is that they are not limited to 
bacteria but can be applied to many other pathogens. In addition, these techniques 
can be effective in window periods where regular screening methods may be 
unable to detect pathogens.  The use of pathogen inactivation techniques in whole 
blood or RBCs has been a challenge because of the absorption of light by 
haemoglobin. The Mirasol pathogen reduction technology system which uses 
riboflavin (vitamin B2) and UV light has recently  been used successfully in whole 
blood against various bacteria and other pathogens (271,272), So far, no treatment 
related toxicity has been identified with the Mirasol system (273). More evaluation 
is however needed. 
Multi-component pathogen reduction implementation may lead to potential 
savings. Elimination or reduction of many donor screening assays, including 
bacterial testing of platelets, and reduction of donor exclusions based on 
geography, may help to offset the cost of the process (274). When pathogen 
reduction becomes available for all components and is adopted by the transfusion 
medicine community, then blood supply may finally reach the goal of near zero risk 
(66). 
 
2.4 TRANSFUSION-TRANSMITTED SYPHILIS 
Introduction  
Syphilis is an infectious disease caused by the spirochete Treponema pallidum 
subspecies pallidum.   Transmission is by direct contact with lesions or body fluids 
(275) but it can also be transmitted vertically from a mother to her baby (276), or 
through receiving a blood transfusion (277).   When syphilis is acquired through the 
transfusion of blood or blood product, it is referred to as transfusion-transmitted 
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syphilis. Transfusion-transmitted syphilis is one of the oldest recognised infectious 
risks of blood transfusion (278).   
 
2.4.1 Epidemiology 
Syphilis in the general population  
Syphilis remains a major public health problem in the world (279).  The WHO 
estimates that 12 million new cases of syphilis occur worldwide each year, mostly in 
developing countries where access to sexually transmitted disease laboratory 
services are limited (280,281).  In South Africa, a syphilis sero-prevalence of 10% for 
women attending antenatal and family planning clinics and between 24%-42% in 
high risk groups has been reported (282). Studies in Ghana have found the 
prevalence to vary from 4.9% to 16.5% ((46,283,284). It is important to know the 
prevalence of syphilis in the general population because such information provides 
clues of disease patterns or outbreaks and may reflect the situation in the blood 
donor population In Ghana for example, the high sero-prevalence reported for 
syphilis in parts of the Central region led to the identification of yaws.   
 
Re-emergence of syphilis 
In recent years there has been an increase in cases of syphilis in some parts of the 
developed world such as in Russia, Australia and the UK (285-287). New cases in the 
UK are reported to have increased eight fold over a five year period, from 1997 to 
2002 (288). The increases are due to outbreaks in particular communities (289-
291).  
Syphilis in North America and Western Europe, and particularly in the UK, has re-
emerged mainly as a disease in injecting drug users and men who have sex with 
men (292,293).  The re-emergence of syphilis in the Russian Federation, Eastern 
Europe and China has been associated with social upheaval and is a potential 
contributor to burgeoning HIV epidemics in these countries (285,294).    
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An increase in recently acquired syphilis in the blood donor population in the UK, as 
observed by Brant et al indicates that risky sexual behaviours are increasing, with 
implications for the microbiological safety of blood (295). In general, a resurgence 
of sexually transmitted diseases in a community may represent an increase in risk in 
the blood donor population. 
Africa does not appear to have seen such epidemics although the data is very 
limited. In the Gambia, for example, the prevalence of syphilis has decreased 
significantly from 11.2 % in 1994 to 1.5% in 2007 (296)  
 
Markers of syphilis in blood donors 
Syphilis sero-positivity in blood donors varies across the world (297) but some 
countries such as the UK have traditionally had low sero-positive rates. The current 
prevalence of syphilis sero-positivity in the UK is 3.7 per 100,000 (298). Among 
donors in Albania, sero-positivity is 70 per 100,000 (299) and that for Italy is 7 per 
100,000 (300). 
In sub-Saharan Africa, the sero-reactivity among donors is generally higher than 
that in developed countries but rates vary from country to country. Sero-reactivity 
has been reported to be as low as 0.05% in Egypt, (301) 0.8% in Senegal (178)  and 
1.2% in Mozambique (302) compared to higher rates such as 9.1% in Cameroon 
(303) and 8% in Nigeria (304).  The prevalence of syphilis sero-reactivity in Ghanaian 
donors is high, ranging between 7.5% and 13.5% (38,39).  
The differences in reactivity reported in specific regions may relate to variation in 
high risk behaviour but may also be accounted for by the kind of donors that are 
screened.  Statistics from the UK (298) shows that first time or new donors have a 
higher sero-positivity (25.4 per 100,000 donations) than repeat donors (0.9 per 
100,000 donations).  It was previously thought that voluntary non-remunerated 
blood donors were safer than family/replacement donors but current evidence 
shows that first time VNRD are no safer than family or replacement donors. Rather, 
repeat donors, whether VNRD or replacement are the safest donors (13).  This has 
been seen in Africa; and also in the US where syphilis sero-positivity in repeat 
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donors and first time donors in the US was 5.7 and 135.2 per 100,000 respectively 
(305).  Sero-reactivity in Nigeria is also higher in commercial (7.5%) than in non-
commercial donors (0.5%) (304).   
The use of different screening tests and/or screenings algorithms may be another 
reason for the different sero-reactivity between countries.  Adjei et al determined 
the sero-positivity of syphilis in blood donor to be 7.5% using a combination of 
Venereal Disease Research Laboratory (VDRL) and Treponema pallidum particle 
agglutination (TPPA) assays (38) whereas in a similar population, a sero-reactivity of 
13.5% was reported when TPPA was used alone (39).  
 
Syphilis in transfusion recipients 
Over 200 cases of transfusion-transmitted syphilis have been published in the 
English literature (306) but over the past 40 years, there have been only 3 reported 
cases of transfusion-transmitted syphilis (307-309).  These cases occurred in the US, 
Indonesia and the Netherlands respectively and in all the 3 cases, initial serological 
screening of donated blood was negative for syphilis and fresh blood was 
transfused.  
The reduction in the risk of acquiring syphilis by transfusion may be due to a 
number of factors including the improved donor selection processes, universal  
serological screening of all blood donors and the shift to usage of refrigerated blood 
components (278).   
There may also be the possibility that clinicians do not diagnose or misdiagnose 
transfusion-transmitted syphilis.  This is because when a disease is reported as 
rarely as transfusion-transmitted syphilis, clinicians are unlikely to recognise a case 
when it occurs.  It has been suggested that a patient who has received a blood 
transfusion and develops unexplained symptoms even months after the 
transfusion, should be checked for syphilis (309).  Also, because it is difficult to 
exclude sexually transmitted syphilis, transfusion-transmitted cases may be 
excluded erroneously (277). 
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2.4.2 Clinical presentations 
Clinical manifestation of venereal syphilis  
Staging and presentation: Syphilis is a chronic infection with diverse clinical 
manifestations that occur in distinct stages. These stages include the incubating, 
primary, secondary, latent and the tertiary stage.  Primary syphilis is characterised 
by a chancre which is painless and occurs at the site of inoculation, most commonly 
the genitalia (310) but can also appear in the mouth and anal mucosa.  T. Pallidum 
then disseminates from the primary chancre through the blood till secondary 
syphilis becomes apparent.  Secondary syphilis is characterised by systemic 
symptoms such as fever, malaise, weight loss and widespread erythematous rash 
(311). 
Symptoms of primary syphilis occur between 10 and 90 days following exposure 
and secondary syphilis 4-10 weeks following the appearance of the primary chancre 
(312). If untreated, the rash gradually fades and the disease enters a latent phase 
during which the patient is sero-positive but asymptomatic and this phase can last 
from a few months to many years (277). Tertiary syphilis is the tissue-destructive 
phase that appears 10 to 25 years after the initial infection in up to 35% of 
untreated patients (313).  
Complications: Complications of syphilis include central nervous system disease, 
cardiovascular abnormalities, eye disease and granuloma-like lesions called 
gummas that can occur in any organ.  Untreated syphilis during pregnancy may 
have serious consequences for the child including spontaneous abortion, stillbirth, 
premature birth or perinatal death (314).   
 
Clinical manifestation of transfusion-transmitted syphilis 
The incubation period for transfusion-related syphilis is between 4 and 14 weeks (6-
8 weeks on the average) and is inversely proportional to the number of live 
treponemes transfused (306).  In contrast to sexually transmitted syphilis, there is 
no primary stage for transfusion-transmitted syphilis.  The disease progress 
immediately to the secondary stage with a generalised rash (307), 
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lymphadenopathy (308) and systemic symptoms and then follows the natural 
course of the sexually transmitted disease if left untreated (315). 
 
2.4.3 Diagnosis of syphilis 
The diagnosis of syphilis depends on clinical findings, examination of lesion material 
and serological tests (316). This section will focus on laboratory diagnosis. Diagnosis 
may be by direct detection or by serological testing (treponemal or non-
treponemal). Serological testing has been recommended for screening blood 
donors (317). 
 
Microbiology of Treponema pallidum 
Treponema pallidum is a fastidious, micro-aerophilic spirochete that has 4 
subspecies; subspecies pallidum causes venereal syphilis, subspecies endemicum 
causes endemic syphilis, subspecies pertenue causes yaws and subspecies carateum 
causes pinta (311). Treponema pallidum stain poorly with Gram’s or Giemsa’s stain 
and cannot be cultured in vitro (318). 
In humans, anti-treponemal IgM antibodies are detectable within two to three 
weeks after infection and IgG detectable about two weeks later (319). The 
detection of these antibodies forms the basis of serological tests and diagnosis, 
especially given the inability to grow the organism in vitro. 
 
Direct detection  
The identification of the spirochete T. pallidum by direct detection is most 
productive during primary, secondary, infectious relapsing and early congenital 
syphilis, when moist lesions containing large numbers of treponemes are present.  
Direct detection can be by animal inoculation, by microscopy or by using nucleic 
acid amplification methods such as the polymerase chain reaction (PCR).   
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Animal inoculation 
Numerous animal species from hamsters to chimpanzee have been used to either 
maintain treponemes or determine infectivity but not all develop visible signs of 
infection or reactive serological tests (320).  The rabbit model has been shown to be 
the best and subsequently, Rabbit Infectivity Testing (RIT) has become the gold 
standard for syphilis infectivity testing (321). Briefly, inter-testicular or intradermal 
inoculation of the rabbit with the infected fluid causes formation of a localised 
tissue lesion that remains infective for life. Blood may be transferred to another 
animal and cause a positive serological test for syphilis. Results from RIT can take up 
to between 3 to 6 months (318), making it impractical to use for screening blood 
donors or for clinical management. 
RIT is used as the gold standard to measure the sensitivity of methods such as PCR 
(322,323). Because this test is impractical and expensive, it is used only in research 
settings and as a sensitivity reference for PCR testing (324).  
 
Microscopy 
The association between syphilis and T. pallidum was first demonstrated by 
Shaudinn and Hoffman on Giemsa-stained smears of fluid from secondary syphilitic 
lesions in 1905 (316).  The dark field examination or immunofluorescent staining of 
specimens from muco-cutaneous lesions is the quickest and most direct laboratory 
method of establishing a diagnosis (324,325).  The sensitivity of the dark-field 
examination approaches 80% (326)and that for the fluorescent testing approaches 
100% when fresh lesions are examined (327). The presence of motile spirochetes 
may be seen using low power microscopy but to verify their long and tightly coiled 
to spiral shape, oil immersion with a 1000X magnification should be used. Although 
the dark field examination depends greatly on technical expertise and the number 
of organisms in the lesion, it can be highly specific when performed on genital 
lesions (311).  The concentration of treponemes in blood is too low to be detected 
by microscopy (275)  and therefore microscopy cannot be used for blood donors.  
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Polymerase chain reaction 
Polymerase chain reaction (PCR) allows direct detection of T pallidum (328). 
Sensitivity and specificity of 94.7% and 98.6% respectively has been reported for 
PCR in samples from lesions in early or primary syphilis (329) but in blood samples 
of donors exhibiting IgM reactivity, PCR is only able to confirm about 25% of 
infections (330). This suggests a low specificity of IgM antibody assays.  PCR is not 
used routinely to screen donors for syphilis.  A recent evaluation of T. pallidum real-
time PCR found it to have no added diagnostic value for secondary syphilis (331).  
The disadvantage of PCR is that it is expensive and is not readily available to many 
centres. 
 
Serology 
Serological tests remain the method of choice for diagnosing syphilis (332).  
Serological test for syphilis can be divided into two main groups; the non 
treponemal and treponemal tests.   
 
2.4.4 Non treponemal tests 
Non treponemal (Reagin) test measure immunoglobulin M (IgM) and G (IgG) 
antibodies to lipoidal antigen released from damaged host cells as well cardiolipin 
released by the treponemes (333,334). This release occurs between 3 to 6 weeks 
after infection making non treponemal tests most sensitive at that time (335).  
Venereal Disease Research Laboratory (VDRL) /Rapid Plasma Reagin (RPR)  
The 2 most commonly used non treponemal tests are Venereal Disease Research 
Laboratory (VDRL) and Rapid Plasma Reagin (RPR) test. Each of these tests is a 
flocculation test, in which soluble antigen particles are coalesced to form larger 
particles that are visible as clumps when they are aggregated by antibodies (311).  
Both tests have the same sensitivity and specificity but their reactivity levels may 
differ because of the variation in antigen preparation (324) 
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RPR and VDRL titres are raised in patients with acute syphilis infection, re-infection 
or reactivation of a past infection that has not been treated (336).  Nontreponemal 
tests are therefore useful not only in identifying active infection but also in 
monitoring the effectiveness of treatment (332).   Nontreponemal tests can be used 
as qualitative or quantitative tests.  They are qualitative when used as initial 
screening tests and they are quantitative test when used to follow treatment. The 
quantitative VDRL/RPR test should become nonreactive 1 year after successful 
therapy in primary syphilis and 2 years after successful therapy in secondary syphilis 
(336,337). 
General advantages and disadvantages:  Nontreponemal tests have the advantage 
of being widely available, with good sensitivity, are simple to perform, and 
inexpensive (324).  They are also convenient to perform on large numbers of 
specimen and are necessary for determining the efficacy of treatment.   However, 
they require cold storage for reagents and samples, and electricity to operate a 
centrifuge (338) and so these tests have not been used often at the primary health 
care settings (332). Other limitations are false positives and the possibility of a 
prozone reaction, which is a false negative test results due to very high 
concentrations of antibody (339).  Biological false positives may occur in as many as 
25% of pregnant women (340).  
 
2.4.5 Treponemal tests 
Treponema pallidum immobilisation (TPI), Treponema pallidum particle 
agglutination test (TPPA), Treponema pallidum hemagglutination assay (TPHA), 
Microhemagglutination assay (MHA-TP), Enzyme immunoassay (EIA) and 
Fluorescent treponemal antibody absorption test (FTA-ABS) are examples of 
treponemal tests.  These tests in general cannot differentiate between syphilis and 
other treponemes such as yaws and pinta (341). This is because they detect 
antibodies directed against treponemal cellular antigens.  The major disadvantage 
of the treponemal test is that once positive, they have limited usefulness because; 
they tend to yield positive results for the rest of the patient’s life.   
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Treponema pallidum immobilisation 
TPI was the first treponemal antibody test (324) but because it is complicated, 
technically difficult, time consuming and expensive to perform, it is rarely used 
today.  Only a few research laboratories have maintained the capability to perform 
the test. It determines the ability of antibody plus complement to immobilize live T. 
pallidum as visualised under a dark field microscope (333). It is less sensitive and 
specific than the other treponemal tests (342).   
 
Fluorescent treponemal antibody absorption test 
 The fluorescent treponemal antibody absorption test (FTA-ABS) detects two 
antibodies; the first called a group antibody reacts with antigens shared with other 
treponemes.  This antibody is present in low titres in most normal non-syphilitic 
sera and may be a biological balance between natural and immune antibody, or it 
may be produced after exposure to other commensal treponemes in the body 
(343). The removal of the group antibody by adsorption, allows for the detection of 
the 2nd T pallidum-specific antibody.  The FTA-ABS test is performed by overlaying 
whole treponemes that are fixed to a slide with serum from patients suspected of 
having syphilis because of a previous positive VDRL or RPR.  The patient’s serum is 
first absorbed with non-T. pallidum treponemal antigens to reduce nonspecific 
cross-reactivity.  Fluorescein-conjugated antihuman antibody reagent is then 
applied as a marker for specific anti-treponemal antibodies in the patient’s serum 
(311).     The FTA-ABS test is considered as the gold standard for treponemal tests 
(344) but it has a number of limitations. The disadvantage of FTA-ABS is that it is a 
subjective test to read and is difficult to standardise (345).                 
 
Treponema pallidum hemagglutination assay 
The T. pallidum hemagglutination assay (TPHA) is a micro-hemagglutination assay 
for IgM and IgG anti-treponemal antibodies (346). It is commonly used as a 
confirmatory test, especially when non treponemal tests are used for initial 
screening of blood.  TPHA tests have detectable reactivity approximately four 
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weeks after exposure (347).  It is simple to perform and does not take much time. A 
major advantage of TPHA is the application of automation (344). Another 
advantage compared with other treponemal tests such as TPI and FTA-ABS include 
the use of standardised reagents in commercial kits.  Like the other treponemal 
tests, it cannot distinguish between antibodies from past or present infection. 
 
Enzyme immunoassay 
T. pallidum enzyme-linked immunosorbent assays (EIA) can detect IgG, IgM or both.  
EIA’s that use recombinant treponemal antigens to detect IgM and IgG antibodies in 
a 96-well plate have equivalent sensitivity to non-treponemal tests and specificity 
equivalent to TPPA, FTA-ABS tests (348,349). Guidelines in the UK were published in 
2000, in which EIA is recommended as the appropriate alternative to the combined 
VDRL/RPR and TPHA screen (345).  In a recent audit of laboratory diagnostic 
methods for syphilis in England and Wales, 94% of them were performing syphilis 
EIA (350).   For large scale screening, the use of EIA is cost effective and less labour 
intensive (332).  The other advantage is that they are automated (or semi-
automated) and therefore less subject to bias than conventional tests (332,348). 
 
Rapid tests 
Treponemal based rapid test kits have recently been developed but have not been 
widely evaluated in blood donors. Most rapid tests detect IgM, IgG and IgA 
antibodies and involve immunochromatographic strips in which one or more T 
pallidum recombinant antigens are applied as capture antigens. They were 
developed as point of care tests for resource poor countries and their reported 
sensitivities range from 84.5% - 97.7% (346). 
 
Western blot 
Testing by Western blot assay allows for the detection of both IgM and IgG 
antibodies, with detection of IgM antibody suggesting recent or active infection 
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(351-353). With clinically confirmed samples, the sensitivity of the assay is 93.8% 
and the specificity is 100% (321). The Western blot method has been used to 
identify syphilis in cases with doubtful serological results (354)and is has been 
suggested as a confirmatory test in blood donors for reactive samples of other 
treponemal test (355) 
 
2.4.6 Syphilis screening in blood donors 
Serological tests for syphilis were the first infectious disease marker tests applied to 
blood for transfusion and was the first test for transfusion-transmitted diseases.  
Transfusion-transmitted syphilis was first described in 1915 (321) and serological 
tests for syphilis have been routinely carried out for more than a half a century 
(356). 
 
Screening algorithms  
Different screening algorithms can be used in different countries to test for syphilis. 
The classical algorithm (figure 2.1) has been used for several years and is 
recommended by the WHO (357). In reality, especially in developing countries, 
single screening tests rather than the algorithms has been used ((39,40,304).  The 
Centre for Disease Control and Prevention (CDC) in the US has released an 
alternative algorithm (Figure 2.2) based on the EIA ((358).  The major difference 
between the 2 algorithms is that while the classical algorithm begins screening with 
a non treponemal test, in the newer algorithm a treponemal EIA is used for initial 
screening.  It has been shown that EIA with treponemal IgG gives comparable 
results to the VDRL and TPHA combination (359,360) and the recombinant antigen-
based treponemal IgG and IgM EIA is most suitable for screening (361).   
Egglestone et al (345) proposed an algorithm which is a modification of the 
alternative algorithm described in Figure 2. In this algorithm, EIA is the test method 
used for initial screening. However when EIA is used as a screening test, an 
alternative treponemal test such as TPHA should be used as a confirmatory test 
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(345).  This algorithm was used for screening donor blood samples in this study and 
further details are provided in chapter 7. 
It is important for clinicians and laboratory personnel to familiarise themselves with 
whatever algorithm they decide to use and be able to interpret their results 
appropriately.  Each approach has its advantages in screening.  EIA has a practical 
advantage in laboratories with large workloads.  When RPR/VDRL is used as the 
initial screen, it will miss previously treated cases and may miss infections from 
many years previously.  This can be an advantage for blood banks in Africa because 
less blood will be discarded. A cost effectiveness analysis has showed that though 
both algorithms yield similar positive results; the classical algorithm is more cost 
effective in a low prevalence setting and more cost saving in the high prevalence 
setting (362).  
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Nontreponemal test 
(RPR or VDRL) 
No syphilis or very recent 
infection; testing concluded 
Treponemal test   (EIA, TP-
PA, TPHA, or FTA-ABS) 
Syphilis (new case or 
previously treated case) 
Biological false positive 
Nonreactive Reactive 
Reactive Nonreactive 
Figure 2.1: Classical algorithm used for syphilis screening 
Figure 2.2: An alternate algorithm used for syphilis screening 
Treponemal EIA test 
Nonreactive 
Testing concludes Nontreponemal test      
(RPR or VDRL) 
Syphilis (new case or 
previously treated case) 
Treated syphilis, very recent infection, 
or false-positive treponemal test; 
second treponemal test performed 
Reactive Nonreactive 
Syphilis (new case or 
previously treated case) 
No syphilis, or a third treponemal 
test can be performed 
Reactive Nonreactive 
Reactive 
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2.4.7 Risk of Transfusion-Transmitted Syphilis 
The risk of transfusion-transmitted syphilis (TTS) though real, is most likely an event 
of low probability. The risk of T pallidum in blood being transmitted to cause 
syphilis in the recipient, will depend on factors such as infectivity, its presence and 
detection in the blood donor, storage conditions of the blood and the recipient 
factors (363,364).  The validity and relative contribution of each of the factors has 
not been determined (310).  
 
Factors affecting transmission 
Infectivity of positive serological blood 
Blood donors that have positive tests for syphilis by any of the serological tests may 
not necessarily be infectious since the current screening tests are unable to 
determine infectivity. The limitation for screening tests for syphilis is that the gold 
standard for infectivity, which is the RIT, is impractical for screening blood donors 
(321). The other limitation is the persistence of reactivity associated with 
treponemal tests so that even after treatment, samples remain positive and cannot 
be differentiated from untreated persons. 
 
Presence in blood 
The presence of T pallidum in blood is difficult to establish with the current 
screening tests for donors as they do not directly detect the DNA, antigen or the 
bacterium. A confirmed reactive test may indicate a recent infection but it is not 
indicative of the presence of T pallidum. Data from a pilot study of 169 serologically 
positive blood donor samples in the US (365) showed that no T. pallidum DNA or 
RNA was detectable.  This lack of demonstrable T. pallidum circulating DNA or RNA 
suggests that blood donors with confirmed positive results are unlikely to have 
circulating T. pallidum in their blood and is unlikely to be infectious.  
T pallidum could be present in blood but missed on screening when blood is 
donated in the window period i.e. the time between acquiring the infection and the 
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identification by serological tests (297). T. pallidum reaches the lymphatics and the 
blood within a few hours of infection during early primary syphilis, and transmission 
of syphilis through blood transfusion is possible before the appearance of serum 
antibodies detected by serological tests (306,309).  Transfusion-transmitted syphilis 
has occurred in the Netherlands, when fresh blood was used for an exchange 
transfusion, although the blood donor had negative serological tests for syphilis 
(309).  A similar case had been reported by Soendjojo et al where the donor was 
negative at the time of donation (308). Later investigations in both cases showed 
both donors had later sero-converted.  In the report from the Netherlands, the 
donor later admitted to sexual contact with a prostitute 10 days prior to his blood 
donation (308).   
In the US, without serological screening of volunteer donors, it has been calculated 
that potentially infectious blood from about 100 persons with early syphilis might 
enter the blood supply system each year (278).   
 
Storage conditions of blood 
The storage temperature and duration of storage of blood are important in 
affecting viability of treponemes.  T. pallidum is fragile and at 4°C, does not survive 
beyond 120 hours (366).  The use of refrigerated blood for transfusion has been an 
important factor in reducing the risk of transfusion-transmitted syphilis (297).  In 
conditions of inadequate blood supply and excessive demand for blood as seen in 
many developing countries, blood will not be stored for long periods, thus the risk 
of transmitting syphilis will remain.   
 
Host factors 
Immunity: Sexually transmitted syphilis may present with non typical features in the 
HIV positive patient (367) but no specific relationship has been established between 
transfusion-transmitted syphilis and recipients with lowered immunity.  The 
HIV/AIDS epidemic has not been associated with an increase in cases of transfusion-
transmitted syphilis. 
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Antibiotic use in recipients:  T pallidum has remained susceptible to the penicillin’s 
and the extensive use of antibiotics among transfusion recipients is one of the 
reasons advanced for the decrease in incidence of transfusion-transmitted syphilis 
(310,368). 
 
2.4.8 Should screening of syphilis be continued? 
In the developed world, especially in the US, the value of syphilis screening has 
been questioned and it has been suggested that testing continues for emotional 
rather than scientific reasons (368). Regulators such as the FDA maintain that there 
is insufficient data to warrant discontinuation of testing blood donors (278). The 
risk for transmission of syphilis may depend on the prevalence of the infection and 
other non-epidemiological factors in that region but considerable disagreement 
exist as to whether testing blood donors for syphilis serves any useful purpose(66) .  
 
Reasons why screening should start or continue 
Identifying high risk donors by means of a detailed donor questionnaire and 
deferring such donors is the first step in screening and it is helpful. However, it has 
been shown that relatively few blood donors with infectious syphilis reported risk 
factors for syphilis and donor –history questionnaire did not result in deferral of 
these donors (278). Some centres do not also question donors at all to identify the 
high risk donors. Serological screening is crucial under such circumstances to detect 
those positive for syphilis. 
An increase in syphilis prevalence in the community may mean an increase in the 
high risk sexual behaviour of potential donors and could lead to less safe blood 
because though testing is done for many pathogens; there is a risk that an 
infectious donation may enter the blood supply (369). Continued vigilance by 
screening is therefore required by blood services as the risk of syphilis increases in 
the general population (295).  
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In developing countries, a multiplicity of factors combines to make the continued 
screening of blood syphilis important. These include: inability to store refrigerated 
blood for prolonged periods (because of the high demand for blood); absent or 
poor supply of electricity leading to inadequate refrigeration; and the major source 
of blood being family replacement donors (usually first time donors) with a higher 
prevalence of transmissible diseases.  
 
Reasons why screening should discontinue 
The absence of any published report of transfusion-transmitted syphilis since 1983 
and the inability of T. pallidum to survive refrigeration implies that transfusion-
transmitted syphilis is nonexistent and therefore screening is not required in blood 
donors (368). 
The significance of a confirmed positive test result is not clear (Orton S 2001). 
Discarding blood which does not contain infectious T pallidum in a community 
where blood is scarce may not be appropriate. The inability of serological tests to 
identify the true infectivity of the blood means many previously exposed donors 
who have been treated are identified as positive though they are not infectious.  
Syphilis testing has previously been used as a surrogate test for HIV, hepatitis B, 
hepatitis C (370).  A correlation between sero-positivity for syphilis and tests for 
hepatitis B and C and HIV in both high and low risk groups, including prostitutes, 
drug users, homosexual men, blood donors and the general population was  
observed in the early 1990’s (371-376).  There are now more sensitive tests for 
these viruses than for those for syphilis. Evidence now shows that syphilis testing 
does not to provide surrogate value for other pathogens such as HIV, HCV and HBV 
(377). 
 
Syphilis policies 
Despite the uncertainty of the infectivity of positive serological sample, syphilis 
screening of blood donations remains a legal requirement in most countries (378). 
68 
 
The World Health Organisation recommends that at the minimum, all donated 
blood to be used for transfusion should be screened for HIV, hepatitis B, hepatitis C 
and syphilis (54).  
 
Syphilis policies in Ghana 
There is a national blood policy in Ghana that proposes mandatory syphilis 
screening for blood donors (379). Though such a policy exists, the National Blood 
Service has not been legally mandated by the parliament of Ghana. Each hospital/ 
blood bank works independently of the NBS and their policy and only screens blood 
with whatever is provided by the individual hospital managements.  This is reflected 
by the fact that only 20% of blood in Ghana is being screened for syphilis (23). 
Furthermore, there is no recommended test algorithm to be used for screening.   
 
Research gap in transfusion-transmitted syphilis 
The follow-up of transfusion recipients for evidence of transfusion-transmitted 
syphilis is urgently required and would address the question of whether 
transfusion-transmitted syphilis exists today   (321).  This is a crucial gap in current 
knowledge that needs answers. This study seeks to provide evidence of transfusion-
transmitted syphilis. 
 
2.5 Summary 
The review of literature in this chapter has shown the paucity of data in Africa and 
the challenges associated with the existing screening methods or tests. These 
shortfalls support the urgent need for studies in these areas. Some of these studies 
were conducted and are presented in this thesis. The next chapter (chapter three) 
gives a general methodology and how the studies were set up in Kumasi, Ghana. 
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CHAPTER 3 
STUDY ORGANISATION AND GENERAL METHODOLOGY 
3.1 Introduction 
The study presented in this thesis has several components and therefore had to 
involve detailed planning including choosing an appropriate study design to answer 
the study questions, the site and the correct staff for the study. This chapter 
describes the planning that went into this study, how the study was set up, 
coordinated and conducted, and the challenges encountered.  Background 
information of the study site and a general methodology of the study are also 
provided in this chapter. 
 
Study overview 
The execution of this project was in three phases:  
Phase 1: This phase involved proposal development, writing up the protocol for the 
study and obtaining ethical approval for the study. These activities took place in 
Liverpool, UK.  
Phase 2: This phase was in Ghana. It involved identifying study staff, setting up and 
conducting the study.  
Phase 3: This phase involved molecular analysis in Liverpool including performing 
malaria PCR and genotyping, data analysis and write up of the thesis.  
 
Study oversight in Ghana 
My supervisors provided study oversight in 2 ways.  
1. Two working site visits were done by my supervisor to Ghana. The first was 
done very early in the study to ensure the set up was appropriate, and 
working well, that the protocol was being followed, that study procedures 
were being followed and samples were being collected and stored 
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appropriately.  The second was completed a couple of months prior to the 
study end.  
2. We established a monthly reporting system where I provided a written 
update on study progress and activities including number of enrolled 
subjects, default rate for follow up, challenges and forecasts. On a few 
occasions, a follow up teleconference was held to discuss issues and to re-
plan where necessary. 
These measures ensured that problems and issues were identified and solved early, 
assuring the overall quality of the study.  
 
3.2 Sample size calculation  
Sample size for transfusion-transmitted malaria 
As the prevalence of plasmodium parasitaemia in the general population in the 
study area is approximately 5%, it is assumed that the same proportion of blood 
donations (5%) will contain malaria parasites.  Data available from 2007 suggest 
that approximately 4000 patients in the three high-risk groups of interest to this 
study receive a blood transfusion per year; 200 (i.e. 5%) of these patients can be 
expected to be transfused malaria parasite infected blood.  Although equipoise 
exists, in that there is no evidence available to indicate the effect giving malaria 
parasite infected blood transfusions has on post-transfusion malaria rate, it is 
anticipated that giving infected transfusions will increase this rate; thus, the study 
has been powered on the basis of non-inferiority (i.e. will assume one-sided 
significance testing at the conventional alpha = 0.05 level). 
The study was to recruit 200 high-risk patients found to have been transfused 
malaria parasite infected blood (exposed cohort); this was to take a maximum of 12 
months to achieve. Patients in the exposed cohort would receive intensive post-
transfusion monitoring for 72 hours and with further review at days 7 and 14 in 
parallel with standard clinical care. 
Each participant in the exposed cohort was to be matched with two participants 
from the same high-risk sub-group (child/immune compromised/pregnant) found 
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to have been transfused non-infected blood (unexposed cohort).  The unexposed 
participants would be the two participants from the same high-risk sub-group 
transfused with non-infected blood closest in time to the date on which the 
matched exposed participant received their infected blood transfusion. 
The total sample size for this study was thus 600, of whom 200 were to be in the 
exposed and 400 in the unexposed cohort.  These numbers were to provide 80% 
power to detect a non-inferiority difference of 5.7% in the post-transfusion malaria 
rate (i.e. the hypothesis of non-inferiority will be accepted if the rate increases from 
5.0% to no more than 10.7%) – and 90% power to detect a non-inferiority 
difference of 7.0% in the post-transfusion malaria rate (i.e. the hypothesis of non-
inferiority will be accepted if the rate increases from 5.0% to no more than 12.0%).  
[Clinically, non-inferiority would be accepted in this context if the rate increases 
from 5.0% to no more than 15.0%.]. This study design was therefore to allow for a 
clinically relevant increased rate of malaria in the exposed group of up to 15% to be 
detected. 
The proposed sample size of 600 patients was not achieved. It became obvious 
early in the study that the frequency of identifying parasitaemia in the blood was 
too low to enable the required sample size to be achieved and for the study design 
to be carried out. It would have taken several years to complete the study if 
matching was to be done.  Screening of blood was carried out for a year without 
any matching of cases. In all, a total of 372 recipients of transfusion were enrolled 
into the study. 
 
Sample size calculation for bacterial contamination study 
The rationale for this sample size calculation was to determine an adequate sample 
size to estimate the prevalence of contamination among donors with a good 
precision.  Based on two previous studies in Ghana (36,37), the prevalence of 
bacterial contamination was assumed to be 15%.  Taking a confidence interval of 
95% the sample size for this study was calculated using the formula 
2
2 )1(
d
P
PZn

     
(380) where:  
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n = sample size  
Z = Z statistic for a level of confidence = 1.96 (for 95% CI) 
P = expected prevalence or proportion = 0.15 (15%) 
d = precision = 0.05 (5%) 
n=Z2P (1-P)/d2     
= 1.96 x 1.96 x 0.15 x 0.85/.05x.05   
= 192 
200 patients were recruited into the study instead of the calculated 192.  
 
Sample size for transfusion-transmitted syphilis study 
Using an expected sero-positivity prevalence of 12% for syphilis, the sample size for 
this study was calculated using the formula n=Z2P (1-P)/d2    (380) where:  
n = sample size 
Z = Z statistic for a level of confidence = 1.96 (for 95% CI) 
P = expected prevalence or proportion = 0.12 (12%) 
d = precision =.05 (5%) 
The calculated size n= (1.96 x 1.96 x 0.12 x 0.88/ 0.05 x 0.05) = 162 
The sample size calculated was 162 but 200 patients were recruited for the study. 
This sample size calculation was based on the assumption that the syphilis sero-
positivity in donors was 12%. The assumed 12% was based on previously reported 
studies from Ghana (38,39). This sample size was expected to detect the sero-
positivity prevalence with a good precision of 0.05. The calculation did not take into 
consideration the detection of active infection because that was not the focus of 
the study.   
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3.3 Study setup in Ghana 
Process of initiating study in KATH 
Permission to carry out this study was sought from the many levels of authority 
including the hospital management, the heads of the departments, and units that 
were to be involved in this study. 
 
Hospital management 
A letter was sent to the hospital management asking for permission to use the 
hospital and its patients for the study. The management required to see all ethical 
approvals and my study protocol. Once they were satisfied with all documents, the 
importance of the study in the hospital and for the scientific community as a whole, 
the Medical Director issued an internal memo to all heads of all concerned 
departments and units, to officially introduce the study.   
 
Departments involved 
The departments of Medicine, Obstetrics and Gynaecology, Paediatrics, Oncology 
and Diagnostics (including microbiology and haematology) were directly involved 
and approvals from their heads of department were required.  These approvals 
were important so as to ensure maximum cooperation from personnel. Meetings 
were organised individually with the heads and when their approval was given, this 
was followed by clinical meetings in the departments where details of the study 
were presented to members of staff of each department. These meetings afforded 
clinical staff the opportunity to ask questions and establish a rapport that was to 
help facilitate the conduct of the study. 
 
Transfusion Medicine Unit 
The unit was central to the success of the study. Frequent meetings were held with 
the head and staff of the Transfusion Medicine Unit (TMU) and my study team to 
ensure that any issues that came up were quickly settled.  These meetings also 
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discussed the benefits from the collaboration for the unit including research 
capacity building and the use of findings from the study to improve practices. 
Coordination and strategies were agreed, including allowing study staff members to 
be stationed in TMU and be responsible for alerting other study team members 
whenever a transfusion request had been made and blood was being prepared to 
be issued out for transfusion. The unit was also to allow study team members 
access to their donor records and all other information required for this study.  
 
Figure 3.1: The accident and emergency building which houses the blood bank 
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Figure 3.2: The blood bank of Komfo Anokye Teaching Hospital 
 
    
Figure 3.3: A biomedical scientist in the grouping and cross matching room and a blood 
fridge containing blood that has been cross matched 
 
 
 
 
76 
 
Maintaining normal work routine 
Care was taken not to disrupt work schedules in the unit or to alter standard 
operating procedures for all activities in the unit. This study was an observational 
study and did not intend staff members to modify any activity.   
Blood screening algorithm in unit 
The process for donation and screening of donated blood is as shown in figure 3.4.   
All blood which was collected into the blood bags had been screened for the major 
viruses already. 
 
 
 
Blood grouping done and unit of 
blood stored in refrigerator  
Donor interview 
and physical exam 
Sample taken for 
Haemoglobin, Hepatitis 
B, Hepatitis C and HIV 
Unit of blood donated 
Hb >12.5g/dl and non-
reactive for viral marker 
Initially reactive for viral 
marker.  Donor deferred and 
invited to Donor Clinic. 
Confirmatory testing done. Donor 
counselled and where necessary 
referred to VCT or for further 
management (elevated ALTs in 
Hepatitis) 
 
ing   
Deferred if found to be 
medically unfit 
Donor deferred if 
Hb<12.5g/dl 
Figure 3.4: The blood donation and screening process at KATH 
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Figure 3.5: A blood donor undergoing a health check prior to blood donation 
 
 
Figure 3.6: Percentage distribution of blood units in KATH by departments 
 
(A&E-Accident and Emergency, Paeds-Paediatrics, O&G- Obstetrics and 
Gynaecology, Onc & Haem- Oncology and Haematology). 
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Maintaining the integrity of the unit of blood 
To prevent iatrogenic contamination, the blood bag was only breached at the 
bedside of the patient at the start of the blood transfusion.  Sampling for grouping 
and cross matching was taken from the accessory tubing. The principle was 
maintained for this study and no samples were obtained from the blood bag prior 
to starting transfusion on the patient. The required volume of blood sample was 
taken from the blood bag at the tail end of the transfusion process after the blood 
bag had been clipped off. For paediatric transfusions which required volumes less 
than a unit of blood, the staff in the blood bank did breach blood units according to 
their protocols to take the amount needed. 
 
Blood use in KATH 
Out of the 15,685 blood units collected in 2010, 64% were used by the Departments 
of Paediatrics, Obstetrics and Gynaecology, Medicine and Oncology, where the 
study took place. The distribution of blood use in the hospital is shown in figure 3.6. 
 
3.4 Study components 
The phase 2 of this project, where the studies were performed in Ghana, was 
divided into four components and conducted in the following order: 
Component I - Conduct of a survey to determine transfusion practices in the 
different departments 
Component II - Conduct of the syphilis aspect of the study to determine syphilis 
prevalence and sero-conversion. 
Component III – Conduct of bacterial contamination portion of the study to 
determine prevalence of bacterial contamination and transfusion-transmitted 
bacterial sepsis 
Component IV – Conduct of the transfusion-transmitted malaria portion of the 
study to determine the prevalence of P. falciparum parasitaemia in donors and the 
incidence of transfusion-transmitted malaria in recipients. 
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The project was separated into these four distinct components for two main 
reasons;  
1. To allow the study team to focus only on one study at a time to ensure 
efficient conduct of the study and of the follow up of patients. Each of the 
studies had different follow up days and therefore there was a potential for 
mix-up. For example, follow up in the bacterial contamination study was up 
to one week and that for the syphilis study was 30 days post transfusion for 
only some recipients.  
2. To ensure that the same patients were not used for all studies thereby 
reducing the amount of blood to be taken from each patient.  If one patient 
were to be enrolled in two or more sub-studies, there would have been 
more blood samples taken 
 
Study team 
Experienced study staff were used as much as possible so that not much training 
was required. This enabled the study to start quickly and smoothly. ‘Dry runs’ were 
practised prior to each of the study components to evaluate how efficiently the 
studies were to be conducted.  
Clinical study team: Three clinical research assistants were involved in this study, 
each one responsible for Medicine and Oncology, Paediatrics and Obstetrics and 
Gynaecology respectively. The research assistants were responsible for all activities 
in their assigned department including obtaining informed consent and monitoring 
transfusions. The research assistants had worked on previous clinical trials in the 
hospital and were trained in principles of Good Clinical Practice. 
Laboratory work: For microscopy and blood cultures, experienced biomedical 
scientists and technicians from KATH were used for this study.   
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3.5 Set up and conduct of studies. 
General conduct of the study 
The principles of Good Clinical Practice were applied throughout the study. All 
patient records and files were kept under lock and key and were only accessible to 
the relevant study team member. The laboratory staff were not given access to 
patient clinical history. This served a dual purpose of maintaining confidentiality 
and avoiding bias.  
 
Timing of studies 
The first component of the study, which involved an observational survey of the 
routine transfusion practices of clinicians on the wards, was conducted immediately 
after permission was obtained from hospital management but before meeting the 
staff of the individual departments. This was to avoid the Hawthorne effect 
whereby the clinicians would change or modify their practice once they knew their 
behaviour was being watched. Once the observational study was completed, clinical 
meetings were held where the study was introduced to raise awareness and the 
design of the other components of the study was presented to staff. 
In addition to observing practices, this survey was to help determine if there were 
some specific practices that would impede the implementation of the other 
components of the study. It was observed from the survey that the use of anti-
malarials with or after blood transfusion was high and that recruiting children into 
the study run the risk of a high dropout rate due to anti-malarial use. 
 
Participants 
The following groups of patients were to be recruited into the study: 
1. Pregnant women 
2. Children 
3. Immune suppressed patients including those with HIV 
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4. Malignancies and Chronic diseases (including sickle cell, liver and kidney 
diseases). 
These patients are known to be highly susceptible to malaria in malaria endemic 
countries. They were chosen as the study population because if transfusion-
transmitted malaria exists, it will be clearly seen in these individuals. All these 
patients were from the departments of Medicine, Oncology, Paediatrics and 
Obstetrics and Gynaecology. The study was therefore limited to these departments 
in the hospital. 
 
Patient care 
The study team provided supplementary care (laboratory results and follow ups) for 
patients enrolled into the study but clinical care provided by the regular hospital 
clinical team was maintained. This was because the study was mainly observational.  
Results of the patients were shared with their respective doctors, allowing the 
obstetricians, gynaecologists, paediatricians, physicians and oncologists to continue 
to give specialised care to their patients.  They were at liberty to decide the 
treatment without seeking approval from the study team. During the study on 
transfusion-transmitted malaria, the patients were reviewed daily and their vital 
signs measured 8 hourly. 
 
Follow up clinic 
A follow up clinic was set up specifically for the study. Prior to discharge, all study 
participants were shown where the follow up clinic was located and where the 
malaria laboratory was. They were then given a card with the dates for each visit 
and the contact details for the study team.  All follow up information was stored 
electronically. At the end of each day, a list of patients who were due to attend the 
clinic for follow up the next day was printed and patients were called on phone to 
remind them of the visit. Patients were also encouraged to come for unscheduled 
visits whenever they felt unwell or had a fever. 
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Follow up strategies 
On recruitment into the study, a detailed home address and telephone contact was 
obtained. This helped the study team to locate patients when they didn’t return for 
follow up.  Patients would be called and then followed up at home if required. 
The advantages of follow up were explained in detail to patients; emphasising that 
they would not pay anything, would not join any long queues and they would 
obtain their results quickly. They were provided with a telephone number of the 
study team to contact if they encountered any difficulties or if they did not feel 
well. 
The participants/relations were given money to cover their transportation costs. 
Initially patients were given the money when they came for the follow up visit. 
However it was noticed that some were unable to come to the hospital on their 
own so they were given these transportation monies on discharge to facilitate their 
return for follow up. 
 
Laboratory work in KATH 
The malaria laboratory was the focal point of all laboratory work for this study.  This 
laboratory was chosen because they have been involved in several clinical trials and 
are familiar with Good Clinical and Laboratory Practices (GCLP). Room, fridge and 
freezer temperatures are measured and recorded daily and an excellent audit trail 
for samples are maintained. Reagents and kit for the study were kept in this lab and 
sample separation, labelling and storage were performed here.  The malaria 
laboratory is not officially accredited. 
Blood cultures were performed in the bacteriology laboratory and assays for 
syphilis and malaria ELISA, TPHA and RPR were performed in the serology and 
virology laboratories. Full blood count, malaria microscopy and malaria rapid 
testing were performed in the malaria laboratory.  
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Test kits and supplies 
Diagnostic kits had to be purchased for two aspects of the study; malaria testing 
and syphilis testing. The logistics of when to buy, and where to ship the kits to, was 
tricky because of the delay in approving the study.  Orders that had been made 
were suspended until approval for the study was received. All syphilis test kits and 
reagents (EIA, TPHA and RPR) were ordered from BIOKIT Ltd, UK and kept in a cold 
room in Liverpool until they were carried in a cold box to Ghana.  Malaria EIA 
ordered from Cellabs, Australia was shipped directly to Ghana. A malaria rapid 
detection test (First Response, manufactured in India) was purchased from the 
National Malaria Control programme. 
 
Sample shipment to Liverpool 
Packing of the blood spots of filter paper were done according to the UN3373 
Biological substance Category B specifications for transport of dangerous goods. 
The necessary documentation and approvals were obtained in Liverpool prior to 
shipment of samples.   Samples were then shipped by DHL courier to LSTM. Upon 
reception, samples were logged in to the LSTM database via the Pro-Curo software 
system and stored in the cold room.    
 
Molecular testing 
Initial plans for the study were for PCR and genotyping to be done in a research 
institution in Ghana.  Performing these tests became problematic and compelled 
the molecular work to be performed in the Liverpool School of Tropical Medicine. 
Two kinds of PCR for Plasmodium falciparum were performed, real-time PCR was 
the method used to screen all samples from donated blood units and nested PCR 
was used for genotyping of the parasites. 
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Data management 
Four different case report forms, each specifically designed were used in this study.  
Double entry of the data was done into electronic databases designed in Microsoft 
Access. Data cleaning was continuous throughout the study after which analysis of 
data was performed using Predictive Analytics Software (PASW®) statistics 18 
package (SPSS Inc, USA).  
Summary of activities 
Table 3.1: Summary of my activities performed in the study 
Activity Place 
Case report forms LSTM & KATH 
Obtaining ethical clearance LSTM & KATH 
Participant recruitment KATH 
Physical examination KATH 
Medical history KATH 
Medical charts review KATH 
Transfusion monitoring KATH 
Follow up clinic KATH 
Sample separation, labelling, storage KATH 
T. pallidum enzyme immunoassay KATH 
Rapid plasma reagin KATH 
T. pallidum hemagglutination KATH 
Malaria microscopy KATH 
Malaria rapid detection test KATH 
Malaria enzyme immunoassay KATH 
DNA extraction LSTM 
Malaria PCR (real-time and nested) LSTM   
Data entry KATH 
Data analysis KATH & LSTM 
LSTM =Liverpool School of Tropical Medicine, KATH = Komfo Anokye Teaching Hospital 
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3.6 Ethical issues 
Ethical approval for the study was sought and granted from the ethics committees 
of the Liverpool School of Tropical Medicine in Liverpool, UK and the School of 
Medical Sciences, Kwame Nkrumah University of Science and Technology in Kumasi, 
Ghana.   
 
Ethical considerations and approval 
In my initial study design for transfusion-transmitted malaria, malaria testing of 
donor blood was not to be done immediately.  Patients were to be followed up 
blindly for 4 weeks, without knowledge of whether the blood they received was 
malaria positive or negative. At weekly intervals they were to have a blood smear 
done for parasitaemia. The end points were to be both clinical malaria and 
parasitaemia. These end points were to be compared retrospectively between 
those who received malaria positive and malaria negative blood. My initial 
estimation was that 5% of donor blood will be P. falciparum positive and that if 
transfusion-transmitted malaria was occurring it will result in 10% of recipients 
becoming positive. This approach was to simply observe the current practices in 
KATH, which are similar to those in most sub-Saharan countries where there is no 
screening of blood for malaria.  
The goal of the study to measure incidence of infections transmitted by transfusion 
had an ethical dilemma of apparently allowing infections to progress without 
intervention. I felt that the current practice of treating patients presumptively with 
anti-malarials without evidence was even more unethical.   
The ethics committee of the Liverpool School of Tropical Medicine (LSTM) however 
had concerns and raised some major issues. These included the following:  
 The committee felt that it was unethical for study participants to be 
transfused with blood that contained malaria parasites and not be treated. 
  The committee wanted assurance that stringent measures were in place to 
ensure safety of participants who received infected blood 
 The committee wanted a  justification for why this approach was to be used 
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Resolving ethical considerations 
Some major and minor modifications were made based on comments and concerns 
raised by the ethical committee.  At various stages, I worked together with a 
paediatrician and a statistician from the ethics committee. The major changes to 
the study design included keeping recipients of blood in hospital for 3 days to 
monitor closely and to perform 8 hourly measurements of vital signs including 
blood pressure, temperature, respirations and pulse rate. The study design was also 
modified to a matched cohort study (but this did not happen because of 
impracticalities; there were so few microscopy positive cases that recipients of 
positive blood could not be matched immediately by department and gender). I 
proposed that the benefits of this study outweighed risk and that practice of 
widespread anti-malarial prophylaxis would help spread parasite resistance and 
was not affordable.   
 
Ethical approval 
Ethical approval from the LSTM ethics committee was difficult to obtain and was 
given only after 4 rounds of re-submissions to the ethics committee.   Interestingly, 
the LSTM ethics committee failed to reach a consensus on the major ethical 
implications surrounding untreated iatrogenic parasitaemia.  An approval was given 
6 months after the first submission the LSTM ethics committee and only after the 
protocol had been referred for an external review.   
During the visit by my supervisor, an issue of how to handle positive blood donors 
was raised. We agreed that syphilis positive donors had to be offered treatment but 
not for malaria positive donors who may have donated several days earlier and 
were not acutely ill. The ethics committee of the Kwame Nkrumah University of 
Science and Technology was consulted but they referred us to the National Malaria 
treatment guidelines of Ghana which unfortunately did not have answers. We 
discussed and agreed that any positive donor be invited for another blood 
screening before treatment. Treatment was to be given if parasitaemia was found 
in the repeat sample or if the donor had any symptoms. 
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Informed consent 
Signed or thumbprint informed consent was obtained from all patients or their 
relatives before being enrolled in the study. This sometimes involved using an 
interpreter. A detailed explanation of the study was given and patient/relatives 
given time to think about it. To ensure a low dropout rate, patients who were 
initially hesitant but later willing to give consent were not enrolled. Also patients 
who were giving consent because they thought ‘the doctor knew best’ were not 
enrolled. This was because from previous experience, such patients were unlikely to 
return for regular follow up. Patients were allowed to withdraw their consent at 
any time during the course of the study. 
 
3.7 Summary 
A description of the study setup including the ethical challenges that were 
overcome has been presented. Collaborations between different units and 
departments and the coordination of activities between different laboratories and 
different personnel is shown to contribute immensely in the setup and completion 
of this study. This chapter provides the rationale for sample sizes and participants 
recruited, and give a background understanding to the studies presented in the 
next four chapters. 
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CHAPTER 4 
THE IMPACT OF INCONSISTENT POLICIES FOR TRANSFUSION-
TRANSMITTED MALARIA ON CLINICAL PRACTICE IN GHANA  
4.1 Introduction 
There are approximately 500 million cases of malaria and 1 million deaths 
worldwide each year (381) and 90% of this burden occurs in Africa (382). Current 
measures to reduce the burden of malaria include insecticide- treated mosquito 
nets, intermittent preventive treatment, indoor residual spraying and malaria 
vaccines.  An area of malaria control which has been neglected in endemic 
countries is malaria transmission through blood transfusion.  
There are no evidence-based international guidelines for the prevention of TTM in 
sub-Saharan Africa and there is lack of harmonisation between policies produced by 
blood safety programmes and those produced by malaria programmes.  The World 
Health Organisation (WHO) recommends that donated blood should be tested for 
malaria “where appropriate and possible” (1) but there is currently no method for 
screening blood for low-level parasitaemia which is sensitive, practical and 
affordable for use by transfusion services in endemic countries (104). Other 
transfusion guidelines suggest that transfusion recipients should be given 
prophylaxis with anti-malarials (185).  In contrast to blood safety policies, malaria 
policies recommend that malaria treatment should only be prescribed on the basis 
of laboratory confirmation of infection (383) in order to reduce the development of 
drug resistance.  
There is very little information in the literature about how African countries have 
incorporated the WHO recommendations concerning transfusion-transmitted 
malaria into their national policies and how these policies have been translated into 
practice.  In the absence of clear national policies clinicians may rely on 
international recommendations which may not be applicable in their setting or they 
use individualised practices that are not based on evidence. As in many other 
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countries in sub-Saharan Africa, the blood transfusion policy in Ghana makes no 
mention of screening donated blood for malaria.  
The aim of this study was to document how these conflicting or absent policies 
relating to malaria transmission and blood transfusion impact on clinical practice in 
a teaching hospital in Kumasi, Ghana.  Analysis of discrepancies between policies 
and practice should enable identification of the priorities for better harmonisation 
of policies and to identify gaps in the evidence regarding TTM.  
 
4.2 Methods 
This study was conducted in the departments of Obstetrics and Gynaecology (O&G), 
Medicine and Paediatrics of the Komfo Anokye Teaching Hospital.  
 
Participants 
Inclusion criteria: Transfusion recipients from the three departments who had 
received a blood transfusion within the previous 24 hours were eligible to take part 
in the study. Within the departments, pregnant women, children, immune 
compromised patients and patients with malignancies and chronic diseases 
(including sickle cell disease, chronic renal failure, and liver disease) were enrolled.  
Exclusion criteria: 
 Any patient whose case notes were not traceable  
 Patient being transferred  to a department not included in this study 
 Patient receiving more than one transfusion within the 24 hour time period.  
 
Enrolment 
The study was a retrospective review of the clinical notes of transfusion recipients. 
Data were collected between October and November of 2009.  The recipients were 
selected by convenience sampling from a list of patients who had received blood in 
the preceding 24 hours. Each day the blood bank staff provided the names of two 
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blood transfusion recipients in each of the three departments. On six occasions 
during the study, a department had less than two transfusion recipients in 24 hours 
and so the name of a replacement participant from another department was 
provided by the blood bank staff.  On one occasion the case notes of a patient from 
obstetrics could not be traced and as no other obstetric patient was eligible, a 
replacement was recruited from paediatrics.  
 
Data collection 
At recruitment, a data collection form (appendix 3.1) was used to extract 
information from the clinical notes of the transfusion recipients. The form was 
adapted from the KATH transfusion monitoring form, which is based on the national 
guidelines for the clinical use of blood in Ghana. There are no hospital based 
guidelines for the clinical use of blood or any written policies or protocols 
concerning transfusion-transmitted malaria but the blood bank has transfusion 
monitoring forms which are given to ward staff when the blood is issued and are 
used for reporting any transfusion reactions. 
The form was expanded to include information about the patient’s diagnoses, 
laboratory tests (such as malaria microscopy, pre-transfusion haemoglobin) and 
treatment type (such as anti-malarials, antibiotics, diuretics). Information was also 
collected concerning monitoring of vital signs, duration of transfusion and 
documentation of adverse events of transfusion.  
 
Analysis 
Predictive Analytics Software (PASW®) statistics 18 package (SPSS Inc, USA) was 
used to calculate frequency statistics including measures of central tendency and 
dispersion and the results were compared between the three departments. The 
practices relating to the prevention and treatment of malaria associated with 
transfusion were compared with known policies.  
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4.3 Results 
Participant demographics 
151 transfusion recipients were recruited into the study from medicine (41, 27.2%), 
obstetrics (51, 33.7%) and paediatrics (59, 39.1%). The majority of the patients 
(64.9%) were female, because of the inclusion of the obstetric department, and the 
median age of all patients was 22.0 years (IQR: 4.0-36.0) (Table 4.1).  
Malaria was the leading cause of admissions in transfusion recipients in the 
department of paediatrics (69.5%) but did not contribute to any admission in the 
department of medicine (0%). In O&G, malaria accounted for only 17.6% of 
admissions (Table4.2).  
 
Transfusion practices 
25 patients (16.6%) had received a blood transfusion during a previous admission 
and the highest rates of previous transfusions were in the department of medicine 
(45.5%). 66% of transfusion recipients from medicine, 65% from obstetrics and 15% 
from paediatrics had received a transfusion during the current admission prior to 
enrolment in the study. All patients received either whole blood or packed red cells. 
The mean duration of transfusion for all study participants was 2.6 hours and was 
longest for paediatric transfusions (3.3 hours). Ninety four percent of all 
transfusions were completed (Table 4.1).   
The mean pre-transfusion haemoglobin in all transfusion recipients in the study was 
4.5g/dl (SD ± 1.2) (Table4.1).  The temperatures charts for all transfusion recipients 
revealed that 34 (23%) developed fever in the 24 hours following transfusion. Post-
transfusion fever was a particular problem in obstetric (24%) and paediatric (32%) 
transfusion recipients (Table 4.1). There were 10 deaths (7%) among recipients 
within 24 hours of transfusion but none of these were attributed to the blood 
transfusions (Table 4.1). 
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Table 4.1: Characteristics and practices among transfusion recipients within three 
departments in a Ghanaian teaching hospital 
 
 
 
 
All 
(N=151
) 
 
Medicin
e 
(N=41) 
Departmen
ts 
Obstetrics 
(N=51) 
 
Paediatric
s 
(N=59) 
Median age (IQR)yrs  22.0 
(4.0-
36-0) 
41.0 
(29.5-
56.0) 
28.0 (22.0-
38.0) 
3.0 (1.0-6-
0) 
Completed transfusion (%) 142 
(94.0) 
36 
(87.8) 
51 (100) 55 (93.2) 
>1 transfusion received (%) 82 
(54.3) 
27 
(65.9) 
33 (64.7) 9 (15.3) 
Mean pre-transfusion  haemoglobin ±SD 
(g/dl) 
4.5 ± 
1.2 
4.4 ± 1.7 4.7 ± 1.2 4.3 ± 0.9 
Mean duration of transfusion ±SD (hrs) 2.6 
±1.2 
2.2 ± 1.1 2.0 ±0.8 3.3 ± 1.0 
Documentation of transfusion reactions 13 
(8.6) 
4 (9.8) 5 (9.8) 4 (6.7) 
Post transfusion fever (%) 34 (23 ) 3 (7) 12 (24) 19 (32) 
Death within 24 hrs of transfusion (% ) 10 
(6.6) 
6 (14.6) 2 (3.9) 2 (3.3) 
     
 O&G represents Obstetrics and Gynaecology; IQR represents interquartile range; 
SD represents standard deviation. 
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Table 4.2: Malaria related clinical diagnoses made in transfusion recipients 
Paediatrics   
Severe malarial anaemia  17 
Malaria in sickle cell disease 7 
Suspected malaria with anaemia 6 
Severe malaria 4 
Cerebral malaria 4 
Malnutrition with malaria 3 
Total cases 41/59 (69.5%) 
  
Obstetrics and Gynaecology  
Suspected malaria with jaundice/haemolysis in pregnancy 7 
Malaria in pregnancy 1 
Sickle cell and malaria in pregnancy 1 
Total cases 9/51 (17.6%) 
  
Medicine  
Malaria (any form) 0 
Total cases 0% 
 
 
 
Figure 4.1: The frequency of vital signs measurements recorded in patient charts 
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Vital signs 
Measurement of temperature, respiration, blood pressure and pulse rate was not 
done in 33.1%, 28.5%, 59.6% and 28.5% of patients respectively during the 
transfusion. For all departments the temperature, pulse rate and respiratory rate 
were frequently measured only once during the transfusion (Figure 4.1).  
 
Anti-malarial drug use 
Sixty six (44%) patients received malaria treatment within 24 hours of their blood 
transfusion. There was marked variation in the use of anti-malarial drugs between 
departments with 51 (87%) children receiving malaria treatment compared to 12 
(24%) obstetric patients and 3 (7%) adult medical patients (Table 4.3). In 51 of these 
patients (78%) the anti-malarials were prescribed at the same time as the blood 
transfusion. 84% (43/51) of those who received anti-malarials with the transfusion 
were children and only one had parasitaemia confirmed by microscopy. In 4 
patients an anti-malarial was prescribed in the 24 hours following the blood 
transfusion, 8 patients had received anti-malarials at least 24 hours prior to 
transfusion and in 3 patients the timing of the anti-malarials was unknown.  Four 
transfusion recipients with post-transfusion fever received anti-malarials but only 
one had malaria confirmed on a blood film (Table 4.3).   
Information from patients’ case notes indicated that clinically-suspected malaria 
was a reason for hospitalisation in 50 (30%) of the transfusion recipients; 70% of 
these were children. Overall 20 transfusion recipients (13%), 10/59 (17%) children, 
3/51 (6%) obstetric patients and 7/41 (17%) medical patients, received malaria 
treatment with their transfusion or within 24 hours post-transfusion despite having 
no underlying clinical diagnosis of malaria, and 64 (42%) transfusion recipients were 
treated for malaria without any laboratory confirmation of parasitaemia. Quinine 
(39% of all anti-malarial prescriptions) and artesunate-amodiaquine (33%) were the 
most commonly prescribed anti-malarial drugs and these were used exclusively by 
the department of paediatrics. 
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Table 4.3: Practices related to transfusion-transmitted malaria in three departments of KATH 
  All (N=151) Medicine(N=41) O&G(N=51) Paediatrics(N=59) 
n (%) n (%) n (%) n (%) 
Clinical diagnosis of malaria at admission (%) 50 (30) 0 (0) 9 (18) 41* (70) 
Anti-malarial use (%) 66 (44) 3 (7) 12 (24) 51 (87) 
Type of anti-malarial given      
 Quinine 26 (40) 0 (0) 0 (0) 26 (51) 
Artemether-Lumefantrine 18 (27) 3 (100) 12 (100) 3 (6) 
Artesunate-Amodiaquine 22 (33) 0 (0) 0 (0) 22 (43) 
Time of prescribing anti-malarial     
With transfusion   51 (77) 1 (33) 7 (59) 43 (84)* 
At least 24 hours before transfusion   8 (12) 1 (33) 1 (8) 6 (12) 
Within 24 hours post- transfusion 4 (6) 0 (0) 3 (25) * 1 (2) 
Unknown 3 (5) 1 (33) 1 (8) 1 (2) 
Other drugs     
               Furosemide (%) 60 (40) 2 (5) 6 (12) 52 (88) 
               Antibiotics use (%) 118 (78) 25 (61) 49 (96) 44 (75) 
Post transfusion fever (%) 34 (23 ) 3 (7) 12 (24) 19 (32) 
*confirmed by positive malaria microscopy in one case 
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Artemether-Lumefantrine (28%) was prescribed in the departments of medicine 
and obstetrics but not in paediatrics.  No chloroquine or sulphadoxine-
pyrimethamine was prescribed for any transfusion recipient. 
 
Other treatments 
Overall 118 transfusion recipients (78%) received antibiotics, with the highest usage 
in obstetrics (96%)(Table 4.3). 81% of antibiotics were prescribed prior to the blood 
transfusion. 40% of all transfusion recipients, predominantly paediatric patients 
(88%), had furosemide prescribed at the same time as the blood transfusion (Table 
4.3). From the clinical notes the reason for prescribing a diuretic was only 
documented for two patients both of whom had heart failure. In 96% of patients 
there was no indication of why furosemide was given. 
 
4.4 Discussion 
In Ghana, as in many other malaria endemic countries in sub-Saharan Africa, blood 
for transfusion is not screened for malaria and there are no clear policies about 
whether or not anti-malarials should be prescribed presumptively with blood 
transfusions.  44% of all transfusion recipients in our study received malaria 
treatment with their blood transfusion (77%) or in the 24 hours following the 
transfusion (6%) but only two (3%) had parasitaemia confirmed on microscopy. This 
practice of routine prescription of anti-malarials with blood transfusions without 
laboratory confirmation of infection occurred predominantly in paediatrics. Many 
of the children had a clinical diagnosis of malaria so it is possible that the anti-
malarials were prescribed presumptively for their suspected infection. However, in 
children, 98% of malaria drugs for which the timing was known, were prescribed 
simultaneously with the blood transfusion and the number of children prescribed 
anti-malarials exceeded the number with suspected malaria.  This indicates that in 
paediatric practice anti-malarial drugs are prescribed routinely with blood 
transfusions.  
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Prescribing malaria treatment routinely for transfusion recipients in endemic areas 
reflects WHO guidelines (185) and the advice in several published papers (194-197). 
In contrast, other papers recommend restricting malaria treatment to selected ‘at 
risk’ transfusion recipients such as neonates (34,179,198). These recommendations 
for neonates were without evidence from the published studies.  Evidence of 
transfusion-transmitted malaria being a significant clinical problem in endemic 
areas is almost non-existent. One study has documented malaria parasitaemia 
occurring in recipients of malaria-positive transfusions in Sudan (101).In contrast, 
the majority of transfusion recipients in Ghana who developed parasitaemia post 
transfusion did not acquire it from the blood transfusion as parasite genotyping 
indicated that malaria transmission only occurred in 2% of those who received a 
malaria-positive blood transfusion (as shown in my results which are presented in 
chapter 5). 
There have been no studies from endemic areas comparing presumptive versus 
targeted malaria treatment for transfusion recipients and there is very scanty 
evidence underpinning recommendations for presumptive malaria treatment of 
transfusion recipients. In contrast, current malaria treatment guidelines 
recommending that treatment should only be given to those with proven infections 
(383) are well supported by evidence and are designed to slow down the 
emergence of P. falciparum resistance to artemisinin (384,385). Worldwide, there 
has been a rise in the proportion of patients with a febrile illness with laboratory 
confirmation of malaria from 5% in 2000 to 35% in 2009 (76).  Although patients 
with negative malaria tests are still being treated for malaria (386) a Ugandan study 
has demonstrated that it is possible to improve the rates of diagnostic malaria 
testing and to restrict malaria treatment to those with positive results (387). 
My study found that the restrictive malaria treatment policy is not implemented for 
blood transfusions in a malaria endemic area.  International guidelines do allow for 
presumptive treatment of malaria if laboratory confirmation is not available (383) 
but any facility that is able to offer blood transfusion will almost certainly have a 
laboratory capable of providing a definitive diagnosis of malaria. The practice of 
treating every fever presumptively for malaria is entrenched (388) and my study 
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demonstrated that in practice, and particularly in paediatric practice, clinicians 
choose presumptive treatment for transfusion recipients rather than laboratory 
confirmation of malaria diagnosis prior to initiation of treatment. Implementation 
of the WHO recommendations to screen donated blood for malaria is hampered by 
a lack of suitable screening methods (104) which may partly explain the emphasis 
on presumptive treatment as an alternative strategy.   
The mean duration of transfusion in children was longer than in adults and diuretics 
were prescribed with the blood transfusion in 88% of children. These practices do 
not appear to be consistent with any policies or guidelines but are based on 
assumptions that the symptoms of severe malarial anaemia, particularly respiratory 
distress, result from biventricular failure (389) and that these children are not 
hypovolaemic (390). Recent evidence has suggested that children with severe 
febrile illness and impaired perfusion do not benefit from fluid resuscitation (391). 
Clinical guidelines (185) indicate that diuretics should only be used in transfusion 
recipients likely to develop or who develop cardiac failure.  88% of children in our 
study were given furosemide with their blood transfusion and in almost all cases 
there was no indication of why it was given.  
The prescription of an antibiotic in transfusion recipients ranged from 61-96% 
across the three departments and is likely to represent treatment for underlying 
conditions.  In clinical practice in Africa it can be difficult to differentiate between 
severe malaria and sepsis, and both conditions may co-exist (392). Ideally blood 
cultures should be taken before empirical antibiotics are started (393) but it is 
common for antibiotics and anti-malarials to be prescribed simultaneously 
(383,394). There is evidence that this approach may reduce mortality in severe 
malaria (159).  
Monitoring of vital signs was poorly performed in all departments. The national 
guidelines (395) recommend that vital signs should be measured 15 minutes after 
the start of transfusion and then hourly until the transfusion is complete. With a 2.6 
hr mean duration of transfusion, at least 3 records of vital signs measurement were 
expected but it they were mostly done once or not at all. 
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Table 4.4: Summary of policies and practices concerning transfusion-transmitted malaria 
WHO recommendations Policies in Ghana Practice in KATH Research knowledge gaps 
Donated blood should be tested for 
malaria (59) 
 
All units to be tested for HIV I & II, 
Hepatitis B and C and syphilis and 
any other transfusion transmissible 
disease (379) 
No malaria screening of 
donated blood 
 
Screening methods for malaria that 
are practical and sensitive enough 
for use by transfusion services 
 
Cost-effectiveness of malaria 
screening in different transmission 
zones 
 
Rates of malaria transmission by 
transfusion with genotyping to 
confirm that malaria was acquired 
through transfusion 
   
Effectiveness of presumptive malaria 
treatment of transfusion recipients 
compared to treatment restricted to 
proven infections  
 
Effective approaches for ensuring 
that transfusion guidelines are 
evidence-based, regularly reviewed 
and implemented  
In endemic areas, there is a high risk of 
transmitting malaria by transfusion. All 
transfusion recipients should receive 
routine treatment for malaria (185) 
 
No  policy on routine treatment for 
malaria 
33% of transfusion recipients 
received anti-malarials with 
their transfusion or within 24 
hours post-transfusion 
 
Anti-malarials should only be prescribed 
for proven malaria infections (383) 
 
Confirm cases of malaria before 
initiating treatment (treatment can 
be started in severe cases but a 
confirmation from the laboratory is 
needed)(396) 
3% (2/66) had a laboratory 
confirmation of malaria before 
treatment 
 
 
   
In patients at risk of circulatory overload, 
red cells are preferable to whole blood.  
Treat volume overload and cardiac failure 
with diuretics(185) 
Diuretics should only be given in 
recipients with heart failure. For 
patients with heart failure lower the 
rate of transfusion(395)  
88% of children were given 
diuretics 
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4.4.1 Limitations of study 
The study was conducted within a two month period, and that may not be 
representative of what happens throughout the year.  Considering the fact that 
October and November represents the end of the rainy season and the incidence of 
malaria is not high, the use of anti-malarials may have reduced. A survey all year 
long or a survey that compares practices during the dry and wet seasons may be 
appropriate. 
The study was unable to establish the rationale for anti-malarial use. It may have 
been helpful through qualitative methods to directly ask doctors the rationale for 
initiating treatment with anti-malarials.  In addition, the period for which clinical 
staff has been in a particular department could influence the practice there. For this 
survey, the duration of employment in the various departments was not 
ascertained. Some factors such as pre-transfusion fever could have influenced 
clinicians practice but this was not evaluated.  
The study was also limited with its restriction to few departments rather than all 
departments in the hospital. Such a survey would have presented a more general 
overview of hospital transfusion practices.  
 
4.5 Summary 
This study has shown that where international malaria and transfusion policies are 
in conflict, such as restricting anti-malarials to proven infections versus presumptive 
treatment of transfusion recipients, clinicians choose to adhere to transfusion 
policies rather than malaria policies (Table 4.4). This is despite the fact that malaria 
policies have a much stronger evidence base than transfusion policies. There is an 
urgent need for harmonised policy-making by malaria and blood transfusion 
programmes so that clinicians, and particularly paediatricians, receive a clear 
message about how to reduce malaria transmission through blood transfusions. 
This harmonisation needs to be preceded by research to generate better 
knowledge about the prevalence and clinical impact of transfusion-transmitted 
malaria, and about the cost-effectiveness of various blood donor screening 
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strategies taking account of the need to avoid exacerbating blood shortages by 
unnecessarily excluding donors. My study has demonstrated that until these critical 
gaps in the evidence about transfusion-transmitted malaria are addressed and the 
relevant policies are harmonised, these mixed messages will continue to be 
translated into inconsistent clinical management to the detriment of patient care 
and public health.  
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CHAPTER 5 
TRANSFUSION-TRANSMITTED MALARIA 
5.1 Introduction 
Blood shortages and unsafe blood, are the two crucial issues relating to blood 
transfusion in the developing world, particularly Africa. These issues can lead to 
serious health consequences such as death from post partum haemorrhage or the 
transmission of life threatening infections (397). As major progress is made in the 
prevention of the major transfusion-transmitted infections namely HIV, hepatitis B, 
hepatitis C and syphilis, one disease that requires attention and which can impact 
on blood safety and a shortage is malaria. 
Malaria is seen as the most devastating parasitic infection in the world (398). P. 
falciparum is the most dangerous species of plasmodium and has the highest rate 
of complications and mortality. In 2007 it caused an estimated 451 million cases of 
clinical malaria in malaria endemic countries (399). When transmitted through 
blood transfusions in non-endemic countries, malaria can have serious 
consequences including being rapidly fatal. The effects of transfusion-transmitted 
malaria (TTM) on recipients living in the endemic regions are yet to be defined.  It 
has been suggested that TTM is a problem experienced by non-immune individuals 
but not the semi-immunes who when transfused with blood infected with malaria 
parasites, acquire infections but may not necessarily exhibit clinical symptoms 
(400). 
In SSA, blood donors are adults, who by virtue of living in a malaria endemic area 
have acquired immunity, which can be associated with low grade parasitaemia 
(401). In screening such donors, the blood may be declared negative only because 
parasitaemia is below the detection threshold of the method used. Such a person 
may still have malaria parasitaemia and will be able to induce TTM if his/her blood 
is transfused.  This poses a diagnostic challenge in screening for malaria in endemic 
areas (402).  Microscopy, rapid detection tests (RDT), enzyme immunoassays (EIA) 
103 
 
and PCR methods are tests used for diagnosis of malaria but their efficacy as 
screening tests has not been demonstrated.   
As discussed in chapter 4, there are policies that recommend screening for malaria 
and that recommend presumptive treatment for transfusion recipients in endemic 
areas but these are not based on evidence. The aim of this study therefore was to 
establish the incidence of TTM in transfusion recipients and to determine which 
test was most appropriate for screening donated blood. 
 
5.2 Materials and Methods 
Study design and sample size modification 
The sample size calculated for this study was not used because of the difficulty in 
enrolling the required 600 subjects within the one year time frame of the fieldwork. 
The study design of matching recipients of parasitaemia positive transfusion 
recipients by age and gender would also have enrolled very few patients so it was 
not pursued. For example, 21 cases of microscopy positive donor blood were found 
for the period of the study, implying that with two controls for each case only 63 
cases would have been recruited for the study. It was decided that enrolment was 
to go on continuously until the end of study period.  
 
Participants and recruitment 
Participants were recruited from the Departments of Obstetrics and Gynaecology, 
Paediatrics, Medicine and Oncology at Komfo Anokye Teaching Hospital (details of 
the study site have been discussed in chapter 3). The following transfusion 
recipients were eligible for enrolment; pregnant women, children (aged between 1 
and 15 years), immune compromised (including HIV and malnourished) patients 
and patients with malignancies and chronic diseases (including sickle cell disease, 
chronic renal failure, liver disease).  
Exclusion criteria: Patients were excluded from the study if they were found to be 
parasitaemic by microscopy at pre-transfusion or if they had taken anti-malarials 5 
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days prior to the transfusion. Patients were also excluded if they were transfused in 
the operating room or considered too ill (unconscious, shocked or delirious) such 
that signs and symptoms could not be elicited. Patients with a clinical diagnosis of 
malaria were not excluded if they did not fulfil any exclusion criteria. 
 
Study enrolment 
Patients for whom a transfusion had been requested were identified from the 
blood bank records. Eligible patients were evaluated by scrutinising their clinical 
notes and interviews before obtaining a written informed consent.  An algorithm 
for the process of enrolment is shown in figure 5.1.    Patients who consented to 
participate were assigned unique study numbers.   Each blood unit received by the 
patient was uniquely identified.   
 
 
 
Patient not 
enrolled  
Obtain baseline clinical details and take sample for 
baseline investigations 
Patient enrolled into study 
Request sent to blood bank for grouping and cross-
matching 
cross-matching 
Investigator reviews request form for eligibility into 
the study 
Yes 
Patient approached for Informed Consent 
No 
Figure 5.1: Process of enrolment into the study 
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Patient monitoring and follow-up 
Patients were followed up for 14 days post-transfusion. They were not excluded 
from the study if they received more than one unit of blood. The duration of 
storage of the transfused blood units was retrieved from the blood bank records. 
Patients’ vital signs, blood pressure, temperature, pulse and respiratory rate, were 
measured at the start of the transfusion, 15 and 30 minutes after the start of the 
transfusion and then hourly until the transfusion had been completed. After the 
transfusion, and for the next 3 days when patients were in hospital, patients were 
examined daily and their vital signs were measured every 8 hours.  Subsequently, 
scheduled follow up of patients was performed on day 7 and 14. The activities 
performed on each day is presented in table 5.1. 
Table 5.1: Study procedures performed for each patient enrolled in the study 
Time point Activities 
Pre-transfusion History and clinical examination 
Blood sample 
During transfusion Vital signs measurement at 15 min, 30 min 
and hrly until transfusion is complete 
Immediate post transfusion Vital signs measurement 
Day 1 Clinical examination 
Vital signs measurement (3X) 
Blood sample taken 
Day 2 Clinical examination 
Vital signs measurement (3X) 
Day 3 Clinical examination 
Vital signs measurement  (3X) 
Blood sample taken 
Day 7 History and clinical examination 
Blood sample taken 
Day 14 History and clinical examination 
Blood sample taken 
 
Patient management 
After transfusion, five follow up visits were planned; the first 3 while in hospital and 
the next 2 were as outpatients. At each of these follow up visits a blood sample was 
examined for parasitaemia by microscopy. In addition, haemoglobin was measured. 
Besides the scheduled visits, patients were encouraged to come back to the study 
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team anytime they did not feel well (unscheduled visit).  The regular physicians of 
the patients were maintained throughout the study. They were provided with all 
results for the patient and for the blood they received and were responsible for 
patients’ treatment.  Any patient who was found to be parasitaemic by microscopy 
was treated with anti-malarials according to local guidelines. Their physicians were 
also free to give patients any other appropriate medications they deemed 
necessary. 
 
Figure 5. 2: Blood transfusion in a paediatric ward 
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Table 5.2: Definitions used in the study 
Serious adverse event 
An event that resulted in stopping an ongoing transfusion. 
An event that occurred in relation to the transfusion, which resulted in death, life 
threatening or incapacitating conditions for patients or which prolonged 
hospitalisation or morbidity.  
 
Post-transfusion malaria 
Parasitaemia occurring after a patient received a transfusion, irrespective of the 
source of the parasitaemia. 
 
Transfusion-transmitted malaria (TTM) 
Parasitaemia occurring in a patient post transfusion, where the parasite was 
genotypically the same as that in the transfused unit of blood.  
 
Clinical TTM 
TTM in a patient with a temperature >37.5 °C. 
 
 
Sample processing and testing   
Transfused blood:  
Two millilitres of blood were obtained from each unit of transfused blood. Blood 
samples obtained from the transfused unit of blood were screened for P. 
falciparum by means of microscopy, rapid diagnostic test (RDT), enzyme 
immunoassay (EIA) and polymerase chain reaction (PCR).  The parasite detection 
focussed on P. falciparum because falciparum is responsible most of severe malaria 
and causes significant mortality and morbidity (403). 
RDT was performed immediately and microscopy was done within 24 hours of 
obtaining sample.  One millilitre of blood was placed in an Eppendorf tube and 
stored immediately in a freezer at -20°C for malaria EIA testing.  Four concentric 
blood spots each about 50µl (2 drops) were placed on 3M filter paper; air dried and 
sealed in a plastic envelope together with a desiccant. The filter paper was stored at 
room temperature until it was transported to Liverpool for PCR and genotyping.  
Recipient blood:  
One millilitre of blood was taken from patients at pre-transfusion and on all the 
follow up days for haemoglobin measurement and detection of P. falciparum.  
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Haemoglobin measurement was by means of a Sysmex KX21N (Sysmex 
Corporation, Kobe, Japan).  Microscopy was performed immediately for P. 
falciparum detection. All samples were in addition stored as spots on filter paper, 
stored at room temperature and for PCR and genotyping. Only patients who 
received P. falciparum positive blood (determined by PCR on transfused blood) had 
their follow up samples tested by PCR. This is because when the donated blood had 
no parasitaemia then there was no basis for comparison.  In situations where the 
follow up sample was also positive, genotyping was done on parasites from the 
transfused unit and the patient to determine if they were the same parasite.   
 
Figure 5.3: The staining area in the malaria laboratory 
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Figure 5.4: The microscopy bench in the malaria laboratory 
 
Test methods 
Microscopy 
Thick and thin blood smears for microscopy were prepared from venous blood that 
had been collected in EDTA bottles.  The detailed preparations for thick and thin 
film are shown in appendix 6.3. The smears were stained with 10% Giemsa and 
examined for the presence of parasites with X100 oil immersion lens of a 
microscope (Olympus, Japan).  Slides were only declared negative after 100 high 
power fields were examined.  Slides were examined by two microscopists and 
reviewed by an expert microscopist when there was disagreement.  Ten percent of 
slides were also reviewed by the expert microscopist. 
Rapid detection test 
First Response® Malaria Antigen test kit (Premier Med Ltd, India), which detects 
Histidine rich protein 2 (HRP2) was used for rapid detection of P. falciparum.  A 
drop of blood (25µl) was placed into a sample well. Two drops of an assay buffer 
was added through a buffer well below it. The results were read in 20 minutes, a 
positive test being the presence of two bands on the control and test lines.  
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Enzyme immunoassay 
The Malaria Antigen CELISA (Cellabs, Sydney, Australia) test kit used for this study is 
based on the detection of HRP2 and was performed according to the 
manufacturer’s instructions. Briefly, 100 µl of each blood sample which had been 
frozen and thawed twice (to ensure complete haemolysis) was pipetted into 
individual micro-wells of the CELISA plate. These wells had been pre-coated with an 
anti-P. falciparum monoclonal capture antibody.  The plate was incubated in a 
humid chamber at room temperature for one hour. After washing five times with a 
wash buffer, 100 µl of the conjugate was added into each well and incubated under 
similar conditions for an hour. The plate was washed again five times and 100 µl of 
freshly prepared substrate pipetted into each well. After incubation at room 
temperature in the dark for 15 minutes, 50µl of a stop solution were added and the 
results read in a spectrophotometer at an absorbance of 450nm.   For each batch of 
samples run, two positive and negative controls were included.  The cut-off level 
was calculated as the sum of the optical density of the negative control plus 0.1.  
Any sample with an absorbance value above the determined cut-off level was 
considered reactive for P. falciparum antigen. No confirmatory tests were required. 
 
DNA extraction from blood spots on filter paper 
DNA was extracted using the chelex/saponin method (404).   A 6 mm punch out of 
the blood soaked filter paper was fully immersed in a 1.5ml Eppendorf tube 
containing 1 ml of freshly prepared 0.5% saponin in 1X PBS and left overnight at 
room temperature.  The saponin solution was removed and 150 μl of 6 % chelex 
suspension made up in nuclease-free water added to fully cover the filter paper.  
The tubes were then placed in dry heating blocks that had been set to 100˚C and 
allowed to boil for between 20 and 25 minutes. Cooling was allowed for two 
minutes on the bench and to allow the chelex to settle. Finally, the Eppendorf was 
centrifuged for 2 minutes and 100µl of the DNA supernatant eluted.  This was 
stored at -20°C until PCR was to be performed. 
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Quantitative PCR 
A SYBR-Green real-time PCR assay, specific for falciparum species, was employed to 
detect P. falciparum DNA extracted from the blood spots.  Brilliant III SYBR Green 
PCR mix (Agilent Technologies, Santa Clara, CA, USA), forward (rtPfa1F) and reverse 
primers (rtPfa1R)( (Eurofins MWG Operon, Ebersberg, Germany) and 1 µl of 
template DNA was used in a total reaction volume of 20 µl.  The amplification was 
performed on a Stratagene MX 3005P real-time PCR system (Agilent Technologies) 
with the following cycling program: 95°C for 3 min; 40 cycles of 95°C for 10 sec, 
55°C for 10 sec and 60°C for 1 min.  The PCR product identity was confirmed using a 
melt curve analysis as previously described (405). Dissociation and amplification 
curves are presented in appendices 6.5 to 6.7.  Serial dilutions of the International 
Standard ranging from 1 X 106 to 103 IU/ µl were included in duplicate in each real 
time PCR run, allowing an approximate quantification of the samples to be carried 
out. The quantification was derived from standard curves which were produced 
from the dilutions of the standard. 
Table 5.3: Primers used for P. falciparum real time PCR 
Name Sequence (5’ ->3’) 
rtPfa1F (forward primer) GCCGAAAGGCGTAGGTAATC 
rtPfa1R (reverse primer) GTACAAAGGGCAGGGACGTA 
 
P. falciparum strain comparison 
Genetic analysis of P. falciparum in patients and the corresponding transfused unit 
of blood were carried out according to published protocol, using nested PCR for the 
detection of allelic diversity at the merozoite surface protein 2 (msp2) loci (172).  
Nested PCR 
Nested PCR involves a primary reaction, where the primers span the entire genetic 
segment of block 3 (Table 5.4) while for the nested reaction primers were specific 
for the 3D7 or FC27 allele (Table 5.5). Both primary and nested amplifications were 
carried out in 25 µl reaction volumes. For the primary PCR, the final concentration 
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of the master mix contained 0.04 U/µl of Taq polymerase 1, 1x PCR buffer, 1.5mM 
MgCl2, 200 µM of dNTPs, 300 nM each of forward and reverse primers (Table 5.4) 
and 5 µl of the extracted DNA.   
Table 5.4: Primers used for primary PCR for msp2 
Name Sequence (5’ ->3’) 
M2-OF ATGAAGGTAATTAAAACATTGTCTATTATA 
M2-OR CTTTGTTACCATCGGTACATTCTT 
 
A Techne TC-4000 thermocycler (Bibby Scientific, Staffordshire, UK) was used for 
amplification under the following cycling conditions: initial denaturation 94°C for 2 
min; 30 cycles of 94°C for 30 sec, 54°C for 1 min and 72°C for 1min, and 72°C for 5 
min.  One µl of the primary PCR product was re-amplified in a separate nested 
reaction for the 3D7 or FC27 family. Each reaction consisted of 1x buffer, 300nM of 
forward primer S1fw, 1.5mM MgCl2, 200 µM of dNTPs,  0.04 U/ µl of Taq 
polymerase and 300nM of a specific 3D7-type or FC27-type allele reverse primer 
(N5 for 3D7 and M5 for FC27) (Table 5.5). The conditions for the nested 
amplification were as follows: initial denaturation 94°C for 2 min; 30 cycles of 94°C 
for 30 sec, 50°C for 45 sec and 70°C for 1min 30 sec, and 70°C for 5 min. 
Table 5.5: Primers used for 3D7 and FC27 allele-specific PCR 
Name Sequence (5’ ->3’) 
S1fw (forward primer) GCT TAT AAT ATG AGT ATA AGG AGA A 
M5rev (reverse primer for 3D7) GCA TTG CCA GAA CTT GAA 
N5rev (reverse primer for FC27) CTG AAG AGG TAC TGG TAG A 
 
Electrophoresis and band detection 
Following the nested PCR reactions, electrophoresis of products was carried out on 
2% agarose gel. 
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Figure 5.5: PCR product detection on agarose gel 
 
Figure 5.6: PCR product detection on polyacrylamide gel 
 
Figures 5.5 and 5.6 shows the 2-step electrophoresis performed after the nested PCR. DNA products 
were initially run on 2% agarose gel (Figure 5.5). When products were identified to be present, they 
were then run on 10% polyacrylamide gel which gives a better resolution (Figure 5.6). Automated 
band sizing was then performed on the polyacrylamide gel.  
Where DNA products were detected in both the transfused blood and in the 
patient’s follow up sample, the paired samples were then run on 10% 
polyacrylamide gel, stained with ethidium bromide and visualised using a Gel Doc™ 
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EZ imaging system (Biorad, Hercules, CA, USA ). Automatic band detection and 
fragment sizing was carried out using Image Lab software (Biorad). For both the 
3D7 and FC27 families, alleles were considered to be the same if molecular weights 
were within 10 base pairs of each other. If alleles from the blood bag and patient 
were the same, transfusion-transmitted malaria was said to have occurred.   
Restriction digest 
To increase the discrimination power of the msp2 genotyping, the products of 
nested PCR amplification for the 3D7 family were subjected to digestion with the 
ScrF I restriction enzyme (Fermentas Inc, Glen Burnie, MD, USA).  A reaction mix 
with a 20 µl total volume, containing the nested PCR product and the enzyme is 
incubated in a water bath at 37°C for 30 minutes.  PCR fragments were visualised 
and sized as described above.    
 
5.2.1 Quality assurance and quality control 
The microscopists were qualified biomedical scientists who have worked as 
microscopists in GCLP compliant malaria drug and vaccine trials. To prevent 
artefacts on slides, only new slides were used and the Giemsa stain for microscopy 
were freshly prepared daily. An experienced microscopist resolved any differences 
and also independently reviewed 10% of slides.  
The RDT was stored in an air-conditioned room to preserve its sensitivity as it is 
known that extremes of temperature can reduce sensitivity. 
Negative and positive controls were included for each batch of samples tested by 
the HRP2 EIA.  The negative control was to have an optical density value of less than 
0.1. For both PCR and EIA runs, some wells were randomly left empty to check if 
spill over was taking place.   
Positive and negative controls were used for all PCR reactions. For all plates, the last 
two rows were used for negative controls and standards. Two types of negative 
controls, negative human sample and water and positive controls including 
international standards in different dilutions were used in duplicates. These are 
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used for the detection of contamination, quality of reagents, normalisation and 
quantification as mentioned earlier. 
In all laboratories, specific standard operating procedures for specific test methods 
were strictly followed to ensure consistency.  
 
Data capture and statistical analyses 
Case report forms designed to capture all relevant information were used to record 
data (see appendix 6.1). Information on the blood including the type of donors and 
the duration of storage of the refrigerated blood was obtained from the donor 
records at the blood bank. All signs and symptoms elicited, diagnoses, 
investigations and treatment given was recorded in these case report forms.  All 
statistical analyses were performed with the Predictive Analytics Software (PASW®) 
statistical package 18 (SPSS Inc, USA). Descriptive statistics including measures of 
central tendency and dispersion were used where appropriate.  Parasite densities 
of P. falciparum identified by microscopy and DNA copies determined by qPCR were 
converted into logarithm values and correlation assessed by Pearson’s coefficient r.   
To compare the accuracy of the four different test methods used to detect 
falciparum parasitaemia, the composite reference standard method was used 
(406). A reference ‘gold standard’ test was constructed by combining the results of 
PCR and microscopy such that a positive result by either test in combination or 
singly (i.e. +PCR/-microscopy, -PCR/+microscopy and +PCR/+microscopy) was 
considered a reference positive. The reference test was negative when both PCR 
and microscopy were negative. Using the constructed gold standard, the sensitivity, 
specificity, negative predictive and positive predictive value of PCR, microscopy, EIA 
and RDT was calculated. This method was used because though microscopy which 
is the gold standard for parasite detection, it is not as sensitive as other methods 
such as PCR. It is therefore be inappropriate for use when assessing the 
performance of malaria screening tests. 
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5.3 Results  
Recipient characteristics 
Three hundred and seventy two patients were enrolled and the majority (43.6%) 
were from the department of medicine (Table 5.6). The department of paediatrics 
had the least number of patients, 6.7% (25/372).  There were more females than 
males (64.5%), the reason being all patients from O&G were females.  Chronic 
diseases accounted for 58.2% of patients in medicine and 37.9% of patients in 
paediatrics and were the most common diagnoses in both departments.  Pregnancy 
related bleeding /anaemia (65.3%) was the most common diagnosis in O&G.  Anti-
malarials had been given to 23.4% of the patients (87/372), either more than 5 days 
before recruitment (50.6%; 44/87) or post-transfusion (49.4%; 43/87). The most 
frequently used anti-malarial (74.7%) was artemether-lumefantrine.  Thirteen 
percent (11/87) of anti-malarials prescriptions were for a single agent artesunate, 
contrary to current WHO recommendations.    
Table 5.6: Characteristics of 372 transfusion recipients 
Characteristics   
Department N (%) Medicine 162 (43.6) 
O & G 141 (37.9) 
Oncology 44 (11.8) 
Paediatrics 25 (6.7) 
Sex N (%) Male 132 (35.5) 
Female 240 (64.5) 
Median age (years)(IQR)  35.0 (25.0 -49) 
Mean transfusions ± SD  2.6 ± 1.6 
Anti-malarials use N (%) > 5 days before transfusion 44 (50.6) 
After transfusion 43 (49.4) 
Antibiotics use N (%)   228 (61.3) 
Characteristics of donated blood 
Voluntary blood donors provided 65.8% of the units of blood transfused (Table 5.7).  
The median duration of storage of units of blood transfused in this study was 2 
days, however the maximum duration observed was 30 days.  There was no 
significant difference for detecting parasitaemia in refrigerated blood stored for 
more than 14 days (2/23) compared to blood stored for 14 days or less (OR 0.418, 
95% CI 0.096-1.829). 
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Table 5.7: Characteristics of 372 donors and donated blood 
Donor characteristic  
Median age Median age (inter-quartile range) years 21.0 (18.0 – 30.0) 
Type of donor Voluntary 
Replacement 
245 (65.8) 
127 (34.1) 
Sex of donor Male (%) 
Female (%) 
275 (73.9) 
 97 (26.1) 
Duration of storage Median duration (inter-quartile range) 
days 
2 (1-6) 
 
Study dropouts 
Although 372 transfusion recipients were enrolled in the study, 136 (36%) did not 
complete the required 14 days for evaluation (figure 5.2).  There were 30 patients 
who withdrew their initial consent and 45 who did not come for a follow up visit.  
There were 20 patients who wanted to remain in the study but did not want their 
blood taken; they were excluded because they could not be evaluated for 
parasitaemia. The majority (76%) of deaths (n= 41) in this study were from the 
department of medicine with only one death (2%) from paediatrics, four (10%) from 
O&G and five (12%) from oncology. Malignancies together with chronic liver and 
kidney disease accounted for 70% of the deaths in this study group. 
Of the 236 patients who could be evaluated, 43 (18%) received anti-malarials from 
their physicians. However only 11 (26%) of these 43 were treated based on 
microscopic parasitaemia.  
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Malaria in transfusion recipients: evaluation by microscopy 
There were 236 recipients who could be evaluated. Sixteen of these transfusion 
recipients received blood that was determined to contain P. falciparum and two of 
the 16 recipients (12.5%) subsequently developed parasitaemia at follow up (Figure 
5.8).  Of 220 recipients who received blood that did not contain P. falciparum, nine 
(4.1%) developed parasitaemia during the 14 day follow up period (Figure 5.8). 
In all, P .falciparum was detectable by microscopy in eleven transfusion recipients 
during the 14 day follow-up period. The incidence of post transfusion malaria was 
therefore 4.6% (95% CI 2.0-7.2%).  Only two (18.2%) of these recipients had 
received a microscopy confirmed P. falciparum positive blood. There were 32 
recipients who were treated with anti-malarials despite having a negative blood 
film for parasites. 
  
372 transfusion recipients 
enrolled into study 
136 recipients excluded     
 30 consent withdrawals            
 45 lost to follow up                  
 41 died                                      
 20 too ill/reject blood 
draws  
 
236 recipients remained in study 
193 completed study (D14) 
without any intervention 
43 treated with anti-
malarials 
Figure 5.7: Study flow chart 
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Malaria in transfusion recipients: evaluated by PCR 
There were 68 recipients of PCR positive P. falciparum blood but only 50 could be 
evaluated (Figure 5.9).  Among those not evaluated, seven died, five were lost to 
follow up and six refused blood draws. Of the 50 that were evaluated, 16 received 
anti-malarials during the study for different reasons. Five were treated for being 
microscopy positive at follow up and the other 11 were treated presumptively, 
based on clinical symptoms but without parasitological confirmation by microscopy. 
 
 
 
 
 
 
 
Figure 5.8: Outcomes in transfusion recipients when parasitaemia detection was by 
the microscopy method. 
236 non-parasitaemic 
recipients evaluated 
2 recipients 
developed 
parasitaemia    
(by microscopy) 
220 recipients of P. 
falciparum negative blood 
(by microscopy) 
16 recipients of P. 
falciparum positive blood 
(by microscopy) 
14 recipients 
remained 
negative            
(by microscopy) 
211 recipients 
remained 
negative             
(by microscopy) 
9 recipients 
developed 
parasitaemia    
(by microscopy) 
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Genotyping demonstrated that P. falciparum in recipient, ID 223, and in the blood 
unit transfused was the same (Table 5.8).  This recipient was afebrile and 
asymptomatic but was treated with anti-malarials because P. falciparum had been 
detected by microscopy.  Genotyping of parasites from patient ID 356 were found 
to be of the same family (3D7) as those in their transfused blood, but the parasites 
were distinguishable on digestion with Scr1F.  Results from patients ID 184, 301, 
and 369 showed that the P. falciparum in the recipient and the transfused blood 
were from the same 3D7 family of msp2 allele but were different clones. For 
patients 9 and 319 the P. falciparum parasites in the patient samples and the 
corresponding blood bag were from different families of the msp2 alleles, 
demonstrating that these were post-transfusion infections and not TTM.   
372 patients 
recruited 
68 recipients of 
PCR +ve blood 
18 excluded (7-
died, 5-lost to f-
up, 6-refused 
blood draws) 
50 recipients 
evaluated for TTM 
7 recipients 
develop post 
transfusion 
malaria 
1 case of TTM 
6 cases of post 
transfusion 
malaria 
43 recipients had 
no post 
transfusion 
malaria 
304 recipients of 
PCR -ve blood 
118 excluded (41-
died, 45-lost to f-
up, 50-refused 
blood draw 
186 completed 
study 
Figure 5.9: Outcomes of patients who received PCR positive P. falciparum blood 
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Thirteen transfusion recipients received blood that was positive for malaria by both 
microscopy and PCR. Three of these recipients developed post transfusion malaria 
detected by PCR alone   and two had post transfusion malaria which was detected 
by microscopy alone. 
Genotypically confirmed TTM therefore occurred in one (2.0%, 95% CI -2 – 6%) of 
fifty patients who received a blood transfusion positive for P. falciparum by PCR.  
There was no case of clinical TTM. 
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Table 5.8: Genotyping of positive paired samples of patients and transfused blood unit 
  Screening results of blood bag Patient results MSP2 Genotyping results 
TTM 
confirmed? 
   
Presence in 
sample Comparison of fragments   
Pt/blood ID Micro RDT EIA PCR 
 day of +ve 
ff-up  PCR 3D7 FC27 3D7 family FC27 3D7 digest Yes/No 
9         D3 + - + ND ND ND No 
BU-9 - - + +     + -         
184     D1 + - + ND ND ND No 
BU-184 + + - +   + -     
223         D1 + + + same same same Yes 
BU-223 + + + +     + +         
301     D7 + + - Different ND ND No 
BU-301 - - + +   + -     
319         D1 + + - ND ND ND No 
BU-319 + + + +     - -         
356     D1 + + - Same ND different No 
BU-356 - + + +   + -     
369         D3 + + - Different ND ND No 
BU-369 + + + +     + -         
TTM=transfusion-transmitted malaria; Micro=microscopy; RDT=rapid detection test; EIA=enzyme immunoassay; PCR=polymerase chain reaction; ND=not 
done; ff-up= follow up; Pt ID=patient identification, BU=Blood unit 
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Table 5.9: Sensitivity and specificity of malaria screening tests using a composite gold standard as the reference test 
Screening test Gold standard result         
    +ve  -ve 
Sensitivity % 
(95% CI) 
Specificity % 
(95% CI) 
PPV % 
(95% CI) 
NPV % 
(95% CI) 
PCR +ve  71 0 93.4 100 100 98.6 
  -ve 5 355 (84.7 - 97.6) (98.7 - 100) (93.6 - 100) (96.6 - 99.5) 
Microscopy +ve  18 0 23.7 100 100 85.5 
 -ve 58 355 (14.9 - 35.1) (98.7 - 100) (78.1 - 100) (82.1 - 89.1) 
RDT +ve  32 25 42.1 92.9 56.1 88.2 
  -ve 44 330 (31.0 - 53.9) (89.6 - 95.3) (42.4 - 69.0) (84.4 - 91.2) 
EIA +ve  47 48 61.8 86.5 49.5 91.4 
  -ve 29 307 (49.9 - 72.5) (82.4 - 89.8) (39.1 - 59.8) (87.7 - 94.0) 
PPV=positive predictive value; NPV=negative predictive value; RDT=rapid detection test; EIA=enzyme immunoassay; PCR=polymerase chain reaction; 
+ve=positive; -ve=negative. 
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Malaria screening tests 
In the study period, 445 units of blood were transfused in 372 patients. The 
prevalence of P. falciparum in the transfused blood units was 4.7% (N=445) by 
microscopy, 13.7% (N=440) by RDT, 18% (N=436) by PCR and 22.2% (N=442) by 
EIA.  Using the composite reference standard method to construct a gold 
standard, table 5.9 shows the accuracy of each of the four test methods used to 
detect parasitaemia.  PCR has the highest sensitivity (93.4%; 95% CI 84.77 -
97.6%) while microscopy had the lowest sensitivity (23.7%; 14.9 – 35.1%). 
Specificity for all tests were high, the lowest being 86.5% (95%CI 82.4 – 89.8%) 
for the EIA method and the highest being 100% for PCR and microscopy (Table 
5.9).    Of the 431 transfused units which had been tested by all four malaria 
screening methods, 67.9% (293) were negative by all 4 tests and 12 were 
positive by all 4 tests (Table 5.10).  
Table 5.10: Comparison of malaria tests on 431 transfused units by four different 
methods 
Number of units that tested 
positive 
Malaria test 
by 4 tests (12)  
12 PCR + RDT + EIA + Microscopy  
by 3 tests (15) 
13 
1 
1 
PCR + RDT + EIA  
PCR + RDT + Microscopy  
RDT + EIA + Microscopy  
by 2 tests (40) 
20 
4 
12 
2 
2 
PCR + EIA  
PCR + RDT  
RDT + EIA  
RDT + Microscopy  
EIA + microscopy  
by 1 test (71) 
35 
13 
2 
21 
EIA  
RDT  
Microscopy  
PCR  
 
In the 13 samples that were positive by both PCR and microscopy the parasite 
densities of transfused blood determined by microscopy were positively 
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correlated with the P. falciparum DNA concentration as determined by real-
time PCR (Pearson’s correlation coefficient r = 0.528, p = 0.043). 
 
Transfusion reactions 
Four hundred and thirty two transfusions were monitored during the period of 
this study. Signs and symptoms that patients experienced are summarised in 
table 5.11.  Severe adverse reactions occurred in 4.6% (20/432) of the 
transfusions given and 17 (3.9%) of these transfusions were stopped before its 
completion. Acute transfusion reactions were the commonest serious adverse 
event, making up 16 of the 20 cases recorded. Death, a transfusion associated 
circulatory overload (TACO) and an acute haemolytic transfusion reaction were 
the other SAEs observed. One patient who was very anxious and hyper-
ventilating but without any pathology on examination could not be categorised.  
Table 5.11: Signs and symptoms experienced post transfusion 
Symptom present Yes N (%) 
Fever 70 (16.2) 
Restlessness 26 (6) 
Rigors/chills 52 (12) 
Cyanosis 1 (0.2) 
Chest pain 2 (0.5) 
Loin/Back pain 7 (1.6) 
Palpitations 39 (9) 
Unexplained bleeding 2 (0.5) 
Wheezes/stridor 3 (0.7) 
Urticaria 6 (1.4) 
Anxiety 35 (8.1) 
Headache 24 (5.6) 
Pruritus 50 (11.6) 
Dyspnoea 11 (2.5) 
Rash 9 (2.1) 
Dark urine 10 (2.3) 
Respiratory distress 4 (0.9) 
 
5.4 Discussion  
My study has found that recipients of blood transfusions who live in malaria 
endemic regions are at risk of TTM but that the incidence of transmission, even 
among particularly vulnerable patients, was not high. Only one out of fifty 
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patients (2%) who received blood which was positive for malaria by PCR 
contracted malaria from the blood transfusion. The other 49 patients who 
received a PCR malaria-positive transfusion had either no molecular evidence of 
infection (43 patients) or the malaria parasite detected post-transfusion was not 
the same as in the transfused blood (6 patients).   
There have been almost no studies documenting the incidence of post-
transfusion malaria in endemic areas and none that have used genotyping to 
confirm parasite transmission. In Sudan, all 12 patients who received malaria 
infected blood developed microscopically confirmed malaria (101) compared to 
only 12.5% (2/16) in this study. Malaria parasitaemia has been documented 
post transfusion in recipients who received microscopy-negative blood although 
the incidence in the 14 days following transfusion was higher in this study (4%) 
compared with the Sudanese study (0.52%).  A study investigating TTM has 
recently been carried out in KATH, where this study was also performed. A 
follow up of transfusion recipients 3 months after their transfusion showed a 
14-28% incidence of TTM (personal communication with Prof Allain). The 
differences between the incidences detected by the two studies may be due to 
the comparatively large sample volume (0.5mls of cellular fraction) from which 
DNA was extracted compared to the blood spots used in this study. 
Refrigeration of blood at 4°C results in a 7.1 fold reduction in P. falciparum 
parasitaemia after 14 days storage (107). In many countries in Africa blood 
shortages are so acute that donated blood is used very rapidly. In our study 
blood was stored for a median duration of two days before being transfused. 
This is insufficient time to destroy the malaria parasites and so refrigeration is 
unlikely to account for the low incidence of TTM observed.   
All transfusion recipients were carefully monitored for signs of malaria after 
their transfusion. For ethical reasons they were treated promptly if malaria 
parasites were detected and this may explain why no recipient developed 
symptoms of malaria. Clinicians who were responsible for the patients in our 
study treated 19% of transfusion recipients for malaria post-transfusion 
although only a quarter of these patients had proven parasitaemia.  WHO 
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recommends that malaria treatment should only be prescribed for confirmed 
infections (383) whereas some national blood transfusion policies indicate that 
transfusion recipients in endemic regions should receive malaria treatment 
routinely (59).  Although we specifically selected recipients who would be at 
high risk of TTM, malaria transmission occurred infrequently suggesting that 
routine prophylaxis for all recipients of blood transfusion is probably 
unnecessary in this group of patients.  
Depending on the number of parasites inoculated, the symptoms of malaria 
may develop days to weeks after transfusion (183). The prompt treatment 
initiated after parasitaemia was found during the active follow up of patients 
did not allow parasitaemia to multiply to show any effects and may be the 
reason for the low number of clinical post transfusion malaria and no clinical 
TTM cases.   
Screening for parasitaemia in blood donors has inherent difficulties. Healthy 
donors who are resident in malaria endemic regions may generally harbour low 
levels of parasitaemia, which will not be detected by tests such as microscopy 
and RDT but will still be a high enough in a unit of blood. The limits of sensitivity 
of microscopy and RDT are 10-100 parasites per microlitre (139,162,407)  which 
would be equivalent to 5-50 x 106 parasites per unit of transfused blood. For a 
test to be useful at ruling out a disease, it must have a high sensitivity and for it 
to be useful in confirming a disease, it must have a high specificity (408). In this 
study, specificity of microscopy and PCR was very high (100%) indicating that 
these two methods may be good confirmatory tests. PCR was also the most 
sensitive test.  Further, the sensitivity of PCR can be increased by using larger 
volumes of blood for testing (409).  PCR is not a practical method for routine 
use where resources are scarce and the relationship between PCR positivity and 
infectivity is not clear. It is capital intensive, requires well trained staff and may 
not be affordable in many blood banks or hospital centres where transfusion is 
done. PCR also requires electricity and this may not be available in many rural 
areas. Even in cities, electricity supply is irregular. PCR as a screening test in 
malaria endemic countries comes with another major challenge of seriously 
128 
 
compromising blood supply. Furthermore, a test which is unnecessarily 
sensitive may result in inappropriately high donor rejection rates which will 
exacerbate blood shortages and increase mortality. For a similar reason of being 
unable to reject all positive blood donors, blood centres in Francophone African 
countries, were all not screening blood for Plasmodium (410). Based on results 
from this study, 18% of blood would have been discarded for being 
parasitaemic. Previously published evidence suggest that up to 50% of donors 
harbour parasitaemia and could be rejected (104).  
The absence of an ideal gold standard in diagnostic or screening studies is not 
peculiar to malaria but occurs in most clinical conditions in medicine (411). 
Various ways have been suggested to overcome this deficiency including the 
composite reference method which was used in this study to assess the 
accuracy of the test methods for malaria parasitaemia. A major difficulty in the 
composite reference standard approach is whether the combination of 
reference test results (in this case PCR and microscopy) results in a ‘true 
positive’.  It however continues to be one of the most used ways of constructing 
gold standard tests in different fields (412,413). 
There is presently no standardized approach to genotyping as this depends on 
the transmission patterns and multiplicity of infections but by increasing the 
resolution of the genotyping method and the number of loci assessed, 
discriminatory power may be increased adequately (414). In an effort to 
harmonise processes, there is recommended genotyping procedures initiated 
by two organisations Medicines for Malaria (MMV) Venture and the WHO (172). 
This recommended genotyping is what was used in this study. Msp1, msp2 and 
glutamate-rich protein (glurp) are the most commonly used molecular markers 
for P. falciparum (415) and we used the msp2 locus as it is the marker with the 
most discriminatory power (416-418). The most commonly used method of 
genotyping involves amplification of specific alleles of msp1 and msp2genes 
using nested PCR and gel electrophoresis (414,415). When used on agarose, the 
interpretation of results may vary but for my study this was averted by using 
10% polyacrylamide gel and digitalised automation which gives better 
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resolution.   Other more sensitive methods for genotyping such as the 
microsatellitism, isoenzyme electrophoresis, and single nucleotide 
polymorphism exist but they are more expensive.  
 
5.4.1 Study limitation 
A limitation of this study may be the inability to detect low level P. falciparum 
clones in the transfused blood. Semi-immune adults living in malaria endemic 
sub-Saharan Africa can have low-level infections with up to 10 genetically 
distinct P. falciparum variants or clones (419) simultaneously and nested PCR 
methods may not be sensitive enough to detect low abundance variants, 
especially if mixed infections are present(416,420).  
The study was unable to follow the original study design and enrol the proposed 
sample size of 600. Age and sex matched exposures may have given a more 
robust outcome with few confounders compared to the current study design. 
Again the bigger sample size may have given better results and eliminated the 
negative confidence interval obtained for the incidence of TTM.  
There was a high dropout rate for a variety of reasons and this contributed to 
reduce the number of recipients who were evaluated. A further limitation of 
this study is the small number of children recruited which related to the high 
number of children already receiving malaria treatment.  The study was 
therefore unable to evaluate TTM in relation to children, who are an important 
high risk group.  
 
5.5 Summary 
TTM occurred in only 2% of recipients of P. falciparum PCR positive blood.  TTM 
also did not occur in majority of recipients of both P. falciparum PCR positive 
and microscopy positive blood.  The widespread practice of treating transfusion 
recipients presumptively for malaria, and the assumption that transfused blood 
is the source of malaria occurring post-transfusion, are based on misperceptions 
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about the true burden of TTM. There is also insufficient evidence to support 
policies that advocate screening donated blood for malaria. Major gaps exist in 
knowledge concerning the risks of TTM and its clinical impact in semi-immune 
populations, and there are no screening tools for malaria which are practical, 
affordable and suitably sensitive for use by blood banks in Africa. The 
prevalence of malaria in blood donors is variable. By EIA, prevalence was 22.2% 
but can reach 50% in some parts of West Africa. Implementation of any policy 
which advocates rejection of all such donors will have a major impact on the 
availability of blood for transfusion and undoubtedly increase mortality 
particularly among pregnant women and children.   
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CHAPTER 6 
BACTERIAL CONTAMINATION AND TRANSFUSION RELATED 
SEPSIS 
6.1 Introduction 
Transfusion of a bacterially contaminated blood product can have serious 
consequences including death and serious morbidity in transfusion recipients 
(421).  The greatest risk of transfusion- transmitted infection in the UK currently 
is bacterial contamination. Between 1996 and 2009, 40 (60%) of 66 reported 
incidents  of transfusion-transmitted infections were due to bacteria compared 
to 17 (25%) that were due to viruses including HBV, HCV, HEV, HIV and human 
T-cell lymphotrophic virus (HTLV).  During the same period, transfusion-
transmitted bacteria caused 73.3% (11/15) of deaths due to transfusion-
transmitted infections (SHOT report). Despite this, blood safety has focussed 
mostly on viral infections resulting in a remarkable reduction of transmission of 
these viruses (215).  
There is little information concerning bacterial contamination in sub-Saharan 
Africa. Evidence has only become available in recent years that bacterial 
contamination occurs in the region, with estimates ranging from 8.8% to 17.5% 
(36,37,205).  Hassall et al showed that the frequency of bacterial contamination 
of whole blood transfused to children in Kenya is 2500 times greater than that 
found in red blood cells in industrialised countries (205).    The effects of such 
bacterial contamination on the recipients of transfusion are unclear as there 
have been no published studies in sub-Saharan Africa.   Bacterial contamination 
of whole blood may be a significant but unrecognised hazard of transfusion in 
Africa.  
This chapter describes a study that investigated the prevalence of bacterial 
contamination of donated blood in Kumasi and the clinical effects it may have 
on recipients of these units of blood.  
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6.2 Materials and methods  
Study site 
This was a prospective study conducted at the Komfo Anokye Teaching Hospital 
(KATH) in Kumasi Ghana.  The background information for KATH has been 
provided in Chapter 1.  
 
Eligibility Criteria 
All transfusion recipients in the hospital were eligible for enrolment into the 
study if they fulfilled the following inclusion and exclusion criteria. 
Inclusion criteria: Patients from the departments of Paediatrics, Obstetrics and 
Gynaecology, Medicine and Oncology; who were to receive blood transfusions 
were eligible for recruitment into the study.   
Exclusion criteria 
 Any patients with an altered state of consciousness such that they would 
be unable to identify and report any symptoms that develop during the 
transfusion. This included:  
1. Patients in shock 
2. Patients who were confused, 
3. Comatose patients  
 Any patients that received a transfusion in theatre or who was being 
sent to the theatre. Such patients will not have the chance to be 
monitored regularly by the study team or have been able to give an 
informed consent.  
 
Study enrolment process 
Informed consent:  Patients due to be transfused were identified by their 
request forms which had been sent to the blood bank and were evaluated by 
the eligibility criteria. If they qualified for enrolment, the details of the study 
133 
 
were explained to either the patient or his/her relative before a signed or 
thumb printed informed consent was obtained. 
Enrolment:  Recruitment into the study was by convenience sampling. Enrolled 
patients were given unique sequential study numbers until the proposed 
sample size of 200 patients had been attained.  The study number was 
subsequently used as the identifier for all study purposes. To ensure reliable 
follow ups, the patient’s home address and telephone numbers were obtained 
so they could be called back for follow up in case the blood they received 
yielded a positive culture result.   
The medical history and clinical examination findings were recorded on a study 
pro-forma prior to the patient receiving the blood transfusion.  The patient’s 
vital signs including blood pressure, temperature, pulse rate and respiratory 
rate measurement were monitored and documented 30 minutes after the start 
of the transfusion and then hourly until the transfusion was complete. Patients 
were reviewed immediately after the completion of the transfusion, 24 hours 
after the transfusion and each day until they were discharged from hospital.  A 
temperature greater than 37.5°C was classified as fever and when it occurred 
within 24 hours after transfusion, it was called post transfusion fever.  
 
Patient follow-up 
Patients who received blood that was found to be contaminated with bacteria 
were followed up. Those who had been discharged were recalled and those still 
in hospital were seen in their ward. They were clinically examined and blood 
samples were taken for bacterial culture, irrespective of whether they looked 
well or unwell, or had been treated with antimicrobials. 
The follow up schedule involved a mandatory follow up when the culture results 
of the donated blood unit was ready. A second follow up was planned for 
patients who were unwell or who had a positive culture result from their follow 
up sample. 
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Classification and diagnosis  
A unit of blood was said to be contaminated when culture of a sample from that 
blood unit yielded a positive isolate. At the end of the study all recipients of 
contaminated blood were classified into one of four case definitions. 
The classification for transfusion-transmitted bacterial infections that I used for 
this study was adapted from the standard definitions from the Canadian Public 
Health Agency’s Guidelines for Investigation of Suspected Transfusion-
Transmitted Bacterial Contamination (210).   
These guidelines were proposed for investigating transfusion reactions and 
therefore made provision in the classification for not performing a blood 
culture. However because our study was prospective and all blood cultures 
were to be done, the criteria was modified to eliminate those uncertainties. A 
summary of the classification of case definitions are shown in table 6.1 
 
Treatment 
This was an observational study so the decision concerning whether and when 
initiate treatment was entirely the prerogative of the patient’s primary 
physician.  The study team provided the physicians with all preliminary and final 
laboratory results, in addition to any other findings made at follow up as soon 
as it became available.  A patient who was unwell at review was immediately 
referred to their physician for evaluation and management after blood culture 
was taken. 
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Table 6.1: Classification of transfusion-transmitted bacterial infection cases used in 
the study 
Case description Criterion used 
Definite transfusion-
transmitted bacterial 
infection 
 Same bacteria found in the transfused blood and 
the recipient  
 Contamination of blood sample or laboratory 
contamination is not suspected.  
Probable transfusion-
transmitted bacterial 
infection 
 Positive culture from transfused blood 
 Contamination of blood sample or laboratory 
contamination is not suspected.  
 Developed signs/symptoms during or within 24 hrs 
of transfusion 
 Recipients blood culture is negative (recipient 
taken/taking antibiotics) 
Possible transfusion-
transmitted bacterial 
infection 
 Positive culture from transfused blood 
 Contamination of blood sample or laboratory 
contamination is not suspected.  
 Presence of signs/symptoms prior to transfusion  
 Worsening or persisting symptoms 
 Recipients blood culture is negative (recipient 
taken/taking antibiotics) 
Unlikely transfusion-
transmitted bacterial 
infection 
 Positive culture from transfused blood 
 No signs/symptoms during or after transfusion 
 Contamination of blood sample or laboratory 
contamination suspected 
 
Sample collection and processing 
Two types of blood samples were obtained for bacterial culture; blood from the 
donated unit of blood that was transfused and blood from patients who had 
received a ‘contaminated’ blood transfusion. 
 
Sample collection from donated blood 
To obtain samples from the donated unit of blood that was being transfused, 
the transfusion was stopped almost at the end, when at least five mls of blood 
remained in the bag. The blood was collected aseptically by using a sterile 
syringe to draw five mls of blood through the port that had been cleaned with 
70% isopropyl alcohol. The blood was immediately inoculated into 20 mls of 
brain heart infusion (BHI) broth.  
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Sample collection from patients 
The antecubital fossa of the patients was vigorously cleaned with 70% isopropyl 
alcohol starting from the centre and cleaning in wider circles. This was done for 
30 seconds and the alcohol allowed to dry before 5 mls of venous blood was 
drawn, using a sterile needle and syringe. The blood was immediately 
inoculated into 20 mls of BHI and sent to the microbiology laboratory. The 
needle used for phlebotomy was changed before inoculation into the blood 
culture broth. 
Sample processing 
The BHI without sodium polyanetholsulfonate (Oxoid Ltd, Basingstoke, 
Hampshire, UK) when sent to the laboratory was immediately incubated 
aerobically for up to 7 days at 37oC.  Anaerobic cultures were not performed. 
The blood culture broth was inspected daily for turbidity as a sign of bacterial 
growth. Sub-cultures of the broth were performed onto 5% human blood agar 
and MacConkey agar (Oxoid Ltd, Basingstoke, Hampshire, UK) plates if the broth 
was turbid, and blindly on days 2 and 7. The plates were incubated aerobically 
at 37 °C for between 18-24 hrs. Colonies that grew on the plates were identified 
by colonial morphology, Gram stain reaction and standard biochemical and 
sugar fermentation tests.  Gram negative organisms were further identified by 
Mini API rapid ID 32E (BioMeriuex) test strips. Serology was not performed to 
confirm the Shigella spp.  
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Figure 6.1: The microbiology laboratory of KATH where the study was conducted 
 
Figure 6.2: Samples being processed in the microbiology laboratory 
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Susceptibility testing 
The antimicrobial susceptibility patterns of Pseudomonas spp, P. aeruginosa, 
Alcaligenes spp, Shigella spp and Citrobacter freundii, were tested using the disc 
diffusion method [CLSI method used]. Single antibiotic impregnated discs from 
Oxoid were tested on Muller-Hinton agar including the following antimicrobials: 
gentamicin (10 µg), amikacin (30 µg), ceftazidime (30 µg), co-trimoxazole (25 
µg), co-amoxyclav (30 µg), chloramphenicol (30 µg), cefuroxime (30 µg), 
ceftriaxone (30 µg), and ciprofloxacin (50 µg).   
 
6.2.1 Quality assurance and control 
Sterility testing was done on the batches of BHI broths, and agar plates used for 
culture to ensure that no contamination had taken place. For the quality control 
in antimicrobial susceptibility testing, control strain E. coli ATCC strains -25922 
was tested against the antimicrobials. The bacteriology laboratory participates 
in the World Health Organisation’s External Quality Assurance System for 
Antimicrobial Susceptibility Testing (EQAS-AST). This proficiency testing has 
been ongoing for nearly a decade and the laboratory has been recording very 
good results. 
As a further part of quality control, sterility testing was also performed on blood 
bags that had not been used to collect blood. The citrate was aspirated and 
cultured to ensure that there was no prior contamination of the blood bags. 
These cultures did not isolate any bacteria. 
 
Data management 
A Microsoft Access based electronic database was used to record data 
generated in this study.  The data was cleaned on an ongoing basis and 
exported into PASW Statistics v18.0 package (IBM, Chicago, IL, USA) for 
statistical analysis.  Descriptive statistics, including measures of central 
tendency, dispersion, cross tabulation and histogram were used where 
appropriate. Odds ratios and the 95% confidence intervals were calculated as a 
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measure of association between the donor and recipients characteristics and 
risk of giving or receiving contaminated blood units.  
 
6.3 Results 
Recipient characteristics 
Two hundred recipients of blood transfusion were enrolled in the study. The 
majority (42%) were from the Department of Medicine and Oncology.   There 
were slightly more females (51.5%) in the study because all patients from the 
department of O&G were females (Table 6.2).  
Table 6.2: Characteristics of transfusion recipients 
  Recipient characteristic   
Total number of recipients 200 
Female recipients (%)  103 (51.5) 
Median age (IQR) years 25.0 (4.2 – 39.0) 
Department of recipient (%) 
          Medicine and Oncology 
          Paediatrics 
         Obstetrics and Gynaecology 
 
84 (42) 
74 (37) 
42 (21) 
Median length of stay in hospital (IQR) days 6.5 (4.0- 13.0) 
Antimicrobial use during admission (%) 129 (64.5) 
Mortality in hospital (%) 21 (10.5) 
 
64.5% of recipients received antimicrobials during their admission. A total of 21 
recipients died giving a mortality rate of 10.5%. None of the deaths were 
considered to result directly from the blood transfusion (Table 6.2).  The 
patients who died included six from paediatrics, all acute infections (3 cases of 
severe malaria, 2 cases of sepsis E. coli and Klebsiella spp and a case of 
meningitis), one death from O&G due to cervical cancer and 14 from Medicine 
and Oncology (8 malignancies, 4 chronic kidney and liver diseases, and 1 case 
each of atypical pneumonia and hypertensive heart disease). 
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Donated blood units 
The characteristics of the donated units are in Table 6.3. Voluntary donors 
accounted for 71.5% of blood used for transfusion in the study.  The mean 
duration of transfusion was 2.3 hours.  A bacterium was isolated from 23 of the 
200 transfused units of blood, a contamination rate of 11.5% (95% CI 7.0-
16.0%).   
Table 6.3: Characteristics of blood from 200 donors 
  Donor and blood unit characteristics   
Voluntary donors (%) 143 (71.5) 
Male donors (%) 132 (66) 
Median duration of storage of blood (IQR) days 3.0 (1.0-5.0) 
Mean duration of blood transfusion ± SD (hours) 2.30 ± 1.5  
Positive culture from blood (%) 23 (11.5) 
 
Contamination rates in blood units sent to different departments 
Almost half of the contaminated blood units were sent to the Paediatrics 
department (Figure 6.3). 30% and 22% of isolates were from blood units sent to 
Medicine and Oncology, and O&G departments respectively. The departments 
of Medicine and Oncology received the lowest number of contaminated units 
while Paediatrics had the highest number.  
 
Bacterial isolates 
The organisms isolated are shown in figure 6.4.  Gram positive organisms 
including Bacillus species and coagulase negative Staphylococcus (CNS) 
accounted for the majority (70%) of organisms and CNS was the most common 
isolate. Gram negative organisms made up 30% and included Pseudomonas 
aeruginosa, Pseudomonas spp, Shigella spp, Alcaligenes spp. and Citrobacter 
freundii. 
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Figure 6.3: Bacterial contamination rates within departments 
 
 
Figure 6.4: Bacterial isolates cultured from donated blood 
 
 
Susceptibility of bacteria isolates 
The susceptibility patterns of the Gram negative organisms are shown in table 
6.4.  All of the three Pseudomonas spp. identified were susceptible to amikacin 
and ceftazidime but two of out of the three were resistant to gentamicin.  
Citrobacter was sensitive to all antimicrobials tested.  Alcaligenes was sensitive 
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to gentamicin, ceftriaxone and ciprofloxacin but resistant to chloramphenicol 
and amikacin. Both Shigella identified were sensitive to co-amoxyclav, and 
ceftriaxone (Table 6.4).  
Table  6.4: Sensitivity pattern of Gram negative bacterial contaminants 
Antimicrobial Susceptibility n (%) 
 Pseudomonas 
(N=3) 
Shigella spp 
(N=2) 
Citrobacter 
(N=1) 
Alcaligenes 
spp (N=1) 
Co-amoxyclav - 2/2 (100%) 1/1 (100%) - 
Co-trimoxazole - 1/2 (50%) 1/1 (100%) - 
Chloramphenicol - 1/2 (50%) - 0/1 
Gentamicin 1/3 (33.3%) 2/2 (100%) 1/1 (100%) 1/1 (100%) 
Amikacin 3/3 (100%) - - 0/1 
Ceftazidime 3/3 (100%) - 1/1 (100%) - 
Ceftriaxone - 2/2 (100%) - 1/1 (100%) 
Cefuroxime - 1/2 (50%) 1/1 (100%) - 
Ciprofloxacin - 1/2 (50%) 1/1 (100%) 1/1 (100%) 
 
Associations of the donor with contaminated units 
Donor characteristics:  Blood stored for up to 10 days was less likely to be 
contaminated than that stored for a greater number of days (OR 0.30, 95%CI 
0.10 -0.87). The gender of donor was not significantly associated with a 
contaminated unit (Table 6.5). Similarly there was not a statistically significant 
difference in contamination rates for the type of donor but the difference was 
large (6.5% in replacement donors compared to 14% in voluntary donors; p 
=0.21). 
 
Associations of the recipient with receiving a contaminated unit 
Fever in recipients:  There were 50 (25%) recipients of transfusion who were 
febrile at pre-transfusion assessment and 22 (11%) of recipients who were still 
febrile 24 hours post-transfusion (Figure 6.5).  The number of patients who 
were not febrile at pre-transfusion but became febrile during or after the 
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transfusion ranged from 30 (15%) at 30 minutes post transfusion to 9 (4.5%) at 
24 hours post transfusion.   
There were 6/23 (26%) recipients who received a contaminated unit and 
became febrile after the start of transfusion compared with 24/177 (13%) 
patients who received an uncontaminated unit and became febrile after the 
start of the transfusion (OR 2.250, 95% CI 0.6921-3.9754) (Table 6.6). There was 
no association between receiving a contaminated unit of blood and developing 
fever even after adjusting for antimicrobial use (OR 1.635, 95% CI 0.623 – 
4.291). 
Figure 6.5: Post transfusion fever in transfusion recipients 
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Table 6.5: Risk determination in the blood donors for contaminated blood units 
Donor characteristic 
  
Contaminated units 
N (%) 
Non-contaminated units 
N (%) 
P Value Odds ratio (95% CI) 
Sex of Donors Male 15 (65.2) 117 (70.5) 0.606 0.785 (0.289 – 2.178) 
 Female 8 (34.8) 49 (29.5)   
Type of Donor Replacement 3 (13.0) 43 (25.9) 0.207* 0.429 (0.096 - 1.633) 
 Voluntary 20 (87.0) 123 (74.1)   
Storage duration 0-10 days 17 (73.9) 150 (90.4) 0.021 0.302 (0.094 - 1.000) 
  >10 days 6 (26.1) 16 (9.6)     
*P value using Fisher’s Exact Test; CI = Confidence Interval 
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Table 6.6: Risk association for contaminated blood units in the transfusion recipients 
 Recipient characteristics 
  
Contaminated 
units (n=23) 
Non-contaminated 
units (n=177) 
P value Odds ratio (95% CI) 
 
Department Paediatrics 11 (48.0) 63 (35.6) 0.260 1.659 (0.637 – 4.310) 
 other 12 (52.0) 114 (64.4)   
Fever Yes 6 (26.1) 24 (13.6) 0.113 2.250 (0.710 - 6.883) 
 No 17 (73.9) 153 (86.4)   
Chills Yes 3 (13.1) 13 (7.3) 0.343 1.892 (0.390 – 8.037) 
 No 20 (86.9) 164 (92.7)   
Antibiotic use Yes 17 (73.9) 118 (66.7) 0.485 1.417 (0.491 – 4.265) 
  No 6 (26.1) 59 (33.3)   
Prolonged admission Yes 9 (39.1) 48 (27.1) 0.230 1.728 (0.640 – 4.608) 
 No 14 (60.9) 129 (72.9)   
Outcome Died 2 (8.7) 19 (10.7) 1.000* 0.792 (0.118 – 3.927) 
 Alive 21 (91.3) 158 (89.3)   
*P value using Fisher’s Exact Test; CI = Confidence Interval 
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Other signs and symptoms 
Recipients of contaminated blood did not exhibit many signs and symptoms besides 
fever.  None of the patients developed post transfusion, hypotension or 
bradycardia. One recipient experienced post transfusion tachycardia.  Two patients 
complained of restlessness and three developed chills post transfusion.  
 
Antimicrobial use 
Among the recipients who received contaminated blood, 17/23 (74%) were treated 
with antimicrobials compared with 118/177 (66.7%) who received uncontaminated 
blood (Table 6.6).  There was no association between being given antimicrobials 
and receiving a contaminated blood unit.  The commonly given empirical 
antimicrobials were gentamicin, chloramphenicol, flucloxacillin and cefuroxime in 
paediatrics and metronidazole in combination with cefuroxime or co-amoxyclav in 
O&G.  In the Department of Medicine, ceftriaxone and metronidazole were 
commonly used but a wide range of other antimicrobials were also prescribed, 
depending on the condition being treated.  The presence of fever at pre-transfusion 
or the development of fever post transfusion was not significantly influenced by the 
use of antimicrobials (Table 6.7).   
Table 6.7: Determination of the effects of antibiotic usage on the presence of 
fever in transfusion recipients 
 Antibiotic use  
FEVER Yes (%) No (%) P-value 
Pre-transfusion fever (yes) 42 (31.1) 20 (30.8) 0.961 
Fever at 30 min post transfusion (yes) 31 (26.5) 11 (19.3) 0.297 
Immediate post-transfusion fever (yes) 32 (24.1) 11 (17.2) 0.274 
Fever 24 hours after transfusion (yes) 20 (15.4) 5 (8.9) 0.236 
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Other recipient characteristics 
There were no association between risk of receiving a contaminated unit of blood 
and death as a study outcome, prolonged admission and receiving blood in the 
paediatrics department (Table 6.6).   
 
Patient follow- up [Table 6.8, 6.9, 6.10] 
Twenty one of the 23 patients who received a contaminated blood unit were 
evaluated within seven days.  Two could not be followed up; one child had died 
from Klebsiella spp. sepsis, which was diagnosed pre-transfusion and an adult died 
from liver cirrhosis.  
There were nine patients still in hospital at the time of follow up. Seven of them 
had received or were still receiving an appropriate antimicrobial. For two patients 
their physicians decided on additional antimicrobials because of the contaminated 
blood they had received. One patient was being treated for puerperal sepsis and 
anaemia and the obstetricians added ciprofloxacin to cefuroxime and 
metronidazole when Alcaligenes spp was isolated from the transfused unit of 
blood. A patient with HIV/TB received additional co-trimoxazole when Shigella spp 
was isolated from the transfused blood.  
Twelve patients had already been discharged home but were recalled. All patients 
were clinically well with no signs of ongoing sepsis. However, one patient, who 
received blood contaminated with Pseudomonas aeruginosa, required readmission 
for anaemia and was transfused again.  He did not show any signs of sepsis and the 
paediatricians decided against treatment with antimicrobials.  
 
Transfusion-transmitted bacterial infections 
The blood cultures taken at follow-up visits did not yield bacteria including those 
identified from the transfused unit of blood. None of the recipients was therefore 
classified as a case of definite transfusion-transmitted bacterial infection.  
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There were 26 % (6/23) probable (Table 6.8) and 21% (5/23) possible cases (Table 
6.9) of transfusion-transmitted bacteria resulting from 23 donated blood units 
contaminated with bacteria. The remaining 53% (12/23) of patients were 
considered unlikely to have had a transfusion-transmitted bacterial infection (Table 
6.10). 
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Table 6.8: Cases of probable transfusion-transmitted bacterial infection cases identified in the study 
Age Diagnosis Pre-
transfusion 
fever 
Post-
transfusion 
fever 
Post-
transfusion 
chills 
Post-
transfusion 
restlessness  
Antimicrobials 
received in 
hospital  
Isolate from 
donated blood 
Outcome at 
Discharge 
Transfusion-
transmitted 
bacterial 
infection 
(TTI) 
25 Antepartum 
haemorrhage 
No No Yes No Co-amoxyclav, 
Metronidazole 
Bacillus spp Alive Probable TTI 
48 Hepatic failure No Yes No No Ceftriaxone, 
Metronidazole 
Citrobacter 
freundii 
Alive Probable TTI 
3 Severe malaria  No Yes No No Co-amoxyclav CNS Alive Probable TTI 
1 Klebsiella 
sepsis 
No Yes No No Gentamicin, 
Cefuroxime 
CNS Dead Probable TTI 
2 Severe 
malarial 
anaemia 
No Yes No No Gentamicin, 
Chloramphenicol 
Pseudomonas 
aeruginosa 
Alive Probable TTI 
34 Post 
Caesarean 
section 
No Yes No No Co-amoxyclav, 
Metronidazole 
Pseudomonas 
aeruginosa 
Alive Probable TTI 
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Table 6.9: Cases of possible transfusion-transmitted bacterial infections identified in the study 
Age Diagnosis Pre-
transfusion 
fever 
Post-
transfusion 
fever 
Post-
transfusion 
chills 
Post-
transfusion 
restlessness  
Antimicrobials 
received in 
hospital  
Isolate 
from 
donated 
blood 
Outcome at 
Discharge 
Transfusion-
transmitted 
bacterial 
infection 
(TTI) 
30 Puerperal 
sepsis 
Yes Yes Yes Yes Cefuroxime. 
Metronidazole 
Alcaligenes 
spp 
Alive Possible TTI 
Ciprofloxacin1 
2 Severe 
malarial 
anaemia 
Yes Yes Yes Yes Flucloxacillin 
Chloramphenicol 
Bacillus spp Alive Possible TTI 
2 Staph aureus 
sepsis 
Yes Yes No No Flucloxacillin 
Chloramphenicol 
Gentamicin 
CNS Alive Possible TTI 
30 Liver cirrhosis 
with sepsis 
Yes Yes No No Ceftriaxone CNS Dead Possible TTI 
25 G6PD full 
defect with 
pancytopenia 
Yes Yes No No Metronidazole 
Flucloxacillin  
CNS Alive Possible TTI 
Co-amoxyclav 
1 Antimicrobial added following receipt of the blood unit bacterial culture result 
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Table 6.10: Cases of unlikely transfusion-transmitted bacterial infections 
Age Diagnosis Pre-
transfusion 
fever 
Post-
transfusion 
fever 
Post-
transfusion 
chills 
Antimicrobials received 
in hospital  
Isolate from donated 
blood 
Outcome at 
Discharge 
Transfusion- 
transmitted 
bacterial infection 
(TTI) 
43 HIV with TB Yes Yes No Anti-TB medications,  Shigella spp Alive Unlikely TTI 
Co-trimoxazole
1
 
43 Liver cirrhosis   No No No Metronidazole Bacillus spp Alive Unlikely TTI 
34 Chronic anaemia No No No - Bacillus spp Alive Unlikely TTI 
24 Severe anaemia 
2IVH 
No No No Cefuroxime,  Bacillus spp Alive Unlikely TTI 
Co-amoxyclav, 
Metronidazole 
12 Sickle Cell anaemia No No No Cefuroxime CNS Alive Unlikely TTI 
3 severe malarial 
anaemia 
No No No - CNS Alive Unlikely TTI 
27 HIV with E.coli 
sepsis 
No No No Co-trimoxazole, 
Metronidazole, 
Ciprofloxacin 
CNS Alive Unlikely TTI 
3 Sickle cell Dx with S. 
aureus sepsis 
No No No Cefuroxime CNS Alive Unlikely TTI 
42 Ca Cervix No No No - Pseudomonas spp Alive Unlikely TTI 
1 Severe malaria No No No - Shigella spp Alive Unlikely TTI 
1 Severe anaemia No Yes No - CNS Alive Unlikely TTI 
2 Severe malaria Yes No No - CNS Alive Unlikely TTI 
All patients did not have post-transfusion restlessness. 1 Antimicrobial added following receipt of the blood unit bacterial culture result 
152 
 
6.4 Discussion 
This study has demonstrated a prevalence of 11.5% of bacterial contamination 
in donated blood. This high prevalence is comparable to earlier studies with 
estimates of 8.8% and 9% in Kenya and Southern Ghana respectively (36,37). An 
even higher level of contamination (17.5%) was found in Northern Ghana (36). It 
has been suggested that prospective bacterial cultures of whole blood or red 
cell units have a higher incidence of bacterial contamination than there actually 
is (246) because of the difficulties in maintaining an aseptic environment during 
sample transfer, leading to false positive test results (223). These consistently 
high rates of bacterial contamination however cannot be ignored and should be 
a cause for concern as we seek to improve blood safety in Africa.  The study 
presented in this chapter is unique because in previously reported studies, 
samples of blood were taken while the blood was in the blood bank. Whereas in 
this study samples were taken right at the end of transfusion and this may be a 
truer reflection of what was transfused to the recipient.  It is possible that 
during or after sampling in the blood bank, even more bacteria may be 
introduced into the blood thereby increasing the patient risk. 
This study has demonstrated some clinical effects on recipients. Although no 
definite case of transfusion-transmitted bacterial infection was identified, 5.5% 
(11/200) of all transfusion recipients had probable or possible transfusion-
transmitted bacterial infection. No comparable studies investigating the clinical 
effects of bacterial contamination on recipients has been identified in Africa. 
Even in developed countries with good haemovigilance systems in place, 
establishing a definite case of transfusion-transmitted bacterial infection has 
not been easy. In Canada, out of 39 reported septic transfusion reactions over a 
4-year period, 20% were classified as definite, 64% as probable and 15% as 
possible bacterial contamination incidents (422). In the US, Benjamin et al 
reported that 12/20 (60%) of septic transfusion reactions were judged to be 
probable because the incriminating organism could not be isolated from the 
patient’s blood; seven of them because antimicrobial therapy had already been 
instituted (423).  
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The prescription of antimicrobials was high in the study population. Although 
there was no statistical difference between antimicrobial usage in recipients of 
contaminated blood and recipients of non-contaminated blood, more (74%) 
antimicrobials were prescribed for recipients of contaminated blood. This may 
be a reason for why bacteria could not be cultured from the recipients.  Apart 
from resulting in a negative blood culture, antimicrobial use can mask overt 
signs and symptoms of septic transfusion reaction (241).   The clinical severity of 
a transfusion- associated septic reaction can vary considerably (213), depending 
on a number of factors. The bacterial species implicated, its virulence and the 
total number of bacteria infused are as important as recipient characteristics 
such as underlying disease, the status of the immune system, and whether the 
recipient is receiving concomitant antibiotic therapy (241).    None of the 
patients in our study showed signs of overwhelming sepsis.  In those who were 
not treated with antibiotics and did not show any signs of sepsis, pathogens 
recovered from their transfused units may have been as a result of 
contamination during sample collection and transport or contamination during 
processing of samples.  
Fever is one of the signs that were evaluated as a possible indicator of sepsis 
but there was no significant association established in this study. This is not 
surprising as there are many other causes of fever. It was seen that fever at all 
times, including at pre-transfusion, 30 minutes after the start of transfusion, 
immediate post transfusion and 24 hours after transfusion, was more common 
in recipients who received antimicrobials than those who did not. This finding 
may not support the suggestion that antibiotics mask signs of sepsis. However, 
because most recipients were febrile pre-transfusion and most antimicrobials 
were also started pre-transfusion, it suggests recipients were prescribed 
antimicrobials for other co-morbid conditions that were present before the 
transfusion started.  
Some organisms are less virulent than others and therefore may cause less 
overt sepsis. For example, CNS may not be considered a serious threat in 
healthy adults with strong immune system. CNS has however been implicated in 
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a number of deaths and severe transfusion reactions (215,246). In this study the 
majority (70%) of the organisms were Gram positive bacteria. CNS and Bacillus 
spp are skin commensals that when found in blood may indicate poor skin 
cleansing techniques before donor blood is obtained. CNS was similarly the 
major cause of contamination in both previous studies conducted in Ghana 
(36,37) but not in the study from Kenya (205). 
Gram negative bacteria may generally be more virulent and can quickly produce 
septic shock through the effects of endotoxin.  Gram negative bacteria such as 
Yersinia spp and Pseudomonas spp can also survive in temperatures of 2-8oC 
and cause bacterial contamination and sepsis even when blood is stored under 
refrigerated conditions (239).  Pseudomonas may be transiently present on skin 
and inadequate skin cleansing of donors can result in the presence of 
Pseudomonas in the donated blood. Pseudomonas was the commonest Gram 
negative bacteria in this study and has been reported in previous studies in 
Africa (37,205).  
Shigella spp was an unexpected finding as a blood contaminant as it is not a 
usual pathogen isolated from blood.  It also is able to survive under refrigeration 
conditions. The clinical details from the 2 donated units and the 2 recipients 
were reviewed but their transfusions were 2 weeks apart and they were from 
different departments. The antimicrobial susceptibility patterns were also not 
the same and therefore it was unlikely to have been the same Shigella from 
both samples. Unfortunately it was not possible to confirm the Shigella species 
because of lack of antisera for the required agglutination tests.  Shigella is 
commonly spread by the feacal-oral route so breaches in aseptic technique 
while collecting the blood could have resulted in the contamination by Shigella.  
The contamination of red cell products may be directly related to its storage 
time. For example, most cases of Yersinia contamination occur in blood bags 
older than 25 days (239) and the majority of septic transfusion reactions 
associated with contaminated RBCs usually occur with units that have been 
stored for more than 21 days (424). In this study, blood stored for more than 10 
days was significantly more likely to be contaminated.   Other published studies 
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from Africa do not establish an association of contamination with duration of 
storage. The 10 day risk of contamination compared to the 21 days found in 
developed countries may be due to unreliable refrigeration conditions which 
have been suggested as a factor contributing to the hazard of bacterial 
contamination (205). Monitoring of the fridges was not performed during the 
study.  
The observation of higher contamination rates in donor blood from voluntary 
donors compared to replacement donors may be due to different skin cleansing 
practices under different conditions. Blood from replacement donors are 
obtained in the hospital while voluntary blood is donated at mobile sessions 
including school outreach programmes and FM radio station blood drives. For 
these mobile sessions which are outside the hospital, there is the likelihood that 
skin cleansing procedures may not be done appropriately. This may be due to 
staff not spending the adequate time to clean the skin because of the many 
donors waiting to give blood or the absence of clean running water for proper 
hand washing. Such conditions may increase the risk of contamination 
compared to conditions which may exist in a hospital setting which has been 
created for blood collection. It may be helpful if larger studies are conducted to 
compare contamination rates. 
Bacterial contamination may result from exogenous sources such as from the 
skin of donors, and manipulation of blood units into smaller volumes. Blood 
units sent to the Department of Paediatrics had the highest contamination rates 
although the likelihood of a paediatric unit being contaminated was not 
significantly higher than blood sent to the other departments. Blood prepared 
for the paediatrics department was usually less than 500 mls and therefore the 
original donated unit had to be breached to take out the required volume. This 
process of manipulation, especially if done without full aseptic conditions, may 
account for the increased pathogen isolation. Leaky seals, damaged tubing, or 
micro-punctures in collection bags have been linked to episodes of bacterial 
sepsis (237). Contamination of blood transfusion bags has also been reported 
(228). Further, heavy contamination of the exterior of blood packs with Serratia 
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marcescens has lead to septicaemia in recipients following transfusions with red 
cells or platelets (425).  Inadequate skin cleansing is one of the commonest 
causes of bacterial contamination. 70% povidine iodine has been recommended 
worldwide but at KATH alcohol is still being used for the skin preparation. 
Sterilization of skin surfaces has limits when the phlebotomy needle cores out a 
skin plug as it passes through the skin. This inherently non-sterile skin plug can 
be carried into and seed the collected blood.  The majority of organisms present 
in both culture studies and case reports of platelet-associated sepsis is usually 
normal skin flora as it may be virtually impossible to decontaminate human 
skin. Blood culture results show an incidence of positive cultures, ranging from 
2% to 6% after the cleansing of the skin (227).   
Contamination can also be from an endogenous source in which a donor may be 
having a transient bacteraemia or a subclinical infection. Donor bacteraemia is 
not easily identified but it may be reduced by an efficient donor screening 
programme. Screening will however not be able to identify donors with 
transient bacteraemia. Individuals infected with Yersinia enterocolitica are 
typically asymptomatic at the time of blood donation (259,426,427).  
Risk reduction strategies include careful selection of blood donors, appropriate 
attention to skin preparation and to the detection of bacteria in samples of 
blood prior to transfusion (241). Sample diversion, where the first 20 -40 mls of 
blood collected are directed away from the blood bag is another method that 
reduces bacterial contamination.  Studies have shown that either alone or in 
combination, improved donor arm disinfection and sample diversion leads to a 
40-88% reduction of bacterial contamination of donated blood (231,264,265).   
6.4.1 Study limitations 
Follow up in this study was limited to patients who received blood that yielded 
bacterial isolates from the laboratory. However, a look back investigation of 
patients who developed signs and symptoms suggestive of transfusion 
associated bacterial infection may possibly have identified some false negative 
culture results.  Such an investigation simulates bedside scenarios where 
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patients who develop transfusion associated bacterial infections are 
retrospectively diagnosed by culturing the donated blood. 
Agar prepared with human blood is associated with poor bacterial isolation 
rates. Human blood agar has been shown to be suboptimal for the growth and 
susceptibility testing of some organisms including Streptococcus pneumoniae, 
Streptococcus pyogenes and Staphylococcus aureus (428). The use of human 
blood agar may have resulted in the recovery of fewer organisms than there 
actually was. 
The inability to recover organisms from the recipients of contaminated blood 
raises questions of whether all organisms isolated from the culture of 
transfused blood was actually transfused into the patient. 
Anaerobic cultures were not done. It is therefore possible that anaerobes, such 
as Clostridium perfringes which has been implicated in transfusion sepsis was 
missed in this study. 
 
6.5 Summary  
Bacterial contamination occurred in 11.5% of donated blood units. Not all 
recipients of contaminated blood units developed clinical sepsis or bacteraemia.  
‘Probable transfusion-transmitted bacterial infection’ occurred in 26% of 
recipients of contaminated units and 21.7% of recipients had ‘possible 
transfusion-transmitted bacterial infection’.  The lack of ‘definite transfusion-
transmitted bacterial infection’ or the apparent lack of clinical effects of 
septicaemia in recipients of contaminated blood may be due to the high rate of 
antimicrobial usage among recipients of blood transfusion or false positive 
cultures.  
Bacterial contamination can occur at different points including collection of 
blood from donor, processing and storage of blood, sample collection and 
laboratory processing. To reduce the risk of transfusion recipients receiving 
blood contaminated by bacterial we recommend a multi-step approach to 
eliminate possible sources of contamination.  A carefully directed donor 
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questionnaire should include a recent history of tooth extraction, 
sigmoidoscopy or minor medical procedures which can cause transient 
bacteraemia. This can be used to identify and defer such donors to eliminate 
endogenous sources of bacterial contamination.  Strict adherence to proven 
skin cleansing procedures before phlebotomy, and a sample diversion strategy 
in which the first 20 mls of drawn blood is discarded, can eliminate exogenous 
causes of bacterial contamination.  Furthermore, the use of paediatric packs if 
available, although expensive, will remove the need for manipulations that 
breech the integrity of donated blood units to produce the smaller volumes 
required for paediatrics.   
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CHAPTER 7 
TRANSFUSION-TRANSMITTED SYPHILIS 
7.1 Introduction 
Syphilis is a public health problem with serious consequences if not prevented 
or treated (279). Worldwide 12 million people are infected with syphilis each 
year and more than 90% of infections occur in low and middle-income countries 
(429).  An estimated 2 million pregnant women are infected with syphilis, 
resulting in the birth of at least 500,000 babies with congenital syphilis (430). 
Congenital infection may cause a further half a million annual abortions, still 
births and other cases of peri-natal deaths each year (431). The burden of 
congenital syphilis is concentrated in Africa where it has not received serious 
attention, hence its description as the ‘forgotten priority’ (432).   
To prevent the transmission of syphilis by transfusion, screening of all donated 
blood donations is recommended (59). Though a legal requirement in most 
countries (378), screening remains a challenge in developing countries. Twenty 
percent of donated blood in sub-Saharan Africa is transfused without screening 
for any of the major transfusion transmissible infections (433) and in Ghana, 
only 20% of donated blood is screened for syphilis (23).  
The burden of syphilis attributable to transfusion-transmitted syphilis is not 
known but pregnant women and children, who are the major recipients of 
blood transfusion in sub-Saharan Africa, are particularly at risk of contracting 
transfusion-transmitted syphilis. Routine screening of blood donors, a decrease 
in the prevalence of syphilis, and the refrigeration of the donated blood prior to 
its use (66,297) may be the reasons why no transfusion-transmitted syphilis has 
been reported over the past few decades.  There has recently been a 
resurgence of syphilis cases across Europe and North America (286,434,435). 
This increase indicates that risky sexual behaviours are increasing in the blood 
donor population and therefore a continuous vigilance is required in blood 
services (295).  
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This chapter deals with transfusion-transmitted syphilis and describes a study 
carried out to establish the prevalence of syphilis in the donor population in 
Kumasi, and to determine if sero-conversion had taken place in transfusion 
recipients. 
 
7.2 Materials and methods   
Participants and recruitment 
Participants were recruited between November and December 2009 from the 
Departments of Paediatrics, Obstetrics and Gynaecology, Medicine and 
Oncology of the Komfo Anokye Teaching Hospital (KATH) in Kumasi, Ghana. The 
blood bank in KATH provides blood and blood products for all transfusions in 
the hospital. Blood donors are currently screened for HIV, hepatitis B and 
hepatitis C infections but not for syphilis. Only donors who are negative by 
these screening tests are allowed to donate blood.  
 
Eligibility 
Inclusion criteria: All recipients of blood transfusion in the three departments 
(Paediatrics, Obstetrics and Gynaecology, Medicine and Oncology) were eligible 
for recruitment into the study if they gave their written informed consent.  
Exclusion criteria:  
i) Patients who were to be transfused in the operating theatres, where 
the transfusion could not be monitored.  
ii) Any patient in shock, unconscious or with an altered mental status 
which prevented them from being able to identify any symptoms 
experienced during transfusion.  
iii) All patients receiving their transfusion before 8am and after 6pm. 
This was because they could not be monitored by the study team. 
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Recruitment into study 
Participants were given consecutive and unique study identification numbers 
upon recruitment into the study. Prior to transfusion, a complete medical 
history was obtained and a clinical examination was performed and 
documented. The patient’s diagnoses was also retrieved from their case notes 
and recorded. Plasma from paired blood samples, namely a pre-transfusion 
sample from the patient and a sample from the unit of transfused blood were 
obtained and stored in a -20°C freezer for later testing in batches. Socio-
demographic data of the blood donors and the duration of storage of the 
transfused blood units were retrieved from the blood bank and recorded in the 
patients case report form. 
 
Patient monitoring and follow up 
Patients were monitored while receiving their transfusion by hourly 
measurement and documentation of their vital signs, including the 
temperature, the pulse rate, respiratory rate and blood pressure 
measurements. Immediately after the transfusion patients were asked for any 
symptoms they experienced during the transfusion.  When testing had been 
carried out on donor blood and patient samples, sero-negative recipients of 
sero-positive blood were recalled for a clinical re-evaluation and re-testing to 
determine if sero conversion had occurred. The recalled patients were also 
questioned for fever or skin lesions on symptoms to determine if they had 
developed any symptoms after the transfusion. Recipients, whose pre-
transfusion samples were sero-positive, were not evaluated for sero-
conversion. All blood donors and transfusion recipients who were found to have 
recent/active syphilis were recalled and if they attended were offered 
counselling and treatment of syphilis in accordance with national guidelines.  
 
 
 
162 
 
Classification of donated blood and recipients 
Based on the EIA and TPHA results, blood donors and recipients were 
retrospectively classified as sero-negative or sero-positive. A sero-positive result 
was defined as a reactive result in both the EIA and TPHA assays and sero-
negativity was defined as a negative result in the EIA assay or a reactive EIA 
result but negative TPHA result. Reactivity to the RPR test in sero-positive 
patients/donors was consistent with recent/active infection and those with 
non-reactive plasma were classified as old syphilis infections (Figure 7.1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sero-positive, old infection 
negative 
negative 
Sample from patient/donor blood 
Sample test by treponemal EIA 
False-positive EIA 
Test with TPHA 
Sero-positive, recent / 
active infection 
reactive non-reactive 
Perform RPR 
reactive 
Sero-negative 
reactive 
Figure 7.1: Screening algorithm used for testing for syphilis 
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Sample collection and processing 
Two mls of the donor blood was obtained from the blood bag at the end of the 
transfusion when the blood bag was clipped off.  The sample was taken at the 
end of the transfusion to ensure that the integrity of the unit of blood was 
maintained and avoid potential iatrogenic contamination during sampling.  At 
pre-transfusion and at follow up, a minimum of one ml of blood each was 
drawn from the patients. Samples were collected in clearly labelled EDTA tubes 
and centrifuged. Plasma was aliquoted from both patient and donor blood into 
labelled corresponding Eppendorf tubes, and stored in a -20°C freezer.  
Sample testing 
Three tests for syphilis were performed in the following order; enzyme 
immunoassay (EIA), treponemal hemagglutination assay (TPHA) and carbon 
agglutination. Bioelisa Syphilis 3.0, (Biokit, S.A. Barcelona-Spain), a third 
generation immunoenzymatic assay was the test kit used for the EIA. Syphagen 
TPHA (Biokit, S.A. Barcelona-Spain) and Biokit RPR Reditest (Biokit, S.A. 
Barcelona, Spain) were the test kits used for TPHA and RPR assays respectively.  
These tests have been used in previously reported studies (299,436-438). All 
assays were performed according to the manufacturer’s instructions. Sample 
testing was done as indicated in figure 7.1.  All samples reactive to the EIA assay 
were confirmed with TPHA. If reactive to TPHA, sample testing was repeated 
with both EIA and TPHA. Samples that were not reactive to EIA did not have a 
TPHA assay or RPR performed on it.  EIA/TPHA positive samples were tested 
with RPR and the RPR was repeated the sample was if reactive. 
 
Enzyme linked immunosorbent assay 
Principle: Bioelisa Syphilis 3.0, used for the initial screening of all samples, 
detects IgG and IgM antibodies to T. pallidum by a sandwich ELISA capture 
process. The wells of the microplate provided are coated with p15, p17 and p47 
T pallidum recombinant antigens which capture the corresponding antibodies.  
The recombinants antigens which have been conjugated to enzyme peroxidise 
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are added to bind the captured antibodies. This complex turns blue when an 
enzyme substrate and chromogen is added, indicating the presence of T. 
Pallidum antibodies.    
Figure 7.2: The ELISA reader and washer used for the study 
 
 
Figure 7.3: An ELISA plate with the yellow wells indicative of a positive test result 
 
 
Procedure: After bringing all materials to room temperature, 50 µl of each 
patient sample was added to 50 µl of sample diluent in individual microplate 
wells. Two negative controls, 3 low positive controls and 2 high positive controls 
were included in each batch of samples tested. The microplate was covered, 
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mixed gently and incubated for an hour at 37°C. The contents of the wells were 
aspirated and plates washed four times using an ELISA washer (BIORAD PW 40 
Microplate Washer) (Figure 7.2) after which 100 µl of diluted conjugate was 
added to individual wells except  that for the blank. Washing was repeated after 
incubating the plate at room temperature for 30 minutes. 
A 100 µl freshly prepared substrate-chromogen was added into each well with 
the solution turning blue if the sample contained anti-T. pallidum antibodies.  
This was incubated at room temperature for 30 minutes and 100 µl of stop 
solution was added, turning the blue solution into yellow. The absorbance was 
read at 450 nm by means of a microplate photometer (Thermo Scientific 
Multiskan EX). 
A mean absorbance calculated from the 3 low positive controls was used as the 
cut-off value in each ELISA assay. A reactive sample was one with an absorbance 
higher than the determined cut-off value.   
 
Treponema Pallidum Hemagglutination Assay 
Principle: The Treponema pallidum hemagglutination assay (TPHA, Biokit 
Syphagen TPHA), used in this study is an indirect hemagglutination test for the 
detection of specific antibodies to T pallidum. Chicken erythrocytes sensitised 
with an antigenic extract of T. Pallidum (Nichols strain) will agglutinate with 
specific antibodies present in the serum or plasma of syphilitic patients 
Procedure: Test samples, round bottom microtitre plates and reagents (antigen, 
control, diluents, positive and negative controls) were brought to room 
temperature by allowing them to sit on the work bench. Each sample used four 
wells, the first two of which were for diluting samples and the other two wells 
were the control and test wells. Using the diluents, the samples in wells three 
and four were made up to a 1:20 dilution. These wells had 75 µl of control and 
antigen reagents added separately to the wells, to bring the final dilution to 
1:80 (Table 7.1).   
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Table 7.1: Summary of steps used for confirming syphilis by the test method of 
Treponema pallidum hemagglutination assay 
Well number 1 2 3 
Control 
4 
Test 
Diluent solution µl 25 100 25 25 
Sample µl 25    
Min and transfer µl 
 
  25   25  25 
 25 25 
Sample dilution 1:2 1:10 1:20 1:20 
Control reagent µl - - 75 - 
Antigen reagent µl - - - 75 
Final dilution   1:80 1:80 
Incubate for 60 minutes at room temperature 
 
The contents were mixed by slightly tapping on the sides of the plate. The plate 
was then covered and incubated for an hour at room temperature. Positive and 
negative controls were included for each batch of samples tested. The results 
were then read qualitatively.  
A positive result was declared when a smooth mat of agglutinated cells covered 
the entire bottom of the well (4+), or a smooth mat partially covered the 
bottom of the well (3+), or a smooth mat of agglutinated cells surrounded by a 
ring of cells (2+), or a smooth mat of agglutinated cells surrounded by a heavy 
ring of cells (1+). A button of cells with or without a very small hole in the centre 
implies a negative result (figure 7.4). 
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In this picture, plate A represents a partially used micro titre plate. Different samples 
are tested in rows A to H but column 1 to 4 have the same sample. Columns 5 to 8 are 
negative (row A) and positive controls (row B).  
 
Rapid Plasma Reagin test 
Principle: Biokit RPR Reditest is a macroscopic non-treponemal test. The RPR 
antigen is a cardiolipin suspension containing charcoal micro particles which 
detects IgG and IgM antilipid antibodies traditionally called ‘reagin’ that are 
present in the plasma of syphilitic patients and also in some acute or chronic 
diseases.  
Procedure: The antigen containing vial, the samples to be tested and the 
controls were left on the bench to allow them to attain room temperature. A 
drop of the sample was placed and spread in each circle on the test card 
provided.  The antigen vial was gently shaken and a drop added without mixing.  
The card was placed on a mechanical rotator for 8 minutes at 100rpm after 
which the test reaction is read macroscopically as the card is tilted from side to 
side. Positive and negative controls were included with each run. A sample was 
said to be reactive to RPR when the characteristic black clumping of charcoal 
particles was observed.   
A 
B 
C 
D 
E 
F 
G 
H 
  1    2    3    4 5    6   7    8 
Negative 
Positive 
Figure 7.4: Picture of a TPHA test performed on EIA positive samples 
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7.3 Results 
Recipient characteristics 
The 200 recipients of blood transfusions recruited into the study had a median 
age of 28 years. The majority of recipients (45.5%) were from the Departments 
of Medicine and Oncology (Table 7.2).  The mortality in this group of transfusion 
recipients was 10.5%. 
Causes of admissions 
The diagnoses of transfusion recipients recorded in their case notes are 
summarized in table 7.3. The majority (45.5%) of the transfusions in paediatrics 
were for malarial anaemia but in medicine/oncology chronic organ (kidney and 
liver) diseases and gastrointestinal bleeding was more common. HIV and 
tuberculosis was more frequently seen in recipients from medicine/oncology 
than in O&G and paediatrics where no HIV was diagnosed. The most frequent 
reason (62.7%) for transfusions in the department of O&G was haemorrhage 
(Table 7.3). 
Table 7.2: Characteristics of transfusion recipients 
Total number of recipients 200 
Number of male recipients (%) 98 (49.0) 
Median age (IQR, range) years 28 (8–39, 1-86) 
Department of recipient (%) 
          Medicine and Oncology 
          Paediatrics 
          Obstetrics and Gynaecology 
 
91 (45.5) 
63 (31.5) 
46 (23) 
Antimicrobial use during admission (%) 131 (65.5) 
Mortality in hospital (%)  
EIA reactive 
EIA and TPHA reactive prior to transfusion (%) 
23 (10.5) 
38 (19.0) 
26 (13.0) 
RPR reactive  (%  RPR reactive/TPHA positive) 9/26 (34.6) 
IQR = inter quartile range, EIA = enzyme immunoassay, TPHA = Treponema pallidum 
hemagglutination assay and RPR = rapid plasma reagin. 
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Sero-prevalence in recipients 
Twenty six transfusion recipients were confirmed sero-positive for syphilis by 
EIA and TPHA prior to transfusion, giving a syphilis infection sero-prevalence of 
13.0% (95% CI 8.3-17.7%) (Table 7.2). Nine of these (34.6%) were RPR reactive, 
giving a prevalence of recent/active infections of 4.5% (95% CI 1.7- 7.3%). Most 
of the EIA/TPHA positive patients were in the Department of Medicine and 
Oncology (84.6%), with 11.5% in Obstetrics and Gynaecology and 3.8% in 
Paediatrics. 
While in hospital, 65.5% of recipients received concomitant antimicrobial 
therapy in hospital for their underlying conditions. 
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Table 7.3: Diagnoses of recipients of blood transfusion in the study 
Medicine/oncology Number (%) Paediatrics Number (%) O & G Number (%) 
Chronic organ disease 20 (21.9) All malaria 30 (45.5) Haemorrhage 32 (62.7) 
GI bleeding 19 (20.9) Sickle Cell disease 10 (15.1) All malignancies 11 (21.6) 
Other anaemia’s 15 (16.5) Sepsis/pneumonia/ 
meningitis 
8 (12.1) Sepsis/pyelonephritis 3 (5.9) 
HIV/Tuberculosis 13 (14.3) All malignancies 7 (10.6) HIV/Tuberculosis 3 (5.9) 
All malignancies 11 (12.1) Malnutrition 4 (6.1) Other anaemia’s 2 (3.9) 
Sickle cell disease 5 (5.5) Other anaemia’s 4 (6.1)   
Septicaemia 4  (4.4) Chronic organ disease 2 (3.0)   
*HMS / 
Hepatosplenomegaly 
4 (4.4) GI Bleeding 1 (1.5)   
  HIV/Tuberculosis 0   
Total 91 (100) Total 66 (100) Total 51 (100) 
 
*HMS represents Hyper-reactive Malarial Splenomegaly; O & G represents Obstetrics and Gynaecology 
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Donor blood characteristics  
Voluntary donors contributed 68% of the 200 blood units transfused to 
recipients in this study. The majority (72.5%) of donors were males (Table 7.4). 
All the 200 donated units of blood were kept refrigerated until they were issued 
for use but 56.8% of the transfused blood was kept refrigerated for less than 4 
days. 
Table 7.4: Characteristics of units of donated blood 
Total number of transfusion units 200 
Donated blood from male donors (%) 145 (72.5) 
Donated blood from voluntary donors (%) 136 (68.0) 
Median duration of storage (IQR, range) days 3.0 (1-5, 1-21)  
Number of blood units kept for ≤3 days (%) 109 (56.8) 
EIA reactive 24 (12.0) 
EIA and TPHA reactive (%) 16 (8.0) 
RPR reactive  (% RPR reactive/TPHA positive) 7/16 (43.8) 
IQR = inter quartile range, EIA = enzyme immunoassay, TPHA = Treponema pallidum 
hemagglutination assay and RPR = rapid plasma reagin. 
 
Syphilis sero-prevalence in donor blood 
Sixteen of the 200 donated units of blood were sero-positive by the EIA and 
TPHA assays, giving a syphilis sero-positivity of 8% (95% CI 4.3-11.7%) in 
donated blood units (Table 7.4). In seven (43.8%) of the sero-positive samples 
the RPR test was positive, giving a 3.5% (95% CI 1.0-6.0%) prevalence of 
recent/active syphilis infection in the donors. There was no significant 
difference in the proportion of samples positive by EIA/TPHA between the 
recipients and donors (p=0.14) or the proportion of samples positive by EI/TPHA 
and RPR between the two groups (p=0.80) 
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Follow-up findings  
There were 16 recipients of sero-positive blood (Table 7.5). Eight were not 
followed up for the following reasons: four of them had died during the hospital 
admission; two were sero-positive at pre-transfusion; and two were lost to 
follow up. Eight recipients of sero-positive blood were followed up and had a 
repeat syphilis screen at 30 days post-transfusion. Six of the eight were EIA 
negative and 2 were reactive. One of the 2 reactive recipients (recipient ID 13) 
was a false positive as sample was not confirmed by TPHA testing (Table 4). The 
other positive sample (patient ID10) was confirmed by TPHA and also reactive in 
the RPR test.   
Nine out of the 16 recipients (56.3%) were prescribed antibiotics during 
hospitalisation. In various combinations, metronidazole and cefuroxime were 
given to four patients, amoxycillin-clavulanic acid given to three patients and 
ciprofloxacin, gentamicin and ceftriaxone were given to 2 recipients. All nine of 
them received an antibiotic closely related to the penicillin’s, which is the 
recommended treatment for syphilis. These were amoxicillin, cefuroxime and 
ceftriaxone.   
 
Recipient with sero-conversion 
The recipient (ID 10) identified as having sero-converted was an 8 year old girl 
who had been admitted for suspected severe malarial anaemia. She was 
transfused because her initial packed cell volume was 12% and she had 
persistent intra-vascular haemolysis with ‘coca-cola urine’. She developed post 
transfusion fever but both blood culture and peripheral blood film for malaria 
parasites were negative. She was treated with cefuroxime and gentamicin and 
discharged after a week. At her follow up visit on day 36, there was no fever or 
relevant sexual history and she had felt completely well for the period since her 
discharge from hospital. Clinical examination did not reveal any muco-
cutaneous lesion or lymphadenopathy.  
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Table 7.5: Characteristics of 16 recipients of syphilis sero-positive blood transfusions 
 RPR results 
for transfused 
blood 
Duration 
of 
storage 
Results for pre-transfusion 
testing 
30 day 
follow 
up visit? 
Recipient post –transfusion 
testing Sero 
conversion Comment 
  RPR Days EIA TPHA RPR Yes/No EIA TPHA RPR Yes/No   
1 Reactive 12 Neg ND ND No     Died 
2 Non-reactive 2 Neg ND ND No         Died 
3 Non-reactive 2 Neg ND ND No     Died 
4 Non-reactive 1 Neg ND ND No         Died 
5 React 4 Neg ND ND No     LFU 
6 Non-reactive 1 Neg ND ND No         LFU 
7 Non-reactive 2 Pos Pos Non-reactive No     PPT 
8 Non-reactive 6 Pos Pos Reactive No         PPT 
9 Non-reactive 3 Neg ND ND Yes Neg ND ND No  
10 Reactive 1 Neg ND ND Yes Pos Pos Reactive Yes  
11 Non-reactive 2 Neg ND ND Yes Neg ND ND No  
12 Reactive 1 Neg ND ND Yes Neg ND ND No  
13 Reactive 3 Neg ND ND Yes Pos Neg Non-
reactive 
No  
14 Non-reactive 2 Neg ND ND Yes Neg ND ND No  
15 Reactive 1 Neg ND ND Yes Neg ND ND No  
16 Reactive 4 Neg ND ND Yes Neg ND ND No  
EIA = Enzyme immunoassay; TPHA = Treponema pallidum hemagglutination assay; RPR = rapid plasma regain; LFU = Lost to follow up; PPT = Positive 
at Pre-transfusion; ND= Not done, Pos = positive; Neg = Negative; + = positive seroprevalence; - = negative seroprevalence 
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The child was referred to the paediatricians after confirmation of her sero-positive 
status and was treated with a course of penicillin. The source of the positive blood 
was a male voluntary donor and the blood was kept refrigerated for only one day 
before being issued for use.   
 
7.4 Discussion 
The positive syphilis sero-conversion in an initially sero-negative child is most 
probably due to transfusion-transmitted syphilis and will be the first report in over 
three decades (439). The last case reported in medical literature was in 1983 (309). 
Other treponemal infections such as yaws cannot be differentiated serologically 
from syphilis. Since yaws is not endemic in Kumasi and because there was no 
clinical evidence, yaws is unlikely to be the cause of the sero-conversion. 
Furthermore, the 8 year old girl was not sexually active and therefore not likely to 
have contacted the infection sexually. The most likely cause of the sero-conversion 
in this patient was the serologically positive blood she received by transfusion.  
The 8% prevalence of sero-positivity to syphilis in donated blood found in this study 
is consistent with previously published rates of 7.5% to 13.5% among donors in 
Ghana (38,39), although the type of donors were different. More than two-thirds of 
the donors in this study were voluntary donors (68%) compared to the study by 
Ampofo et al where 96.3% were replacement donors (39). 
The sero-reactivity prevalence rates of 7.5-13.5% in Ghana published in the peer-
reviewed literature are at variance with sero-reactivity rates in donor blood 
reported by the national transfusion service of Ghana of 0.75% - 2.14% (23). This 
disparity may be related to the different methods of testing used. The tests used for 
screening in the blood service are the non treponemal tests such as RPR and 
Venereal Diseases Research Laboratory (VDRL) which detect only recent infections. 
For the published studies Treponema pallidum EIA or particle agglutination assays 
which were used have a better sensitivity (346) and in addition to recent infections 
can detect old infections,   
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The difference in sero-positivity prevalence among donors (8%; 95% CI 4.3-11.7%) 
and recipients (13%; 95% CI 8.3-17.7%) was not significant. The HIV positive donors 
and donors with other high risk factors have been eliminated by the screening 
process prior to the syphilis testing and may account for the low prevalence seen in 
donors compared to  the recipients in this study that include HIV positive patients 
who may have a higher risk for syphilis. Also pregnancy and malignancies are known 
to be associated with false positive results (344). These may account for the 
difference in prevalence between the donors (that did not include pregnant 
women, people with malignancies or HIV) and the recipients. 
The risk of acquiring transfusion-transmitted syphilis in Ghana is not known. A high 
syphilis sero-prevalence among donors may increase the risk posed to the 
recipients. However, factors that may reduce the risk include refrigeration of blood, 
antimicrobial use, passive surveillance and an efficient donor deferral system (356).   
More than half (56.8%) of the donated blood used in this study was stored for 3 or 
less days, and this is insufficient time to kill T. pallidum (366). The current average 
blood storage duration in Ghana does not provide an adequate margin of safety 
against transfusion-transmitted syphilis. This is the situation that prevails across 
many blood banks in sub-Saharan Africa where replacement donation is the major 
source of blood and where, because of inadequate supply, blood is used as soon as 
it becomes available (440). In Kumasi, refrigeration is not one of the factors that 
reduce the risk of transfusion-transmitted syphilis. 
The use of antimicrobials has been one of the reasons proposed for the decline of 
TTS (321) because T pallidum remains very susceptible to penicillin. Many recipients 
of blood transfusion in Africa are sick enough to require antimicrobials. This is likely 
to kill any bacteria that may have been transfused thereby preventing syphilis in 
recipients.  In my study, 56.3% of the recipients who received EIA/TPHA sero-
positive blood were prescribed antibiotics. At least one of the antibiotics received 
by each recipient is closely related to the recommended drug (penicillin) for T. 
pallidum.  These were cefuroxime, ceftriaxone and amoxicillin-clavulanic acid. 
Amoxicillin and cefuroxime are not routinely used to treat syphilis but ceftriaxone is 
a recommended alternative for penicillin.  Besides the recipient who sero-
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converted, there were two other recipients who received blood from donors who 
were sero-positive with a recent infection. All three donations were stored for only 
one day and the three recipients had concomitant antibiotics but one recipient 
sero-converted (Table 7.5). The recipient who sero-converted was treated with 
cefuroxime and gentamicin while the other 2 received cefuroxime only and 
amoxycillin-clavulanic acid and metronidazole respectively.  Since the true presence 
of T. pallidum could not be ascertained, the efficacy of the antimicrobials used 
cannot be established. It is possible that T. pallidum would be killed if it were 
present in the transfused blood. All the antimicrobials given were for treatment of 
other co-existing conditions and not to treat suspected syphilis.  
It has been shown that relatively few blood donors with infectious syphilis report 
relevant risk factors for syphilis and donor questionnaires did not promptly defer 
these donors (278). This may be particularly relevant for replacement donors as 
such donors may not volunteer a history of risky behaviour because of their 
concern that their relative may not get the required blood. Under these 
circumstances, screening for syphilis cannot be compromised. 
There is a shortfall of blood supply in sub-Saharan Africa with an average annual 
blood collection rate of 5.14 units per 100 populations (17). The consequences of 
such shortages can be severe as seen in a systematic review which identified that 
26% of maternal deaths was due to lack of blood (12) Such consequences could be 
further worsened if 8% of blood is to be discarded due to syphilis sero-positivity.  
What is needed is a way of identifying the true infectious units of blood thereby 
saving and using blood from treated donors who may be sero-positive but not 
infectious. 
 
7.4.1 Study limitations 
1. It would have been ideal to titrate the positive TPHA and RPR results. A 
rising titre would indicate the presence of an acute or ongoing infection. 
There was however insufficient plasma to carry out these added tests.  
177 
 
2. The serological tests used for the diagnosis of syphilis are indirect methods 
and they do not tell us whether the positive blood is infectious or not. The 
existence of cross reactivity to other treponemes suggests that there is the 
possibility that not all serologically positive samples are cases of syphilis.  
 
7.5 Summary 
There is a sero-positivity prevalence of 8.0% in blood donors in Kumasi, Ghana. This 
high syphilis prevalence and the identification of syphilis sero-conversion in a child 
indicate that transfusion-transmitted syphilis is still a problem in Kumasi, Ghana. 
Transfusion recipients are therefore at risk in centres where donated blood is not 
screened for syphilis. Because blood is not stored for prolonged refrigeration 
periods, there is an added risk of transfusion-transmitted syphilis. Urgent steps 
should be initiated to establish syphilis screening in Kumasi and other centres 
where screening is not done and to achieve a 100% syphilis screening of all donated 
blood at all blood centres.  A follow up study to determine cost effectiveness of a 
screening algorithm is recommended.  
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CHAPTER 8 
GENERAL DISCUSSION 
Introduction 
In this thesis, I have presented a series of studies that investigated the prevalence, 
and effects of P. falciparum malaria, bacterial contamination and syphilis on 
transfusion recipients. In chapters four, five, six and seven, results and a detailed 
discussion of the results of the specific disease areas were presented. In this 
chapter, the results are discussed in the broad context of transfusion medicine and 
blood safety.   
 
8.1 Donor screening and blood safety 
Screening constitutes the mainstay of ensuring the safety of our blood supplies. In 
developed countries, improved screening methods have drastically reduced 
transfusion-transmitted viral infections (441). Screening with microscopy or highly 
sensitive EIA is recommended by WHO to prevent TTM (59).  My study has shown 
that of four methods used for P. falciparum detection in donated blood, only PCR 
had a high sensitivity and can be used as a screening test. The sensitivity of 
microscopy and EIA was low. The four indices of test validity (sensitivity, specificity, 
positive predictive value and negative predictive value) were all high for PCR. In 
addition to PCR, microscopy had a specificity of 100%. Tests with high specificity are 
good confirmatory tests so microscopy may be used as a confirmatory test in 
screening blood for P. falciparum.  In assessing a screening test, the disease under 
consideration and the proposed policy should be considered in addition to validity 
of the test (442,443). The disease should constitute a significant public health 
problem, and should be readily treatable. Concerning policy, the screening 
programme must be cost effective and facilities for diagnosis and treatment must 
be readily available.  The incidence of TTM in this study was low and does not 
constitute a major public health problem in these patients. The incidence of TTM 
should however be compared across regions of different malaria transmissions to 
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establish whether the burden of TTM is different. Cost effective studies will be 
needed in specific regions before any particular screening intervention is 
recommended for routine use. Very few cost effective studies exist in Africa. In the 
only study retrieved, Rajab et al determined that the cost per case prevented of 
TTM is higher for recipient anti-malarial prophylaxis than pre-transfusion screening 
with an automated technique (192).   
Routine screening for bacterial contamination is not realistic.  Blood culture, which 
is the gold standard, is expensive, requires expertise and cannot be done in many 
district and lower level centres where regular electricity is not available.  A 
limitation with blood culture is that it can take up to 7 days for a final result to be 
declared. Delayed results will not be clinically relevant for the physician or the 
patient who will have received the blood already. My study has also demonstrated 
the difficulty of interpreting results from blood culture as the laboratory is unable 
to determine whether all culture isolates were true contaminants of transfusion or 
if they were due to poor aseptic techniques in collecting the blood culture. The 
presence of a bacterial isolate at culture does not necessarily imply the organism 
was in the donated blood and has been transfused into the transfusion recipient. 
Further, not all recipients of such ‘contaminated blood’ develop transfusion 
reactions associated with these bacteria.  
Screening for syphilis presents a different challenge.  Whereas screening for malaria 
and bacteria are not routine, routine screening is recommended for syphilis.  An 
argument against screening has been made in some developed countries where the 
incidence of syphilis is low, donors repeatedly give blood and the blood is kept 
refrigerated for prolonged periods that inactivate T. Pallidum. These factors, which 
all significantly reduce transmission risk, were not seen in this study. Rather, my 
study has shown shorter refrigeration storage conditions and high syphilis 
prevalence. These conditions may increase the risk of syphilis transmission. In my 
study only one case of probable transfusion-transmitted syphilis was found. These 
conditions may give cause for concern in especially in centres not screening for 
syphilis.  
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In summary, based on my study findings, routine screening for Plasmodium and 
routine blood cultures to detect bacterial contamination cannot be recommended 
but syphilis screening, which is already a worldwide recommendation, should be 
implemented in KATH and all centres not screening for syphilis. 
 
8.2 Donor screening and blood supply 
The adequacy of blood supply is a critical issue that faces transfusion services in 
Africa (13). Bates et al showed that 26% of maternal haemorrhage deaths were due 
to lack of blood (12). These shortages could be further compromised if screening 
tests are introduced without adequate evaluation. Using the prevalence found in 
my study, about 13% (8% for syphilis and 4.7% for P. falciparum) of blood units 
would have been rejected. In previously reported studies across Africa where 
incidence of syphilis in donors is over 10% and up to 50% for malaria, the 
consequences on blood supply of rejecting these blood units will be disastrous.  
Screening for syphilis presents a dilemma because testing is by indirect means and 
does not identify infectious samples. Antibodies to T. Pallidum remain positive even 
after treatment at a time when the blood is no longer infectious. Such treated and 
non infectious donors should be able to donate blood. The use of reactivity to RPR 
assays in some centres to identify and reject only donors with recent infections 
helps reduce the rejection rate by half as seen in my study. There is however no 
evidence that all recent infections result in infectious donors (444). Making donated 
blood units available that are rejected unnecessarily could save many lives. A test is 
urgently needed that will identify infectious samples. Until such a test is available, 
current algorithms will have to be re-evaluated to establish, not only the most cost 
effective but also the test that yields the lowest rate of false positivity. 
 
8.3 Transfusion monitoring and blood safety 
Blood transfusion monitoring is one of the measures which improve blood safety, 
especially when transfusion-transmitted bacterial sepsis is involved. The onset of 
signs and symptoms is very rapid for transfusion related bacterial sepsis, usually 
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within a few hours of starting the transfusion (241). If the transfusion is being 
monitored, such reactions can be quickly identified and the transfusion stopped.  
Efficient monitoring which results in an immediate stoppage of the transfusion, 
investigation and immediate treatment can be life saving. My observation of 
transfusion practices in KATH as presented in chapter 4 showed that vital signs 
were often not measured at all or measured only once. Similarly in Uganda, there 
was no recording for vital signs in 97% of transfusions that took place in a regional 
referral hospital (445).  It is unclear why monitoring of transfusion is not being done 
in Africa.  Haemovigilance is generally lacking in Africa and only few countries such 
as South Africa and Zimbabwe have developed some systems (200). Transfusion 
monitoring is an important part of blood transfusion safety and its implementation 
in Africa should become a priority.  
As was expected, immediate transfusion reactions did not have an association with 
TTM. Even for the non immune transfusion recipients TTM takes several days to 
weeks for symptoms to develop. Beyond 24 hours, there are many other causes of 
fever, including malaria not caused by the transfusion. In my study post transfusion 
malaria (12%) was more common than TTM (2%). Transfusion monitoring does not 
have a role to play in TTM and neither can it be used to identify transfusion-
transmitted syphilis. 
 
8.4 Anti-malarial and antimicrobial usage in transfusion recipients 
The use of anti-malarials was high in transfusion recipients especially in paediatrics. 
In KATH, 77% of children were given anti-malarials with their transfusion. This high 
use of anti-malarials in paediatrics prevented many children from being enrolled 
into my study.  It was often not clear whether children were being treated for 
malaria as a possible cause for anaemia or were being given anti-malarials 
presumptively for TTM. Therefore in relation to TTM in children, it is difficult to 
make any conclusions. For the recipients who were enrolled into the study, 25% 
received anti-malarials, but only 12% (11/93) of those prescriptions were based on 
microscopic confirmation. This observation is intriguing because physicians knew 
that patients were being actively followed up for malaria and yet still felt inclined to 
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give anti-malarials when microscopy was negative. This practice is clearly against 
the WHO treatment guidelines for malaria (383). Two possible reasons for this 
behaviour may be the recommendation of presumptive treatment for TTM and the 
old teaching of ‘every fever is malaria unless proven otherwise’. The use of anti-
malarials must be rational and evidence based to protect the development and 
spread of resistant strains.  
Antimicrobial use was also observed to be very high among transfusion recipients. 
In all studies presented in this thesis, the rate of use of antimicrobials was 
consistently between 60 -66%. The concomitant use of antimicrobials results from 
two reasons; non surgical recipients being sick enough to warrant blood culture 
investigations and antimicrobial therapy, and the surgical patients being given 
prophylactic antimicrobials. The high use of antimicrobials has two potentially 
beneficial effects in the context of blood transfusions. It may prevent the 
development of a severe septic reaction to bacterially contaminated blood and it 
could be treatment for syphilis. Antimicrobial use has been one of the reasons given 
for the low incidence of transfusion-transmitted syphilis (310). Antimicrobials may 
have some beneficial effects on transfusion recipients but studies are needed to 
clearly define these benefits including whether they prevent transfusion 
transmitted syphilis and bacterial infections. But just like anti-malarials, misuse or 
abuse of antimicrobials could lead to the development of resistant strains of 
bacteria (446). Antimicrobials should not be used as prophylaxis in transfusion.  
The frequent use of anti-malarials and antibiotics is of interest to paediatricians, 
physicians and public health specialists. This is because malaria and bacterial 
infections cannot easily be differentiated clinically and therefore doctors may start 
both anti-malarials and antibiotics until a firm diagnosis is made (394).  There is also 
concern that a dogma that translates as ‘anti-malarials for RDT positive, antibiotic 
for RDT negative’ is in the offing (447). A concerted effort from clinicians, 
microbiologists, public health and transfusion practitioners and policy makers is 
required to ensure we do not ‘shoot ourselves in the foot ‘ but rather provide 
guidance in judicious use of antimicrobials and anti-malarials. 
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8.5 Blood safety and blood storage duration 
The duration of storage of refrigerated blood has different effects on TTM, bacterial 
contamination and syphilis.   
The viability of T. Pallidum is lost when blood is stored beyond 5 days at 4°C (448). 
The start of blood banking and the associated extended storage of blood in fridges 
has contributed to the low levels of transfusion-transmitted syphilis. In many 
developing countries where blood donation is by replacement donors and the 
blood collection is hospital based, blood is not usually kept for long periods. There 
are however some countries such as Kenya where a National Blood Service exists 
and blood is collected centrally for distribution. In such systems blood is likely to be 
refrigerated for longer periods. In KATH, where this study took place in Ghana, the 
median duration of storage is 2 days. To keep blood for more than 5 days will 
probably require a well thought out written policy which all staff has to be aware 
off. This will most likely not be feasible unless blood supply is plentiful.  This will not 
come without operational and ethical challenges.  In dire obstetric emergencies, 
staff will grapple with whether to issue blood not stored for stipulated period in 
order to save a patient versus keeping the blood to kill T pallidum. People who 
donate blood will not wait for several days before their relative receives a 
transfusion.  There are many scenarios that will challenge such a policy especially 
during ‘lean seasons’ in blood banks. 
Prolonged refrigeration is unattractive when bacterial contamination of donor 
blood is considered because my study has shown that storage for more than 10 
days is associated with increased chance of contamination. Other published studies 
suggest that the risk of contamination of blood is highest after storage for 14 to 25 
days (215,426). Irrespective of the number of days, the evidence suggests that the 
longer the period of storage of blood, the more likely the risk of bacterial 
contamination. In 1991, a recommendation to reduce the storage duration of blood 
from 42 to 25 days generated controversy and was finally rejected because of the 
potential impact on blood supply. Additionally it was argued reducing the storage 
duration would only reduce but not eliminate contamination (215). Prolonged 
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storage will have challenges in settings where a regular supply of electricity is not 
assured leading to temperature fluctuations in fridges. 
It is uncertain whether P. falciparum lose viability after 14 days of refrigeration. The 
blood of the patient who developed TTM in my study had been stored for 2 days.   
Prolonged storage of blood as a way of reducing the risk for transfusion-transmitted 
syphilis has many potential challenges and may not be the best alternative. 
 
8.6 Pathogen reduction and transfusion safety 
Pathogen inactivation technologies for treatment of platelet or plasma components 
based on methylene blue, psoralen and riboflavin technologies are in routine use. 
Technologies for treatment of whole blood are in development, making pathogen 
reduction of all blood products using one system achievable (271).  Many bacteria, 
protozoa and viruses are susceptible to pathogen inactivation. The broad 
applicability of pathogen inactivation therefore holds promise and is seen as an 
important safeguard against future and emerging infectious risks. Implementation 
of pathogen inactivation technology could decrease or eliminate the residual risk of 
infectious complications (449). There are still safety concerns that must be 
addressed but sufficient benefit and cost-effectiveness of the technology must be 
established to warrant implementation.  
 
8.7 Policy making in transfusion 
As discussed in chapter four, the recommended policies in blood safety for malaria 
conflict with each other and do not give a clear direction. The WHO recommends 
screening for malaria in endemic countries and also recommends presumptive 
treatment (59).  This is confusing because it does not state whether malaria positive 
blood should be discarded or if only malaria negative blood should be transfused 
and presumptive treatment given.  Combining these two recommendations may be 
expensive but the end result will probably be the same as giving every recipient 
presumptive treatment.  
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Also current recommendation for parasitological confirmation before malaria 
treatment contradicts with the policy of presumptive treatment (59,383).  Policies 
and guidelines should not be ambiguous so that they can be interpreted the same 
way by everyone. This ambiguity may account for the different transfusion practices 
within different departments. For example, in paediatrics, anti-malarials are used 
frequently with transfusion and across all departments anti-malarials are used 
without parasitological confirmation. 
 
These policies as they exist now need revision and harmonisation. The revision 
should be based on evidence and any region or country that takes on board a policy 
should ensure that the evidence used for those policies is relevant to that particular 
area. For policies in TTM, malaria control programmes and transfusion services will 
have to review the evidence available to come out with evidence based practices 
which do not conflict with each other. Guidelines can be developed along 
standardised formats such as the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) approach.  It offers a transparent and 
structured process for developing and presenting summaries of evidence and is 
now used widely (450,451).  
 
Summary 
Table 8.1 summarises three criteria used to assess whether a screening test should 
be introduced for transfusion-transmitted syphilis and transfusion-transmitted 
malaria. Transfusion-transmitted syphilis has been a well known problem and 
screening is already taking place. A good reason is needed to discontinue a process 
that has been so effective in making transfusion safe. My study has provided 
evidence to the contrary and found that syphilis transmission goes on in the 
absence of screening. In institutions such as KATH, where syphilis screening is not 
being performed, the implementation of a screening strategy is recommended. 
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A policy of routine screening for TTM has not been implemented and the burden of 
TTM has not yet been established. Although my study suggests the incidence of 
TTM is low, larger studies are needed to establish the magnitude of the problem. 
PCR may be a good test but it needs to be validated as a screening test. It is 
currently not affordable and is impractical to implement on a large scale. In this 
study PCR will reduce blood supply by 18% but on the continent up to 50% of 
donors are positive. Such a reduction will compromise blood supplies. Cost 
effectiveness studies have not shown that the benefits of introducing screening 
outweigh any harm that results from screening. Under the current circumstances, 
routine screening for malaria parasites is not recommended. 
 
Table 6: Criteria assessed for implementing a screening test 
Criteria Transfusion-transmitted 
syphilis 
Transfusion-transmitted 
malaria 
The disease:  Is the 
disease a public health 
problem? 
 
Transfusion transmitted 
syphilis is a well known public 
health problem (but possibly 
on the decline) 
. 
Transfusion-transmitted 
malaria may not be a huge 
public health problem 
 
 
The test:  Is it reliable 
and valid (i.e. sensitivity, 
specificity, positive and 
negative predictive 
values)? 
 
 
There are recommended 
screening algorithms which 
have been validated 
 
There are no valid tests 
recommended for screening  
 
The policy: Is screening 
cost-effective? How 
implementable?   
 
Screening is cost effective and 
has been accepted worldwide. 
Exact policy is unclear (anti-
malarial prophylaxis or 
screening donor blood or 
both). Cost effectiveness has 
not been assessed. 
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CHAPTER 9 
CONCLUSIONS AND RECOMMENDATIONS 
9.1 Conclusion 
The aim of my study was to determine the effects of blood transfusions containing 
malaria or bacteria (including syphilis) on transfusion recipients living in a malaria 
endemic area.  There were four specific objectives to which this study sought 
answers in order to achieve the study aim. The conclusions of this study are 
provided according to each objective in this chapter. In addition the implications of 
this study and recommendations are presented.  
 
Objective 1: To describe the impact of policies relating to malaria transmission and 
blood transfusion on clinical practice in endemic countries. 
Conclusion 
Clinical practice differs among hospital departments. Anti-malarial drugs are 
commonly prescribed routinely with blood transfusions. This contravenes malaria 
treatment guidelines of laboratory confirmation before treatment but is in 
accordance with less well-evidenced blood safety guidelines. 
 
Objective 2: To determine the prevalence of malaria parasitaemia and bacterial 
contamination in donated blood and blood products for transfusion. 
Conclusion 
The prevalence of P. falciparum in donor blood was 4.7% by microscopy, 13.7% by 
RDT, 18% by PCR and 22.2% by EIA. 
The prevalence of syphilis sero-positivity in blood donors was 8% for all infections 
and 3.5% for recent infections. 
The prevalence of bacterial contamination in donated blood units was 11.5%. 
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Objective 3: To identify any adverse effects on recipients of donated blood/blood 
products that had malaria parasites or bacterial contamination.  
Conclusion 
The incidence of transfusion-transmitted malaria (TTM) was 2.0% (one patient). The 
patient with TTM did not show any clinical signs and symptoms of malaria. 
The incidence of transfusion-transmitted syphilis was 0.5% (one patient). 
The incidence of probable or possible transfusion-transmitted bacterial sepsis was 
5.5%. 
 
Objective 4: To compare microscopic, serological and molecular methods for 
screening blood for malaria parasites 
Conclusion 
The PCR test method showed the highest sensitivity (93.4%), specificity (100%), 
positive predictive value (100%) and negative predictive value (98.6%).  Microscopy 
had the lowest (24%) sensitivity but had the highest specificity (100%) and positive 
predictive value.  The sensitivity and specificity of RDT and EIA were low. 
 
Summary of the conclusions 
Overall, this study showed that malaria and syphilis were transmitted by blood 
transfusions but at low rates. Transfusion recipients did not show any clinical 
effects of TTM and transfusion-transmitted syphilis. On the other hand bacterial 
contamination in donated units was high (11.5%) and half of recipients of these 
units developed signs of sepsis.  
 
 
9.2 Dissemination of study findings and implications 
Throughout the period of the study, regular formal and informal meetings were 
held within departments and units in KATH to provide feedback of results. On two 
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occasions, study results were presented to the hospital’s Transfusion Committee. A 
presentation of my results was also held in the Department of Haematology and 
Transfusion in Korle-Bu hospital in Accra, the biggest teaching hospital in Ghana. My 
research topic generated not only local but international interest and I was invited 
to present papers in International meeting and conferences. The topics of my 
presentations are listed in table 9.1.   
 
Table 9.1: Presentations at international meetings 
Meeting Title of presentation 
7th International Alliance for Biological 
Standardization (IABS) symposium on 
Advances in Transfusion Safety, 
Singapore. July 2011 
Malaria and transfusion in endemic areas 
21st Regional Congress of the 
International Society of Blood 
Transfusion (ISBT), Lisbon, Portugal. 
June 2011 
Malaria in the blood supply in Africa: Is it a 
problem? 
British Society of Haematology, 
Brighton, UK. April 2011 
Feasibility of screening for malaria and syphilis 
in endemic countries 
31st International Congress of the ISBT, 
Berlin, Germany. June 2010 
1. Transfusion practices in a teaching hospital 
in Ghana. 
2. Bacterial Contamination of donated blood 
3. Syphilis screening in a teaching hospital in 
Ghana. 
International Plasma Fractionation 
Association, Zagreb, Croatia. May 2010 
Screening or Treatment: The dilemma of 
malaria safety in hyper endemic area. 
Division of Transfusion Medicine, 
Haematology Department, Cambridge, 
UK. May 2010 
Malaria blood safety; approaches in West 
Africa 
 
 
The publications that have resulted from my study are shown in Table 9.2.  The 
published articles and abstract of my presentations are provided in appendices 1.1 
to 1.6.  
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Table 9.2: Publications arising from thesis 
Published manuscripts 
1. Transfusion transmitted syphilis in teaching hospital, Ghana. Owusu-Ofori AK, Parry 
CM, Bates I. Emerging Infectious Diseases 2011 Nov; 17(11): 2080-2. Letter 
 
2. Transfusion transmitted malaria in countries where malaria is endemic: a review of 
the literature. Owusu-Ofori AK, Parry CM, Bates I. Clinical Infectious Diseases 2010 
Nov 15; 51(10):1192-8. Epub 2010 Oct 7. Review 
 
 
Submitted manuscripts 
1. Impact of inconsistent policies for transfusion-transmitted malaria on clinical 
practice in Ghana. Accepted by PLoS One journal 
2. Transfusion transmitted malaria in Ghana. Submitted to The Lancet 
 
Manuscript in preparation 
Bacterial contamination of donated blood and its effects on transfusion recipients. 
 
 
The justification for performing this study arose from the apparent lack of evidence 
in Africa about these transfusion transmissible diseases, namely malaria, syphilis 
and other bacterial infections (49). It was therefore not surprising that my 
presentations generated a lot of interest. One interesting but worrying feedback in 
Ghana was that despite the evidence that was presented, clinicians were sticking to 
their previous opinions.  For example, physicians thought parasitaemia should be 
higher than my findings showed. Many physicians thought patients should be given 
anti-malarials even if no parasitaemia was found in the recipients after transfusion.  
Some ‘experts’ were of the opinion that refrigeration of blood should be able to 
eliminate T. pallidum from blood and therefore, refrigeration for at least 5 days 
should be mandatory.  This was a preferred option for many local physicians and 
also for the transfusion committee, rather than screen with indirect tests that result 
in unnecessary rejection of non-infectious blood. The logistics, science and ethics of 
keeping blood for prolonged periods have been discussed in chapter 8. 
Scientists at the international meetings were of the opinion that the findings, 
especially for malaria and syphilis, were important but larger sample sizes were 
needed to adequately portray the true incidence of these transfusions transmitted 
infections. 
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My findings in this study will provide a basis that will stimulate further research to 
provide more evidence in transfusion-transmitted malaria and bacterial infections. 
 
9.3 Recommendations 
1. Presumptive treatment of transfusion recipients in malaria endemic areas is 
not warranted and should be discontinued.   
2. Routine screening of donated blood for Plasmodium falciparum is not 
recommended for transfusions in adult patients. 
3. A study to compare the incidence of TTM in different malaria endemic 
regions and different transmission seasons is recommended. 
4. Komfo Anokye Teaching Hospital and other blood centres that are presently 
not screening for syphilis should re-institute screening.   
5. Training of clinical staff on the need for transfusion monitoring is crucial and 
should be done regularly in hospitals. Transfusion monitoring should be 
performed for all blood transfusions taking place in the hospital and 
transfusion reactions systematically investigated. 
6. To reduce bacterial contamination and transfusion related sepsis strict 
adherence to proven skin cleansing procedures before phlebotomy, 
particularly for mobile blood drives. 
7. Transfusion service and malaria programme managers in each country 
should collaborate to harmonise policies related to prevention of TTM and 
develop systems that will encourage adherence to these policies.   
8. Pathogen inactivation is a promising intervention in whole blood with the 
potential to make blood safer. Feasibility of clinical trials in this area should 
be explored in Africa.  
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9.4 Research questions arising from my thesis 
Transfusion-transmitted malaria 
Children and infants were not adequately represented in this study. Therefore a 
study to determine the incidence of TTM in children is needed to provide evidence 
that will support or refute the current practice of presumptive treatment in children  
 
Bacterial contamination 
Sources of contamination were not established in my study. Blood units sent to 
department of paediatrics had the highest contamination rate. However 
contamination also occurred in units sent to other departments.  Further studies 
are required that will identify specific causes and sources of contamination so that 
targeted solutions can be implemented to avoid contamination. 
 
Syphilis screening 
The syphilis screening algorithm that includes enzyme immunoassay, T. pallidum 
hemagglutination (TPHA) and rapid plasma regain (RPR) assay is highly sensitive.   
The complexity of this three tier screening may result in poor user compliance and 
is more expensive than the single RPR assay commonly used. Different screening 
algorithms should be compared to establish the most cost effective screening 
method. 
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Transfusion-
transmitted 
Syphilis in Teaching 
Hospital, Ghana
To the Editor: Transfusion-
transmitted syphilis, which is caused 
by Treponema pallidum subspecies 
pallidum, is one of the oldest recognized 
infectious risks of blood transfusion (1). 
Routine screening of blood donors and 
refrigeration of donated blood before 
its use has resulted in only 3 reported 
cases of transfusion-transmitted 
syphilis over the past 4 decades (2–6).
The World Health Organization 
recommends screening all donated 
blood for syphilis (7), but doing so 
is challenging for many developing 
countries. Many blood banks in low-
income countries, including Komfo 
Anokye Teaching Hospital in Kumasi, 
Ghana, do not screen donated blood 
for syphilis. 
This study was conducted at 
Komfo Anokye Teaching Hospital. 
The purpose of this study was to 
determine the prevalence of syphilis 
among blood donors and whether 
seroconversion occurred in transfusion 
recipients. The study was approved 
by the ethics committees in Kumasi, 
Ghana, and Liverpool, UK.
Pretransfusion plasma samples 
from 200 conscious transfusion 
recipients in adult, pediatric, and 
obstetric inpatient departments and 
samples of their transfused blood 
were tested for syphilis. A positive 
initial result by enzyme immunoassay 
(EIA) (Bioelisa Syphilis 3.0; Biokit, 
Barcelona, Spain) was confi rmed by 
using a T. pallidum hemagglutination 
assay (TPHA) (Syphagen; Biokit). 
A rapid plasma reagin (RPR) assay 
(RPR Reditest; Biokit) was used to 
determine whether seropositivity 
was caused by recent infection. 
Seronegative recipients who had 
received seropositive blood were 
retested 30 days posttransfusion to 
identify seroconversions. All donors 
and recipients with recent infections 
were offered counseling and treatment 
in accordance with national guidelines.
A total of 145 (73%) blood donors 
were male, and 109 (57%) units of 
blood had been stored for <4 days. 
Sixteen units (8%, 95% confi dence 
interval [CI] 4.3%–11.7%) were 
seropositive for syphilis by EIA and 
TPHA. Of these units, 7 (44%) were 
RPR reactive, which indicated a 
prevalence of recent infections of 3.5% 
(95% CI 1.0%–6.0%) (Table). Twenty-
six transfusion recipients (13%; 95% 
CI 8.3%–17.7%) were seropositive by 
EIA and TPHA. Of these recipients, 
blood samples from 9 (35%) were 
RPR reactive, indicating a prevalence 
of recent infection of 4.5%.
One recipient, an 8-year-old girl 
with severe malarial anemia (recipient 
10), showed seroconversion after 
receiving an RPR-reactive unit of 
blood that had been refrigerated for 
only 1 day before being issued for 
2080 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 11, November 2011
LETTERS
use. Posttransfusion fever developed 
in this recipient, who responded 
to treatment with cefuroxime and 
gentamicin, although results of blood 
culture for bacteremia and peripheral 
blood fi lm for malaria parasites 
were negative. She had no relevant 
sexual history, had been febrile 
after the transfusion, and showed no 
evidence of mucocutaneous lesions 
or lymphadenopathy at her follow-up 
visit 1 month after the transfusion. 
She was referred to pediatricians for 
treatment of syphilis. 
This recipient who showed 
seroconversion most likely had a case 
of transfusion-transmitted syphilis. 
Other treponemal infections such 
as yaws cannot be differentiated 
serologically from syphilis, and a 
diagnosis of yaws is based on clinico-
epidemiologic features (8); however, 
yaws is not endemic to Kumasi, and 
because this child had no clinical 
evidence of yaws, this disease 
is unlikely to be the cause of the 
seroconversion.
Refrigeration of units of blood for 
≥5 days kills T. pallidum, but 57% of 
the donated blood in this study was 
stored for <4 days before use. This 
situation prevails across many blood 
banks in sub-Saharan Africa where, 
because of inadequate supply and high 
demand, blood is used as soon as it 
becomes available. Such short periods 
of blood storage do not provide an 
adequate margin of safety against 
transfusion-transmitted syphilis. 
Findings from this study have been 
discussed with the hospital transfusion 
committee, and new syphilis screening 
guidelines and testing algorithms are 
being developed.
The high prevalence of syphilis 
seropositivity in blood donors and 
seroconversion of a transfusion 
recipient shows that in centers where 
screening is not conducted, recipients 
of blood transfusions are at risk for 
contracting transfusion-transmitted 
syphilis. This fi nding is likely in blood 
banks that have a high demand for 
blood and where blood is stored only 
for a few days. This study highlights 
transfusion-transmitted syphilis 
as a serious public health issue in 
developing countries and demonstrates 
that screening of donor blood for 
syphilis should be conducted.
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Congenital 
Syphilis, Réunion 
Island, 2010
To the Editor: Syphilis, caused 
by the bacterium Treponema pallidum, 
is primarily a sexually transmitted 
infection, but T. pallidum can also 
be transmitted by infected pregnant 
women to their children. Every year, 
at least 500,000 children are born with 
congenital syphilis (CS); maternal 
syphilis causes another half million 
stillbirths and abortions, usually in 
countries with limited resources (1). 
However, CS has been recently found 
in industrialized countries such as 
the United States, where the CS rate 
increased by 23% during 2005–2008, 
after a 38% increase in the syphilis rate 
among US women and girls during an 
earlier period (2004–2007) (2).
Réunion Island, a French over-
seas territory with 810,000 inhabitants, 
has a health care system similar to 
that in continental France. Neither 
syphilis infection, CS, nor other 
trepanomatosis (yaws) is notifi able. 
Since 2006, an increase in early 
syphilis was documented, fi rst in 
men who have sex with men infected 
with HIV and second in the general 
population.
In 2009, we conducted a retro-
spective study by using data from 
2004–2009 to document the situation 
of CS on the island. Data from all public 
(n = 4) and private (n = 2) hospitals 
on the island with neonatology 
and obstetrical departments were 
investigated. Birth deliveries at 
home were not included. Inclusion 
criteria were positive specifi c (T. 
pallidum hemagglutination assay) 
and nonspecifi c (Venereal Disease 
Research Laboratory [VDRL]) test 
results for Treponema spp. among 
children <2 years of age during 
2004–2009. Additionally, hospitalized 
children coded as having congenital 
syphilis (International Classifi cation 
of Diseases [ICD] 10 codes A50.0 
to A50.9) in the French national 
hospital database were included. After 
reviewing medical fi les of mothers and 
their children, cases were classifi ed as 
confi rmed or probable CS according 
to the case defi nition of the Centers for 
Disease Control and Prevention (2).
Eighteen children had positive 
syphilis serologic results by T. 
pallidum hemagglutination assay and 
VDRL tests, according to the selection 
criteria. Among these 18 test results, 
7 were classifi ed as probable CS (late 
treatment for mother or symptoms 
linked to CS), 3 in 2008 and 4 in 2009 
(Table). The male:female sex ratio was 
0.75. Five case-patients were preterm 
newborns; 3 of the most premature 
babies had signs linked to CS, such 
as hepatosplenomegaly, cutaneous 
mucosal signs, neurologic signs, 
radiographic signs of CS in long bones, 
edema, and biologic anomalies. All 
were screened for T. pallidum–specifi c 
IgM by using fl uorescent treponemal 
antibody absorption or IgM capture 
ELISA from immediately after birth 
to 15 days old. Two case-patients had 
positive results; 1 was symptomatic. 
Six of the 7 children who had probable 
CS received appropriate penicillin G 
treatment, except for 1 asymptomatic 
baby for whom long-term medical 
supervision was recommended by 
the pediatrician. Survival rates at 3 
months of age reached 100%.
Median age of mothers at delivery 
was 22 years. All mothers were natives 
of Réunion Island except 1 who was 
born in Madagascar and received no 
antenatal follow-up. Medical history 
indicated previous genital herpes for 3 
women. Social diffi culties or alcohol 
consumption were reported for 3 
women. The mean age of gestation at 
which the fi rst syphilis screening was 
conducted was 23 weeks (5–33 weeks). 
Two mothers were symptomatic. 
Syphilis was diagnosed after delivery 
for 3 mothers; seroconversion occurred 
during the pregnancy. Except for 
missing data on 1 mother, all mothers 
were HIV negative.
In Réunion Island, in our 
retrospective review, we found 7 CS 
cases during 2008–2009 but none 
during 2004–2007. The incidence rate 
of probable CS cases was estimated 
to be 28 cases per 100,000 live births 
during 2009. However, results may 
have been underestimated because 
not all parturients with a positive 
syphilis test result and fetal deaths 
were investigated. Meanwhile, a 
fetal death at 30 weeks was reported 
during the investigation but not 
included in the selection criteria. 
The Centers for Disease Control and 
Prevention defi nition of CS based 
on maternal status can also lead to 
an overestimation. Late screening of 
syphilis in mothers, lack of antenatal 
follow-up, higher VDRL titer, or 
unknown stage of the disease at 
time of diagnosis have already been 
described in other studies (3–5).
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Appendix 1.3: Presentation at the 21st Regional Congress of the ISBT, Lisbon, 
Portugal. 2011 
 
Abstract 4C-S17-01 
MALARIA IN THE BLOOD SUPPLY IN AFRICA: IS IT A PROBLEM? 
 
Although international policies recommend that blood for transfusion should be 
screened for transfusion-transmitted infections, malaria screening is not carried out 
in most malaria-endemic countries in sub-Saharan Africa (SSA). There are several 
reasons why this recommendation may not have been implemented. Serological 
screening tests are unhelpful in areas where malaria is endemic as most of the 
population have anti-malaria antibodies. There is a lack of evidence to indicate 
which malaria screening methods are effective for use by transfusion services in 
malaria-endemic countries in SSA. This is important because alternative malaria 
screening tests, such as microscopy, ELISA or rapid tests, are not sensitive enough 
to detect low levels of parasites in potential blood donors.  
 
Critical shortages of blood are common; for example in SSA 26% of maternal 
haemorrhage deaths between 1970 and 2007 were due to lack of blood for 
transfusion.  Blood transfusion services are understandably reluctant to implement 
any policy which is likely to exacerbate blood shortages. A review of the literature 
indicated that 10% of 33,029 blood donors in SSA were positive for malaria. 
Rejection of all these malaria-positive donors would undoubtedly have a major 
impact on the blood supply. A further complication is that the prevalence of malaria 
varies widely across Africa from 0.7% in Kenya to 55.0% in Nigeria making it difficult 
to devise a single policy that is appropriate for the whole continent.  
 
Even more fundamental is the question of whether or not the transfusion of low 
levels of malaria parasites to recipients living in endemic areas has adverse clinical 
consequences and therefore whether a policy recommending malaria screening is 
justified at all. Prior to the introduction of artemisinin combination therapy (ACT), 
pre-emptive treatment of transfusion recipients with chloroquine was cost 
effective. Given the higher cost of ACT’s and the need to prevent the spread and 
rapid development of resistance, screening policies will become invaluable. Despite 
the considerable costs associated with implementing a malaria-screening policy for 
blood transfusion, we have not been able to find any studies from SSA that 
investigated the clinical outcomes of receiving malaria-infected blood. We urgently 
need to fill these gaps in our knowledge about the benefits, risks and processes for 
screening blood for malaria so that appropriate and feasible policies about 
screening blood for malaria can be developed for the SSA region.  
 
 
  
Appendix 1.4: Presentation at the 31st International Congress of the ISBT, Berlin, 
Germany. 2010 
Abstract P-0935 Transfusion practices in a teaching hospital in Kumasi, Ghana 
Background: Information concerning transfusion practices in developing countries is 
scanty. The World Health Organization has published several guidelines and policies to help 
improve transfusion practices and safety. Ghana published a national guideline for blood 
transfusion in 2001. The level of adherence to these guidelines is not known.  
Aims: This study was undertaken to determine whether current transfusion practices in 
different departments in a teaching hospital in Ghana followed the published guidelines.  
Method: Over a four week period, a retrospective review of the notes of transfusion 
recipients was performed. A standardized pro-forma was used to extract the required 
information. The pro-forma was adapted from the hospital’s transfusion monitoring forms. 
It included information on patient demographics, diagnoses, use of antimalarials and 
premedication and information related to the transfusion including monitoring of vital 
signs, duration of transfusion and documentation of adverse events. Patients were 
randomly selected from the Departments of Obstetrics and Gynaecology (OBGY), 
Paediatrics and Medicine.  
Results: 151 patient records were reviewed during the four week study period, 
representing 10.4% of transfusion recipients.  These patients comprised 41 (27.2%) from 
Medicine, 51 (33.7%) from OBGY and 59 (39.1%) from Paediatrics. The median age was 
23.5 yrs (range: 1 – 83 yrs). 64.7 % of patients in OBGY, 61.9% of patients in Medicine and 
15% of patients in Paediatrics received multiple transfusions (2 or more transfusions). The 
mean duration of transfusion was 2.6 hours (range 1-6 hrs) and 6.3% of transfusions 
exceeded the recommended 4 hr duration. Frusemide was used as premedication in 89.7% 
of Paediatric, 12.2% of OBGY and 6.3% of Medicine patients. Blood pressure (BP) was not 
monitored in 59.6% of transfusions, was monitored once in 26.5% of cases, twice in 5.3% of 
cases and more than twice in 4% of cases. The pulse rate was not measured in 28.5% of 
transfusions, was measured once in 55.6% of cases, twice in 7.9% of cases and more than 
twice in 3.4% of cases. The monitoring of respiration and temperature followed a similar 
pattern. 43.7% of patients had received antimalarials within 24 hrs of transfusion and 75% 
of the antimalarials given were prescribed at the time the transfusion and were given in the 
absence of a positive malaria test. Paediatrics had the highest usage of antimalarials at 
86.5% and Medicine the lowest at 7.3%. Adverse reactions were documented in 8.6% of 
the transfusions and treatment of these reactions was documented in 6.6% of patient 
notes. 7% (10/151) of transfusion recipients died within 24h of the transfusion. It was not 
possible to determine whether these deaths were directly related to the blood transfusion.  
Conclusions: This survey shows that monitoring of vital signs during blood transfusion is 
not performed according to recommended guidelines. Presumptive malaria treatment is 
common in the Department of Paediatrics. Transfusion practitioners need regular training 
about the guidelines for transfusion monitoring to improve practice. Studies are required 
that provide evidence to guide the rational use of antimalarials in blood transfusion.  
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Germany. 2010 
Abstract P-0589:  Bacterial contamination of donated blood in a teaching hospital in 
Ghana 
Background: Transfusion associated bacterial sepsis from bacterial contamination of 
blood/blood products is associated with a high mortality. In developed countries bacterial 
contamination has usually been associated with transfusion of platelets rather than red 
cells or whole blood. Whereas red cells and whole blood are stored refrigerated, platelets 
are stored at room temperature and this can provide a suitable environment for bacterial 
proliferation. In developing countries where fridge temperatures are not monitored and 
electricity supply is erratic, whole blood may be subject to similar bacterial contamination 
and proliferation. There is little data about bacterial contamination of donated units of 
blood and its effects on recipients in Africa.  Aim: The aim of the study was to determine 
the level of bacterial contamination in donated blood in Ghana and its effects on 
transfusion recipients. Method: This was a prospective study conducted at the Komfo 
Anokye Teaching Hospital. Consent was obtained from the patients prior to starting 
transfusion. At the tail end of the transfusion, 5 mls of blood was taken aseptically from the 
blood bag and immediately inoculated into 20 mls of brain heart infusion broth. The broth 
was transported to the microbiology laboratory and incubated for up to 7 days. Blind sub-
culture of the broth onto blood and MacConkey agar plates was performed on days 2 and 
7. Patient’s vital signs were monitored and documented hourly until the transfusion was 
complete. Patients were clinically reviewed immediately after the transfusion, 24 hours 
after the transfusion and each day until discharge. If bacteria were isolated from the blood 
unit after the patients discharge, the recipient of the blood was immediately recalled for 
re-evaluation and a blood culture taken.  Results: Voluntary donations comprised 71.5% of 
the blood that was transfused and 34.0% of donors were females.  The blood was stored in 
the fridge for a median of 3 days (range 0 – 21 days). 23 bacteria were cultured from 200 
transfused units of blood, a positivity rate of 11.5%. Coagulase negative Staphylococcus was 
the most common isolate (47.8%). Other organisms were Bacillus species (21.7%), 
Pseudomonas aerugenosa (13%), Shigella species (8.7%) and Alkaligenes spp. and 
Citrobacter freundii (4.4% each). There were no overt clinical signs of sepsis in patients who 
received these contaminated units of blood. Follow up blood cultures from the recipients 
of contaminated units were negative. One patient, who received blood contaminated with 
Pseudomonas aeruginosa, although not showing any signs of sepsis required readmission 
for anaemia and was re-transfused. 64.5% of the transfusion recipients received antibiotic 
therapy during admission for underlying conditions. The mortality was 10.5%, none of 
which resulted directly from the blood transfusion. 
Conclusion: There were no apparent clinical effects of bacterially contaminated blood on 
recipients of such transfusions. It is unclear whether these organisms were in fact 
transfused into the transfusion recipients. The bacterial isolates may have resulted from 
contamination during the process of obtaining samples, transport to the laboratory or in 
the laboratory. Further studies are required to determine the true occurrence and effects 
of bacterial contamination of blood in this setting.  
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Germany. 2010 
Abstract 5D-S54-03: Syphilis screening of donated blood in a teaching hospital in 
Ghana 
Background: Screening of syphilis is one of the WHO recommended strategies for reducing 
transfusion transmitted infections. It has however been suggested by some experts in the 
developed world that screening should be discontinued. Transfusion transmitted syphilis 
(TTS) is now a rare occurrence and has not been reported in the international literature for 
>25 years. Storage of blood in temperatures at 2-80C, which is lethal to Treponema 
pallidum, largely accounts for the elimination of TTS. In developing countries, however, 
where blood is in high demand and blood supply is largely by replacement donation, blood 
units are kept in the fridge for only a short time. In such conditions, it is possible that TTS 
still occurs.    Aim: This aim of this study was to determine if syphilis sero-conversion occurs 
in transfusion recipients in a hospital where screening of blood units for syphilis is not 
routinely performed.   Methodology: This study was conducted in Medicine, Obstetrics and 
Gynaecology and Paediatrics departments of the Komfo Anokye Teaching Hospital (KATH) 
in Kumasi Ghana. KATH does not screen its donated blood for syphilis. After obtaining 
informed consent, a pre-transfusion sample from the patient and another sample from the 
unit of blood being transfused were obtained. Plasma was aliquoted, stored in a -20 freezer 
and later tested in batches. Samples were screened for syphilis initially using an enzyme 
immunoassay (EIA, Bioelisa Syphilis 3.0, Biokit). Confirmation of positive EIA results was by 
the Treponema pallidum haemagglutination assay (TPHA, Biokit Syphagen TPHA). A rapid 
plasma regain test (RPR, Biokit RPR Redirect) was used to determine disease activity in 
EIA/TPHA positive samples. Recipients who were sero-negative prior to transfusion and 
who received a syphilis positive blood unit were recalled for follow up testing with EIA, 
TPHA and RPR to determine if sero-conversion had occurred. Patients with positive 
serology results prior to transfusion and those who received blood with positive serology 
results were given appropriate counseling and treatment.   Results: Voluntary donors 
comprised 68% of donations.  27.5% of the donors were female. 200 transfusion recipients 
were recruited into the study; results are currently available for 150. 7.3% of donated 
blood units and 13.3% of transfusion recipients were EIA/TPHA positive. 36.6% and 30% 
respectively were also RPR positive. Two recipients were initially EIA/TPHA positive and 
went on to receive EIA/TPHA positive blood. Two patients who received EIA/TPHA positive 
blood died before subsequent samples could be obtained to test for sero-conversion. One 
patient became EIA/TPHA positive one month after receiving syphilis positive blood. The 
blood had been transfused after 1 day’s storage in the blood bank fridge. Serum has been 
stored for further confirmatory tests. This donated blood came from a walk in voluntary 
donor.      Conclusion: This study shows that transfusion transmitted syphilis could 
potentially be a problem in our hospital. Further patient follow up and testing for sero-
conversion is planned. Discussions are ongoing with the hospital management and 
transfusion committee to institute syphilis screening of all donated blood.  
 
  
Appendix 2.1: Informed consent form 
INFORMED CONSENT FORM 
 
INFORMATION SHEET 
 
Title of the research:  
Transfusion Transmitted Malaria and Bacterial Infections in Ghana.  
 
Name(s) and affiliation(s) of researcher(s) of applicant(s):  
Dr Alex Owusu-Ofori of the Komfo Anokye Teaching Hospital (KATH), Dr. Imelda 
Bates and Dr Chris Parry of Liverpool School of Tropical Medicine 
 
Introduction:  
I am a member of a research team carrying out this research in KATH and Bekwai 
and wish to explain this study to you and to obtain your consent to participate in this 
study. 
 
Purpose(s) of research:  
The purpose of this research is to determine whether donated blood for transfusion 
has bacteria (including syphilis) or malaria parasites, and what effects there are (if 
any), when such blood is transfused. 
 
Selection of participants:  
This study involves all children, pregnant women and immuno-compromised 
patients who are to receive blood transfusion. 
 
Procedure of the research, what shall be required of each participant and 
approximate total number of participants that would be involved in the 
research:  
You/your child/your relative is about to receive a blood/blood product transfusion.  
This blood has been investigated for HIV, Hepatitis B and C and is considered safe. 
However malaria parasites and bacteria have not been looked for because it is not 
routinely done in this country. What this study seeks to do is to look for the malaria 
parasites and bacteria (including syphilis) in the blood and investigate if it has any 
effects.   
If you agree to be enrolled into this study, before the transfusion is started, we will 
take six millilitres (a little over 2 teaspoonful) of your blood.  This will be tested and 
compared to any later findings we make. We will also check your vital signs before 
the start of the transfusion.  
 
When the transfusion starts, we will monitor your vital signs regularly until the end 
of the transfusion.  At the end of the transfusion, the leftover of the blood in the 
transfusion bag will be taken to the laboratory and tested for malaria and bacteria. 
We will know within 24 hours whether the blood you received had malaria or not. 
Based on this result, you will be allocated into either of two groups; those whose 
blood had malaria (‘cases’) or those whose blood did not have malaria (‘controls’). 
There will be a total of 200 cases and 400 control participants for this study.  
Participants allocated into both groups will be asked to stay in hospital for 72 hours 
during which we will monitor you intensively, including 8 hourly vital signs 
examination until you are discharged. 
 
  
On discharge you will have to come back to see us after one week, two weeks and 
four weeks.  We have a special clinic for you so that you can see us directly. When 
you come for each of these follow-up visits, we will ask you to tell us about your 
health since you went home and we will examine you fully. We will take a small 
amount of blood, equivalent to about half a teaspoon.   
If at any point before you come back to the hospital we find some bacteria in the 
blood that was given you, we will call you back, examine you and refer you for 
treatment. If at any time before you are scheduled to come back you feel unwell, you 
can call us or come to the hospital.  We will like you to always come to us when you 
don’t feel well and not go anywhere else so we can investigate you properly and 
have well trained people treat you. 
Once this study is completed, any of your sample left, will be destroyed. 
 
Risk(s):  
There is the possibility of feeling pain when we are taking your blood and the place 
from where we take the blood may be bruised.   
 
Benefit(s):  
The immediate benefit for you in this study is that you will have direct access to a 
medical team in the event that you develop any symptoms and at no extra expense to 
you.  
The goal of this research is to find out if there are malaria parasites and bacteria in 
the donated blood and what happens when such blood is given to people. What we 
find will be able to help us provide safer blood and in the event of not finding 
anything, our current practice will continue. 
Our findings may go on to affect how we give blood in the future so that in case you 
or someone else comes for blood, we will know that the blood we are giving is safe.  
We will reimburse your transportation cost to the hospital for all your follow-up 
visits. 
 
Confidentiality:  
All the information collected from you in this study will be well kept by us and not 
given to anybody. However, the people who approved this study may sometimes 
carry out inspections, so if that happens in this study, we will show them the 
information collected but without your personal details. 
Your name will be initially recorded to be able to trace you in case of any 
eventuality.  However all names will be deleted from our records immediately the 
study ends.  
Your name will not be published. 
 
Voluntariness:  
Your participation is entirely voluntary and can decide to participate in this study or 
not.  
 
Alternatives to participation:  
If you chose not to participate in this study, it will not affect the way you will be 
treated in this hospital. 
 
Consequences of participants’ decision to withdraw from research and 
procedure for orderly termination of participation:  
You may choose to withdraw from this study at anytime. Please note that some of 
the information that has been obtained about you before you chose to withdraw may 
  
have been used in reports and publications and cannot be removed anymore. 
However we promise to comply with your wishes as much as is practicable. 
 
Dissemination of results: 
Results of this study will be shared with the management of the hospital and the 
ministry of health.  It will also be published in international journals.   
 
Study contact person: In case you have any questions, difficulties, or emergencies, 
you can contact Dr Alex Owusu-Ofori, Directorate of Diagnostics, KATH, Kumasi; 
Phone number 0244 605 543. 
 
CONSENT FORM 
 
Statement of person obtaining informed consent: 
I have fully explained this research to ____________________________________ 
and have given sufficient information, including about risks and benefits, to make an 
informed decision. 
 
DATE:_____________________SIGNATURE: _____________________________ 
 
NAME: ______________________________________________ 
 
 
Statement of person giving consent: 
I have read the description of the research or have had it translated into language I 
understand. I have also talked it over with the interviewer to my satisfaction. I 
understand that my participation is voluntary. I know enough about the purpose, 
methods, risks and benefits of the research study to judge that I want to take part in 
it. I understand that I may freely stop being part of this study at any time. I have 
received a copy of this consent form and additional information sheet to keep for 
myself. 
 
 
DATE:_________________SIGNATURE/THUMBPRINT: ___________________ 
 
WITNESS’ SIGNATURE (if applicable): ________________________________ 
 
WITNESS’ NAME (if applicable): ______________________________________ 
 
Tel number:______________________________________ 
 
Address:_____________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________ 
  
Appendix 3.1: Data collection form for survey on transfusion practices 
Survey on Transfusion Practices 
Age:  Sex: Unit/Directorate: 
................................................................. 
Folder number: Date:  
 
The ff details required relate to the latest transfusion episode 
Date of admission_______________ 
Date of transfusion_______________ 
Duration of current transfusion(hrs) 
____________       
Was the transfusion completed?   [Yes]    [No] 
 
Frequency of observation of vital signs during transfusion: 
Vital sign Temperature Pulse Respirations BP 
Frequency     
1a. Pre-medication given? [Yes] [No]   1b)Name of medications:__________________ 
2. Pre-transfusion Hb___________________ 
3. Patient diagnosis? 1. _________________________________________________________ 
                                 2.  __________________________________________________________ 
4. Any transfusion prior to this admission? [No]   [once]   [twice]  [thrice]  [more than 3X]  
5. How many transfusions have been received during this admission?  [1] [2] [3] [4][>4] 
6a. If pregnant, has patient taken any iPT during the pregnancy?     [YES]    [NO]    [Not stated] 
b. How many doses were taken? [1] [2] [3]   [Not stated] 
c. Name of drug _________________________ d. How long ago was it taken (weeks)?_____ 
7a. Has patient received antimalarials during this admission?   [YES]    [NO]     
b. Which antimalarials were given?____________________________________________ 
c. When was antimalarials given? 
[A] Given at the time of requesting transfusion without a positive malaria test 
[B] Given at the time of requesting transfusion; patient positive for malaria 
[C] Given post transfusion due to fever, without a positive malaria test. 
[D] Prescribed post transfusion, patient positive for malaria. 
[E] Given post transfusion due to fever, without a positive malaria test. 
[F] Other.................................................................................................................... ...................... 
 
8a. Has patient received antibiotics during this admission?  [YES]    [NO]     
b. If antibiotics were given, was it prescribed after the transfusion?  [YES]    [NO]     
 
9a. Did patient have an increase in temperature within 24hrs of the transfusion?  [YES]  
[NO] 
b. If there was fever, what was the highest temperature difference from baseline? _____ 
c. If there was fever, did it subside within 24 hours?  [YES]  [NO]   [NA] 
 
10a. From the review of the case notes, is there any indication/ documentation that a 
transfusion reaction occurred?  [YES] [NO] 
b. Details: ........................................................................................................................................ 
11a. Is there any treatment in the notes that indicate that patient has been treated for a 
transfusion reaction?   [YES] [NO]    
b. Medications given_____________________________ 
 
12. Outcome at 24 hour:   [Alive] [Died]. 
  
Appendix 4.1: Classification of adverse events of transfusion 
 
CATEGORY DEFINITION* 
Acute transfusion 
reaction (ATR) 
 
Reactions occurring at any time up to 24 hours following a 
transfusion of blood or components, excluding cases of acute 
reactions due to incorrect component being transfused, haemolytic 
reactions, transfusion-related acute lung injury (TRALI), 
transfusion-related circulatory overload (TACO) or those due to 
bacterial contamination of the component. Examples of ATR are: 
Isolated febrile – a rise in temperature of > 1oC +/- minor rigors 
and chills.  
Minor allergic – skin +/- rash 
Anaphylactic – hypotension with one or more of: urticaria, rash, 
dyspnoea, angioedema, stridor, wheeze, pruritus, within 24 hours of 
transfusion. 
Severe allergic reaction – Severe allergic reaction with risk to life 
occurring within 24 hours of transfusion, characterised by 
bronchospasm causing hypoxia, or angioedema causing respiratory 
distress. 
Hypotension – a drop in systolic and/or diastolic pressure of 
>30mm Hg occurring within one hour of completing transfusion, 
provided all other adverse reactions have been excluded together 
with underlying conditions that could explain hypotension. 
Febrile with other symptoms/signs – rise in temperature of >1oC, 
with no features of an allergic reaction, but with one or more of 
myalgia, nausea, change in blood pressure or hypoxia. 
Acute Haemolytic 
transfusion reaction 
(HTR) 
Acute HTRs are defined as fever and other symptoms / signs of 
haemolysis within 24 hours of transfusion; confirmed by a fall in 
Hb, rise in LDH, positive DAT and positive cross match. 
Delayed Haemolytic 
transfusion reaction 
(HTR) 
Delayed HTRs are defined as fever and other symptoms / signs of 
haemolysis more than 24 hours after transfusion; confirmed by one 
or more of: a fall in Hb or failure of increment, rise in bilirubin, 
positive DAT and positive cross match not detectable 
pretransfusion.  
Simple serological reactions (development of antibody without 
positive DAT or development of haemolysis) are excluded. 
Cases with relevant features should be reported together with 
results of all laboratory investigations and antibody identification 
  
results if available. 
Cases will be included with no clinical or laboratory features as 
long as DAT is positive. 
Transfusion related 
acute lung injury 
(TRALI) 
Acute dyspnoea with hypoxia and bilateral pulmonary infiltrates 
during or within six hours of transfusion, not due to circulatory 
overload or other likely cause. (Suspected cases should be 
discussed with a Blood Service Consultant, and reported if there is 
a high index of suspicion, even if serological investigation is 
inconclusive). 
Post transfusion 
purpura (PTP) 
Thrombocytopenia arising 5 – 12 days following transfusion of red 
cells, associated with the presence in the patient of alloantibodies 
directed against the HPA (Human Platelet Antigen) systems. (Cases 
where the platelet count drops more than 50% following 
transfusion should be investigated and reported if complete or 
partial serological evidence is available). 
Transfusion 
associated graft 
versus-host disease 
(TA-GvHD) 
Characterised by fever, rash, liver dysfunction, diarrhoea, 
pancytopenia and bone marrow hypoplasia occurring less than 30 
days after transfusion. The condition is due to engraftment and 
clonal expansion of viable donor lymphocytes in a susceptible host.  
Transfusion 
transmitted 
infections (TTI) 
 
Include as a TTI if, following investigation, the recipient had 
evidence of infection post transfusion, and there was no evidence of 
infection prior to transfusion and no evidence of an alternative 
source of infection. 
Plus; Either at least one component received by the infected 
recipient was donated by a donor who had evidence of the same 
transmissible infection. 
Or at least one component received by the infected recipient was 
shown to contain the agent of infection. 
Transfusion 
associated 
circulatory overload 
(TACO) 
 
Any four of the following occurring within six hours of transfusion: 
° Acute respiratory distress. 
° Tachycardia. 
° Increased blood pressure. 
° Acute or worsening pulmonary oedema. 
° Evidence of positive fluid balance. 
*Classification as defined by SHOT  
  
Appendix 5.1: Transfusion monitoring form 
 
Transfusion monitoring form 
Blood ID: Study Number : 
 
Date of transfusion (dd/mm/yy): ___/___/___         
Type of component received: [whole blood] [packed cells] [FFP] [Cryoprecipitate] 
Time transfusion was started (24 hr clock): ………………………………………..  
Time transfusion was completed or stopped (24 hour clock): …………………….. 
Duration of transfusion (in hours): ………………………………………………...  
Monitor patients vital and complete the table below: 
Time point Temperature Respiratory 
rate 
Pulse Blood pressure 
Pre-transfusion 
T = 0 
    
15 min after start of 
transfusion 
    
30 min after start of 
transfusion 
    
1 hr after start of 
transfusion 
    
2hrs after start of 
transfusion 
    
3hrs after start of 
transfusion 
    
7-12  hrs after the 
start of the 
transfusion 
    
 
Did the patient develop any of the following during transfusion? 
Sign/symptom Yes No Sign/symptom Yes No 
Fever   Urticaria   
Restlessness   Anxiety   
Rigors/chills   Headache   
Cyanosis   Pruritus   
Chest pain   Dyspnoea   
Loin/Back pain   Rash   
Palpitations   Dark urine   
Unexplained bleeding   Respiratory distress   
Wheezes/stridor      
 
Was the transfusion stopped before the unit finished?   [Yes]   [No]  
 
If yes, estimate how much of the unit was transfused before it was stopped?                        
A. [Less than 10% transfused]   B. [10-<25 % transfused]       
C. [25-<50 % transfused]  D. [50-<75 % transfused]             E. [75-<100 % 
transfused] 
 
Did the patient have a severe adverse reaction?  [Yes]   [No] 
 
  
If yes, please complete the transfusion reaction form and the required investigations: 
 
Take immediate post transfusion blood samples from the vein opposite the infusion site and send to 
the transfusion lab for:  
Repeat blood group and cross matching with the offending unit 
Direct Antiglobulin test 
Return the ‘offending’ blood unit and giving set containing the remaining of the donor blood to the 
transfusion lab. 
Take blood for FBC including retics 
Take blood in appropriate bottle for blood culture 
Blood for urea, creatinine and electrolytes. 
 
 
 
TRANSFUSION REACTION INVESTIGATION 
Has the unit being transfused returned to blood bank?    [Yes]    [No] 
Has patient sample been taken for culture and sensitivity?  [Yes]    [No] 
Has blood culture from the transfused unit been taken?   [Yes]    [No] 
Has sample for biochemistry been sent?    [Yes]    [No] 
Has sample for full blood count been sent?    [Yes]    [No] 
Laboratory results  
Investigation Result Comment 
ABO   
RhD   
Direct Antiglobulin Test   
Urea and Creatinine   
Full Blood Count   
Blood culture  
(patient) 
  
Blood culture  
(transfused unit) 
  
 
Any other investigations and Results: 
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
______________________________________________________ 
 
What type of transfusion reaction occurred? (Support diagnosis with reasons why. Please 
see appendix 3 for a classification of the adverse events of transfusion) 
_______          
           
           
 ______      ________________________
 __________________________________________________________________
 __________________________________________________________________ 
 
 
 
  
Appendix 6.1: Case report form for Transfusion transmitted malaria study 
 
Name:      ___________Department/ward  
  
Sex: [M] [F]     Age (yrs):       Hospital number:    
 
Date of admission (dd/mm/yy): ___/___/___Date of transfusion (dd/mm/yy): ___/___/___     
Initial diagnosis:          
Indication for transfusion:         
 
This section to be filled if patient is pregnant 
LMP:___/___/___ Is patient a regular ANC attendant [Yes] [No] 
Gestation: no.of weeks …………..…..[1st trimester][2nd trimester][3rd trimester][puerperium] 
Parity:   [Nullip]   [Primip]    [Multip (no) …….]     [Grand multip (no)………..] 
Is patient on IPT (antimalarials)? [Yes] [No]          How many doses [1]  [2]  [3]  [dont know] 
If yes, name of antimalarial…………………………how long ago was it taken?(weeks).......... 
 
Monitoring of signs and symptoms after transfusion; Please indicate yes or no in each box 
Sign/Symptom Pre-transfusion 
(day 0) 
Day 1 Day 3 Discharge  
( Day……) 
Headache     
Chills/rigors     
Coca-cola urine     
Palpitations     
Urticaria     
Bodily pains     
Fever     
Restlessness     
Wheezes/stridor     
Other……………     
 
 
Monitoring of vital signs after transfusion 
Day Time point Temperature Respiratory 
rate 
Pulse Blood 
pressure 
Day 1 Morning     
Afternoon     
Evening     
Day 2 Morning     
Afternoon     
Evening     
Day 3 Morning     
Afternoon     
Evening     
 
 
 
 
 
  
 
Discharge summary 
Did the patient receive antimalarials?     [Yes]   [No] 
Name of antimalarials…………………………………………………………………….. 
If yes, when was it given? 
i)  [A] before transfusion    [B] after transfusion 
ii) Number of days………………………………………………………………………… 
 
Did patient receive antibiotics during this admission?  [Yes]   [No] 
Name of antibiotics……………………………………………………………………….. 
 
 
How many units of blood/blood components did patient receive? ___________________ 
 
Discharge diagnosis          
 
Date of discharge (dd/mm/yy): ___/___/___ Days on admission_______________ 
 
Outcome:  [alive]   [died]     
 
 
FOLLOW UPS 
 
Day 7 
Did patient come for visit?      [Yes]  [No] [Still on 
admission]      
Has patient had fever since day 3      [Yes]  [No] 
Has patient taken any antibiotics or antimalarials since discharge?   [Yes]  [No] 
[NA] 
If yes, give details: ________________________________________________________ 
 
 
Does patient have any of the following symptoms? 
i) Headache [Yes] [No]          ii) Fever [Yes] [No] 
iii) Vomiting [Yes] [No]          iv) Chills/rigors [Yes] [No] 
v) Bodily pains [Yes] [No]         vi) loss of appetite [Yes] [No] 
vii) Coca cola urine [Yes] [No] vii) others………………………………………….. 
 
Has blood for Hb and malaria parasites been taken?   [Yes]    [No] 
Has patient been referred for treatment?    [Yes]    [No] 
 
 
Day 14 
Did patient come for visit?      [Yes]  [No] [Still on 
admission]      
Has patient had fever since day 7      [Yes]  [No] 
Has patient taken any antibiotics or antimalarials since discharge?   [Yes]  [No] 
[NA] 
If yes, give details: ________________________________________________________ 
 
 
  
 
Does patient have any of the following symptoms? 
i) Headache [Yes] [No]          ii) Fever [Yes] [No] 
iii) Vomiting [Yes] [No]          iv) Chills/rigors [Yes] [No] 
v) Bodily pains [Yes] [No]         vi) loss of appetite [Yes] [No] 
vii) Coca cola urine [Yes] [No] vii) others………………………………………….. 
 
 
Has blood for Hb and malaria parasites been taken?   [Yes]    [No] 
Has patient been referred for treatment?    [Yes]    [No] 
 
 
 
Study Conclusion 
[A] Patient completed study without getting malaria 
[B] Patient developed malaria during the study 
[C] Lost to follow up 
[D] Consent withdrawn/refused to return for visit 
[E] Patient still on admission 
[F] Patient died 
[G] Other:………………………………………………………………………………………. 
 
  
Appendix 6.2: Results sheet for transfusion transmitted malaria study 
 
 
Results sheet for Transfusion transmitted malaria 
Blood ID: Study Number : 
 
 
 Donor characteristic 
Age of donor               Sex of donor: [M] [F]   Blood Grp:___________   
Date of was donation:         /         /          Date of transfusion:  ___/____/_____  
How many days was blood kept before being given out? _____________ 
Type of donor: [voluntary] [replacement] [other………………………………….]   
  
Malaria microscopy  
Date done (dd/mm/yy):  ___/____/_____   Result: [Positive]   [Negative] 
Count:___________________  Density____________ Species__________________ 
 
RDT 
Date done (dd/mm/yy):  ___/____/_____ 
Result: [positive] [negative]   Species____________________    [   ] Not done 
 
Enzyme Immunoassay  
Date done (dd/mm/yy):  ___/___ 
 
PCR  
Date done (dd/mm/yy):  ___/____/_____ 
Result: [positive] [negative]  
 
Genotyping___________________________________________________________ 
 
General comment:______________________________________________________ 
__________________________________________________________________________
________________________________________________________________ 
 
 
Patient results: 
Malaria 
  Microscopy PCR 
Time points Hb  Parasite  
count 
Parasite  
density 
Species Positive/ 
negative 
Genotyping 
Pre - transfusion       
Day 1       
Day 3       
Day 7       
Day 14       
Unschedule 
(Day…..) 
      
 
 
 
  
Appendix 6.3: Thick and thin film preparation 
 
Preparation of thick and thin films preparation for malaria microscopy 
 
Thick and thin blood films were prepared from venous blood that had been collected from 
the patient or blood bag into EDTA tubes. A capillary tube was used to transfer blood 
samples from EDTA tubes unto the glass slides. The same glass slide was used to prepare 
both thick and thin films. Slides were labelled appropriately with the study number, date 
and study day. 
Thin films 
A drop of blood was placed in the middle of glass slide.  
Another glass slide was placed in contact with the drop of blood but at an angle of 45° such 
that the blood spreads along the edge of the second glass slide which acts as the spreader.   
The spreader was pushed forward quickly to the end while maintaining the angle. This 
ensures that the blood is spread thinly. 
The slide was air dried and fixed by dipping into 100% methanol for a half a minute. The 
slide was placed on its side for the alcohol run off and dry. 
The smear was then stained with 10% Giemsa stain for 15 minutes and washed with the 
clean water. 
The slide was then placed on a drying rack and allowed to dry at room temperature. 
 
Thick films  
A drop of glass was placed on one side of the glass slide. 
Using the corner of another glass slide, the drop of blood was spread evenly in a circular 
fashion to ensure an even spread the blood with moderate thickness. 
The blood was air dried but not fixed in alcohol. 
The smear was then stained with 10% Giemsa stain for 15 minutes and washed with clean 
water. 
The slide was then placed on a drying rack and allowed to air dry at room temperature. 
 
 
The stained blood smears were examined with 100X oil immersion objective for both think 
and thin films. 
 
 
  
Appendix 6.4: Standard curve derived from real-time PCR assay 
 
 
  
Appendix 6.5: Amplification plots for a P. falciparum real–time PCR assay 
 
 
 
  
Appendix 6.6: Dissociation curves for standards in a P. falciparum real–time PCR assay 
 
 
 
 
  
Appendix 6.7: Dissociation curve for blood samples in a P. falciparum real–time PCR assay 
  
 
Appendix 7.1: Case report form for bacterial contamination study 
Patient demographics 
Name:      _________Department/ward    
 
Sex: [M] [F]       Age (mths):____                  Hospital number:    
 
Date of admission (dd/mm/yy): ___/___/__Date of transfusion (dd/mm/yy): ___/___/___     
 
Initial diagnosis:          
 
Indication for transfusion:         
 
Pre-transfusion Hb or PCV:__________________________________________________ 
 
Donor characteristics 
Date unit was collected (dd/mm/yy):         /         /             Blood ID:___________ 
Date of issue (dd/mm/yy):  ___/____/_____  
Type of donor:    [voluntary]        [replacement]    Sex: [M] [F]  
Was blood kept in fridge before being given out?      [Yes]    [No] 
How many days was blood kept before being given out? __________ 
 
 
Monitoring of patient vital signs after transfusion 
Timepoint Temperature Respiratory rate Pulse Blood pressure 
Pretransfusion     
30 min post transfusion     
1 hr after transfusion     
2hrs after transfusion     
3hrs after transfusion     
4hrs after transfusion     
24hrs post transfusion     
 
Monitoring of signs and symptoms after transfusion; please indicate yes or no in each box 
Sign/Symptom Pre-transfusion 
 
Immediate Post 
transfusion 
Day 1 
Headache    
Chills/rigors    
Coca-cola urine    
Palpitations    
Urticaria    
Bodily pains    
Fever    
Restlessness    
Wheezes/stridor    
Other……………    
 
Total duration of transfusion (hours)_________________________________________ 
Was sample obtained from transfusion bag?     [Yes]    [No] 
Has patient received antibiotics during this admission?     [Yes]    [No]  
If so, name of antibiotics          
  
 
How many units of blood did patient receive? ___________________________________ 
 
Discharge diagnosis:          
________________________________________________________________________ 
Outcome:  [alive]   [died]    [alive but with some sequele] 
Date of discharge (dd/mm/yy): ___/___/___ 
How long was patient on admission (days)?______________________________________ 
 
Did patient have a blood culture done prior to transfusion?   [Yes]   [No] 
Was there an isolate?         [Yes]   [No] 
What was the isolate?________________________________________________________ 
Sensitive to:_______________________________________________________________ 
Resistant to: _______________________________________________________________ 
 
Day 7 
Is patient still on admission?       [Yes]   [No] 
Did patient come for visit?       [Yes]    [No]  
Did patient receive more than 1 pint of blood during admission?  [Yes]    [No] 
Has patient taken any antibiotics since discharge?    [Yes]    [No]  [NA] 
If yes, give details: ________________________________________________________ 
Did patient have a fever after discharge?    [Yes]    [No]    
Is patient well?        [Yes]    [No]   
 Does patient require any further treatment?    [Yes]    [No] 
 
 
RESULTS 
Isolate from blood culture?        [Yes]  [No] 
Name of isolate____________________________________________________________ 
Sensitive antibiotics_________________________________________________________ 
Resistant antibiotics_________________________________________________________ 
Day of isolate: ______________________________________________________________ 
 
Comments:_________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________ 
 
STUDY CONCLUSION 
Patient called back earlier than day 7 and referred for management due to isolate. 
Patient came for follow up visit on day 7. No further action/treatment needed 
Patient referred to his/her primary care physician/obstetrician/paediatrician 
Contact made with patient but he/she refuses to come to hospital 
Patient lost to follow-up/cant be traced 
Patient came back after day 7. No further action. 
Other (specify)______________________________________________________ 
 
 
 
 
 
 
 
  
 
Appendix 8.1: Case report form for syphilis  
Patient demographics 
Name:      __________Department/ward    
 
Sex: [M] [F]       Age (yrs):____                  Hospital number:    
 
Date of admission (dd/mm/yy): ___/___/___Date of transfusion (dd/mm/yy): ___/___/___     
 
Initial diagnosis:          
 
Indication for transfusion:         
 
Pre-transfusion Hb or PCV:__________________________________________________ 
 
Donor characteristics 
Date unit was collected (dd/mm/yy):         /         /             Blood ID:___________ 
Date of issue (dd/mm/yy):  ___/____/_____  
Type of donor:    [voluntary]        [replacement]    Sex: [M] [F]  
Was blood kept in fridge before being given out?      [Yes]    [No] 
How many days was blood kept before being given out? __________ 
 
 
Monitoring of patient vital signs after transfusion 
Timepoint Temperature Respiratory rate Pulse Blood pressure 
Pretransfusion     
Immediate post 
transfusion 
    
     
 
Monitoring of signs and symptoms after transfusion; please indicate yes or no in each box 
Sign/Symptom Pre-transfusion 
 
Post transfusion Comment 
Headache    
Chills/rigors    
Coca-cola urine    
Palpitations    
Urticaria    
Bodily pains    
Fever    
Restlessness    
Wheezes/stridor    
Other……………    
 
Total duration of transfusion (hours)_________________________________________ 
Was pretransfusion sample obtained?      [Yes]    [No] 
Was sample obtained from transfusion bag?     [Yes]    [No] 
Has patient received antibiotics by the end of the transfusion?    [Yes]    [No]  
If so, name of antibiotics       __  
 
Discharge diagnosis          
  
 
Outcome:  [alive]   [died]    [alive but with some sequele] 
Date of discharge (dd/mm/yy): ___/___/___ 
 
Day 30 
Did patient come for visit?       [Yes]    [No]  
Did patient receive more than 1 pint of blood during admission?  [Yes]    [No] 
Has patient taken any antibiotics since last admission?    [Yes]    [No] 
If yes, give details: ________________________________________________________ 
Does patient require any further investigations?    [Yes]    [No] 
Has blood been taken for syphilis testing?    [Yes]    [No] 
 
 
 
RESULTS 
 
      
Test Date of 
test 
Donor 
blood 
Pre-
transfusion 
30-day post 
transfusion 
Comment 
ELISA      
TPHA      
RPR      
      
      
 
 
 
 
STUDY CONCLUSION 
Patient called and told not to come for 30 day follow up 
Patient came for follow up visit. No further action taken 
Patient referred to his/her primary care physician/obstetrician/paediatrician 
Contact made with patient but he/she refuses to come to hospital 
Patient lost to follow-up/cant be traced 
Patient dead 
Other (specify)______________________________________________________ 
 
 
 
 
 
 
 
 
 
  
 
Appendix 8.2: Syphilis recall case report form 
Syphilis-Recall Data Sheet 
(The patient has been called back because he/she received a blood transfusion that has 
been identified to be serologically positive for syphilis.  The patient is therefore to be 
assessed for any clinical evidence of syphilis) 
Date (dd/mm/yy) ___/___/___  Study number___________________ 
 
Have you been unwell since your last visit? [Yes] [No] 
Have you visited any clinic since you last visit here? [Yes] [No] 
Have you had any of the following symptoms since your last visit? 
Fever  [Yes] [No]             Skin lesions [Yes] [No]                               Itching [Yes] [No]  
Headache   [Yes] [No]                Bone pain [Yes] [No] 
Any other complaint (give 
details):....................................................................................................... 
Clinical examination 
Muco-cutaneous lesions?  [Yes] [No]                                                                                                                       
If yes, give details: 
............................................................................................................................. ...... 
Generalised lyphadenopathy?  [Yes] [No]                                                                                                        
If yes, give details: 
............................................................................................................................. ...... 
Any other clinical findings?  [Yes] [No]                                                                                                        
If yes, give details: 
............................................................................................................................. ...... 
...................................................................................................................................................
............................................................................................................................. ...................... 
Sample taken for syphilis confirmation?   [Yes] [No]                                                                                                        
Patient referred to specialist for treatment?   [Yes] [No]                                                                                                         
 
Final Diagnosis.............................................................................................................. ........... 
 
  
 
 
